idarubicin has been researched along with cytarabine in 775 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (2.71) | 18.7374 |
| 1990's | 160 (20.65) | 18.2507 |
| 2000's | 289 (37.29) | 29.6817 |
| 2010's | 252 (32.52) | 24.3611 |
| 2020's | 53 (6.84) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Huguet, F; Hurteloup, P; Michallet, M; Reiffers, J; Stoppa, AM | 1 |
| Amadori, S; Giona, F; Iori, AP; Mandelli, F; Meloni, G; Miniero, R; Moleti, ML; Pigna, M; Testi, AM | 1 |
| Di Mario, A; Etuk, B; Leone, G; Pagano, L; Salutari, P; Sica, S | 1 |
| Cersosimo, RJ | 1 |
| Berman, E | 1 |
| Abgrall, JF; Desablens, B; Dufour, P; Guyotat, D; Harousseau, JL; Herve, P; Ifrah, N; Milpied, N; Pignon, B; Solary, E | 1 |
| Resegotti, L | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W | 1 |
| Banks, PL; Bartolucci, AA; Flaum, MA; Gerber, MC; Omura, GA; Velez-Garcia, E; Vogler, WR; Weiner, RS | 1 |
| Coppetelli, U; del Poeta, G; Papa, G; Stasi, R; Tribalto, M; Venditti, A; Zaccari, G | 1 |
| Carella, AM; Carlier, P; Defferrari, R; Frassoni, F; Gaozza, E; Guerrasio, A; Lercari, G; Raffo, MR; Sessarego, M; Valbonesi, M | 1 |
| Arlin, ZA; Banks, PL; Case, DC; Enck, RE; Periman, PO; Ritch, PS; Todd, MB; Weitberg, AB; Wiernik, PH | 1 |
| Wiernik, PH | 1 |
| Ardia, A; Di Pietro, N; Di Raimondo, F; Falconi, E; Ganzina, F; Geraci, E; Ladogana, S; Latagliata, R; Mandelli, F; Petti, MC | 1 |
| Annino, L; Arcese, W; Carotenuto, M; Giona, F; Iori, AP; Madon, E; Meloni, G; Resegotti, L; Testi, AM; Vegna, ML | 1 |
| Baccarani, M; Cenacchi, A; Damiani, D; Fanin, R; Fogli, M; Gamberi, B; Revignas, G; Russo, D; Tura, S; Visani, G | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, S; Kolitz, J; McKenzie, S; Santorsa, J | 1 |
| Fields, SM; Koeller, JM | 1 |
| Amadori, S; Carella, AM; Carotenuto, M; Colella, R; Giona, F; Grotto, P; Leoni, P; Meloni, G; Resegotti, L; Testi, AM | 1 |
| Buscarini, L; Cavanna, L; Civardi, G; Di Stasi, M; Fornari, F; Moretto, M; Sbolli, G | 1 |
| Chapuis, B; Grob, JP; Helg, C; Pugin, P | 1 |
| Boschetti, C; Cofrancesco, E; Cortellaro, M; Moreo, G; Pogliani, E; Salvatore, M | 1 |
| Carella, AM; D'Amico, T; Damasio, E; Gaozza, E; Giordano, D; Nati, S; Piatti, G; Pungolino, E; Spriano, M | 1 |
| Dufour, P; Facon, T; Guy, H; Harousseau, JL; Hurteloup, P; Ifrah, N; Milpied, N; Reiffers, J; Rigal-Huguet, F | 1 |
| Omura, G; Raney, M; Velez-Garcia, E; Vogler, WR | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Lazzarino, M; Merante, S; Morra, E | 1 |
| Annino, L; Avvisati, G; Carella, AM; Caronia, F; Carotenuto, M; Giona, F; Mandelli, F; Meloni, G; Petti, MC; Testi, AM | 1 |
| Andreeff, M; Berman, E; Clarkson, BD; Gabrilove, J; Gee, TS; Gulati, S; Kempin, SJ; Raymond, V; Wiernik, PH; Young, CW | 1 |
| Carella, AM; Cerri, R; Giordano, D; Nati, S; Piatti, G; Pungolino, E; Risso, M | 1 |
| Arlin, ZA; Berman, E; Clarkson, BD; Daghestani, A; Gee, TS; Hancock, C; Kempin, S; Raymond, V; Stevens, YW; Williams, L | 1 |
| Mandelli, F; Petti, MC | 1 |
| Annaloro, C; Cortelezzi, A; Cortellaro, M; Della Volpe, A; Lambertenghi-Deliliers, G; Maiolo, AT; Mozzana, R; Pogliani, E; Polli, EE; Pozzoli, E | 1 |
| Arlin, ZA; Case, DC; Periman, PO; Ritch, PS; Todd, MB; Weitberg, AB; Wiernik, PH | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, SJ; Kolitz, J; Raymond, V; Young, CW | 1 |
| Coccia-Portugal, MA; Dreyer, R; Falkson, G; Terblanche, AP; Vorobiof, DA | 1 |
| Fülle, HH; Hellriegel, KP | 2 |
| Annaloro, C; Cortelezzi, A; Ganzina, F; Lambertenghi-Deliliers, G; Maiolo, AT; Pogliani, E; Polli, EE | 1 |
| Carella, AM; Cerri, R; Congiu, A; Damasio, E; Gaozza, E; Giordano, D; Martinengo, M; Nati, S; Risso, M; Santini, G | 1 |
| Carella, AM; Cerri, R; Congiu, A; Frassoni, F; Giordano, D; Marmont, A; Martinengo, M; Nati, S; Risso, M; Santini, G | 1 |
| Lambertenghi-Deliliers, G; Maiolo, AT; Pacciarini, MA; Pogliani, E; Polli, EE | 1 |
| Annaloro, C; Baldini, L; Lambertenghi-Deliliers, G; Maiolo, AT; Pogliani, E; Polli, E | 1 |
| Dardenne, M; de Witte, T; Fenaux, P; Hayat, M; Jaksic, B; Peetermans, M; Selleslag, D; Strijckmans, P; Suciu, S; Zittoun, R | 1 |
| Bergamaschi, G; Carella, AM; Cazzola, M; Ferrero, R; Podestá, M; Pollicardo, N; Pungolino, E; Raffo, MR; Rosti, V; Saglio, G | 1 |
| Baer, MR; Bloomfield, CD; Brunetto, VL; Christiansen, NP; Frankel, SR; Herzig, GP; Mrózek, K | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Pierce, S; Robertson, L | 1 |
| Carella, AM; Ferrero, R; Frassoni, F; Podestá, M; Pollicardo, N; Pungolino, E; Soracco, M | 1 |
| Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F | 1 |
| Amadori, S; Avvisati, G; Cedrone, M; Cimino, G; Mancini, F; Mandelli, F; Moleti, ML; Testi, AM; Todisco, E | 1 |
| Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Heimpel, H; Heit, W; Huber, C; Kolbe, K; Maschmeyer, G; Mitrou, PS | 1 |
| Carella, AM; Frassoni, F; Parodi, C; Podesta, M; Pollicardo, N; Pungolino, E; Rabitti, C; Raffo, MR; Sessarego, M; Vimercati, R | 1 |
| Chalmers, EA; Clarke, R; Franklin, IM; Goldstone, AH; Hepplestone, A; Kelsey, S; Sharp, S; Sproul, AM; Tansey, P; Watson, W | 1 |
| Caporale, R; Cervi, L; Ciolli, S; Giuliani, G; Leoni, F; Pascarella, A; Rossi Ferrini, P; Salti, F | 1 |
| Mehta, J; Philpott, N; Powles, R; Treleaven, J | 1 |
| D'Onofrio, G; Di Mario, A; Etuk, B; Leone, G; Salutari, P; Sica, S | 1 |
| Cenacchi, A; Gamberi, B; Manfroi, S; Ottaviani, E; Tosi, P; Tura, S; Visani, G | 1 |
| Caron, PC; Finn, RD; Jurcic, JG; Larson, SM; Maslak, P; Miller, WH; Scheinberg, DA; Warrell, RP; Yao, TJ | 1 |
| Cianfriglia, M; Eisterer, W; Gotwald, M; Hilbe, W; Hofmann, J; Ludescher, C; Thaler, J; Zabernigg, A | 1 |
| Götzl, M; Gsur, A; Kyrle, PA; Lechner, K; Pirker, R; Zöchbauer, S | 1 |
| Welborn, JL | 1 |
| Conley, NS; Doughney, KB; Durkin, WJ; Favis, GR; Siddiqui, T; Smith, AE; Weiss, R | 1 |
| Cedrych, I; Hołowiecka, B; Hołowiecki, J; Kachel, L; Krawczyk, M; Krzemień, S; Rudzka, E; Wacławik, A; Wojciechowska, M; Wojnar, J | 1 |
| Amadori, S; Annino, L; Arcese, W; Camera, A; Di Montezemolo, LC; Giona, F; Ladogana, S; Liso, V; Meloni, G; Testi, AM | 1 |
| Aul, C; Burk, M; Gogolin, F; Heyll, A; Meckenstock, G; Runde, V; Söhngen, D; Winkelmann, M; Wolf, HH; Zahner, J | 1 |
| Belloc, F; Boiron, JM; Cony-Makhoul, P; Dubosc-Marchenay, N; Dumain, P; Fabères, C; Lacombe, F; Marit, G; Montastruc, M; Puntous, M | 1 |
| Eardley, AM; Heller, G; Warrell, RP | 1 |
| Kaletin, GI; Pirogova, NA; Volkova, MA | 1 |
| Perilov, AA; Poddubnaia, IV | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Ohhashi, Y; Yamada, K | 1 |
| Almqvist, A; Hallman, H; Honkanen, T; Järvenpää, E; Järventie, G; Koistinen, P; Koivunen, E; Lahtinen, R; Lehtinen, M; Ruutu, T | 1 |
| Estey, EH; Kantarjian, H; Keating, M | 1 |
| Del Valle, F; Döhner, H; Ehrhardt, R; Fischer, JT; Haas, R; Ho, AD; Huberts, H; Hunstein, W; Kaplan, E; Witt, B | 1 |
| Annaloro, C; Cofrancesco, E; Cortelezzi, A; Cortellaro, M; Della Volpe, A; Lambertenghi Deliliers, G; Mozzana, R; Oriani, A; Pozzoli, E; Soligo, D | 1 |
| Cerutti, I; Fernández-Barbieri, MA; Gomel, M; Kvicala, R; Matus-Ridley, M; Negri-Aranguren, P; Rosso, A; Sackmann-Muriel, F; Santarelli, MT | 1 |
| Carella, AM; Carlier, P; Iacopino, P; Liso, V; Mirto, S; Montillo, M; Pagano, L; Pungolino, E; Resegotti, L; Stasi, R | 1 |
| Pratila, MG; Pratilas, V; Steinherz, LJ | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Yamada, K | 1 |
| Berman, E; Gaynor, J; Gee, T; Kempin, S; Kritz, A; Little, C; Scheinberg, D; Sogoloff, H; Telford, P; Weiss, M | 1 |
| Estey, EH; Simon, RM; Thall, PF | 1 |
| Berman, E; Golde, DW; Maslak, PG; Scheinberg, DA; Tyson, D; Weiss, MA; Yao, TJ | 1 |
| Baldicchi, L; Corneo, GM; Mangiagalli, M; Miccolis, IR; Pioltelli, P; Pogliani, EM | 1 |
| Gibney, MD; Nelson-Adesokan, P; Penneys, NS | 1 |
| Falk, RE; Fuerst, MM; Giles, FJ; Kusuanco, DA; Lawrence, GN; Lim, SW; Look, RM | 1 |
| Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Liu, JH; Tzeng, CH; Wei, CH; Yu, IT | 1 |
| Annino, L; Mandelli, F; Rotoli, B | 1 |
| Catalano, L; Frigeri, F; Luciano, L; Notaro, R; Pane, F; Rotoli, B; Salvatore, F; Santoro, LE; Selleri, C | 1 |
| Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M | 1 |
| Attal, M; Berthaud, P; Broustet, A; Danel, P; Fabères, C; Gastaut, JA; Hollard, D; Huguet, F; Hurteloup, P; Lepeu, G; Maraninchi, D; Marit, G; Mercier, M; Michallet, M; Molina, L; Pris, J; Reiffers, J; Stoppa, AM; Tellier, Z | 1 |
| Bandini, G; Belardinelli, A; Fiacchini, M; Geromin, A; Gherlinzoni, F; Manfroi, S; Mangianti, S; Miggiano, MC; Motta, MR; Ricci, P; Rizzi, S; Rosti, G; Testoni, N; Tura, S; Visani, G | 1 |
| Carella, AM; Frassoni, F | 1 |
| Chiusolo, P; Di Mario, A; Leone, G; Micciulli, G; Salutari, P; Sica, S; Tommasi, M | 1 |
| Constantinidou, M; Dervenoulas, J; Economopoulos, T; Kostourou, A; Papageorgiou, E; Parharidou, A; Raptis, S; Stathakis, N | 1 |
| Kiyota, T; Kuriyama, H; Watanabe, A | 1 |
| Kearns, P; Majumdar, G; Partridge, F; Richardson, W; Wilcox, R | 1 |
| Estey, E; Kuschel, B | 1 |
| Dardenne, M; De Witte, T; Hayat, M; Kurstjens, R; Labar, B; Muus, P; Ribeiro, M; Roozendaal, K; Selleslag, D; Solbu, G; Suciu, S; Zittoun, R | 1 |
| Aulitzky, WE; Busemann, C; Huber, C; Huhn, D; Kolbe, K; Neubauer, A; Peschel, C; Schleiermacher, E; Schneller, F; Siegert, W | 1 |
| Audhuy, B; Bergerat, JP; Berthaud, P; Dufour, P; Giron, C; Herbrecht, R; Hurteloup, P; Lamy, T; Lioure, B; Maloisel, F; Mors, R; Oberling, F | 1 |
| Escudier, SM; Estey, EH; Kantarjian, HM | 1 |
| Belotti, D; Corneo, G; Maffè, PF; Pogliani, EM; Rivolta, GF | 1 |
| Görg, C; Havemann, K; Köppler, H; Pflüger, KH; Wacker, HH; Weide, R | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Ohashi, Y; Yamada, K | 1 |
| Allford, S; Glynne, P; Hamblin, M; Horton, C; Mackay, H; Mehta, J; Powles, R; Prendiville, J; Saso, R; Singhal, S; Treleaven, J; Zomas, A | 1 |
| Ahn, HS; Cho, KS; Choi, YM; Chung, TJ; Hwang, TJ; Kim, CC; Kim, DW; Kim, HJ; Kim, HK; Kim, HS; Kim, JS; Lee, KS; Park, HS; Park, JW; Song, HS | 1 |
| Chen, TP; Chen, TY; Chen, YC; Lin, SF; Tsao, CJ; Yao, M | 1 |
| Kidd, P; Quien, ET; Saidi, P; Sandhaus, L; Strair, R; Wallach, B | 1 |
| Cortés, MA; Hermida, G; Iriondo, A; Mozota, ML; Olalla, I; Ortín, M; Richard, C; Zubizarreta, A | 1 |
| Chaibi, P; de Revel, T; Dombret, H; Gardin, C; Micléa, JM; Nédellec, G; Rousselot, P; Turlure, P | 1 |
| Degenhardt, F; Ganser, A; Geissler, RG; Hertenstein, B; Karthaus, M; Prahst, A | 1 |
| Chalmers, EA; Clark, RE; Crotty, G; Fielding, A; Franklin, IM; Goldstone, AH; Hepplestone, A; Kelsey, SM; McCann, SR; Newland, AC; Sharp, RA; Sproul, AM; Tansey, P; Watson, W | 1 |
| Amiot, L; Caulet-Maugendre, S; Diebold, J; Drénou, B; Fardel, O; Fauchet, R; Lamy, T; Le Prisé, PY; Sasportes, M | 1 |
| Elonen, E; Hänninen, A; Järventie, G; Kätkä, K; Koistinen, P; Koivunen, E; Nousiainen, T; Oksanen, K; Pelliniemi, TT; Remes, K; Ruutu, T; Timonen, T; Volin, L | 1 |
| Belloc, F; Bernard, P; Besnard, S; Boisseau, MR; Dumain, P; Lacombe, F; Reiffers, J; Vial, JP | 1 |
| Campbell, J; De La Serna, J; Diaz-Mediavilla, J; Francisco Tomás, J; García de Paredes, ML; Grande, C; Solano, C | 1 |
| Daibata, M; Ido, E; Kubonishi, I; Kuzume, T; Miyoshi, I; Murakami, K; Taguchi, H | 1 |
| Albitar, M; Anderlini, P; Andersson, B; Beran, M; Champlin, R; Claxton, D; Estey, E; Gajewski, J; Giralt, S; Kantarjian, H; Keating, M; Khouri, I; Koller, C; Kornblau, S; Kørbling, M; Mehra, R; O'Brien, S; Przepiorka, D; Rondón, G; van Besien, K | 1 |
| Capria, S; Mandelli, F; Meloni, G; Modena, V; Vignetti, M | 1 |
| Amadori, S; Annino, L; Arcese, W; Camera, A; Fioritoni, G; Giona, F; Ladogana, S; Leoni, P; Liso, V; Mandelli, F; Meloni, G; Moleti, ML; Resegotti, L; Rondelli, R; Tabilio, A; Testi, AM | 1 |
| Hall, JL; Hamblin, TJ; Myint, H; Ross, FM | 1 |
| Ohnishi, K; Ohno, R; Shinjyo, K; Takeshita, A; Tobita, T; Yanagi, M | 1 |
| Avvisati, G; Capria, S; Diverio, D; Lo Coco, F; Mandelli, F; Meloni, G; Petti, MC; Vignetti, M | 1 |
| Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S | 1 |
| Heitjan, DF | 1 |
| Mandelli, F | 1 |
| Abgrall, JF; Audhuy, B; Briere, J; Cahn, JY; Caillot, D; Casassus, P; Delain, M; Desablens, B; Francois, S; Guilhot, F; Guyotat, D; Harousseau, JL; Herve, P; Hurteloup, P; Lamy, T; Lioure, B; Milpied, N; Pignon, B; Tellier, Z; Witz, F | 1 |
| Rayon, C | 1 |
| Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S | 1 |
| Borg, AG; Burgess, R; Fisher, A; Grey, M; Wood, P; Yin, JA | 1 |
| Amadori, S; Arcese, W; Ceci, A; Comis, M; Giona, F; Madon, E; Mandelli, F; Meloni, G; Moleti, ML; Pession, A; Pillon, M; Rondelli, R; Testi, AM | 1 |
| Cullis, JO; Czepulkowski, B; Gover, PA; Grace, R; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE; Rassam, SM; Samaratunga, IR | 1 |
| Alcorn, MJ; Cook, G; Farrell, E; Franklin, IM; Marinaki, P; Pearson, C; Sharp, RA; Tansey, PJ | 1 |
| Carella, AM; Celesti, L; Corsetti, MT; Dejana, A; Frassoni, F; Lerma, E; Panagiotis, Z | 1 |
| Barbui, T; Bassan, R; Chiodini, B; Cornelli, PE; Cortelazzo, S; Lerede, T; Zucchetti, M | 1 |
| Badri, N; Boogaerts, M; Carella, AM; Dabouz-Harrouche, F; Gautier, L; Gorin, NC; Lennard, A; Link, H; Simonsson, B; Tomas-Martinez, JF | 1 |
| Bernasconi, C; Brusamolino, E; Castagnola, C; Lazzarino, M; Pagnucco, G; Passamonti, F | 1 |
| Apel, D; Maj, S; Mariańska, B; Seferyńska, I | 1 |
| Drullinsky, P; Golde, DW; Maslak, P; Scheinberg, D; Weiss, MA | 1 |
| Claahsen, HL; Mattijssen, V; Semmekrot, BA; van Dongen, PW | 1 |
| Alfaro, E; Casak, S; Cygler, A; Felice, MS; Fraquelli, L; Gallego, M; Pérez, LE; Quinteros, R; Sackmann-Muriel, F; Zubizarreta, P | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Borleri, G; Buelli, M; Lerede, T; Rambaldi, A | 1 |
| Baccarani, M; Baraldo, M; Damiani, D; Ermacora, A; Fanin, R; Furlanut, M; Michieli, M; Pea, F; Russo, D; Zaja, F | 1 |
| Bode, U; Fleischhack, G; Graf, N; Hasan, C; Mann, G | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Brusamolino, E; Canevari, A; Castagnola, C; Castelli, G; Lazzarino, M; Pagnucco, G | 1 |
| Fusaoka, T; Kataoka, A; Tunamoto, K; Wakazono, Y | 1 |
| Itoh, R; Mizuno, T; Morita, K; Suzuki, H; Tanaka, I | 1 |
| Chalmers, EA; Clark, RE; Crotty, G; Franklin, IM; Goldstone, AH; Hepplestone, A; Kelsey, SM; McBride, N; McCann, SR; Newland, AC; Sharp, RA; Singer, IO; Sproul, AM; Tansey, PJ; Watson, W | 1 |
| Boiron, JM; Cardinaud, JP; Gbikpi-Benissan, G; Gruson, D; Guisset, O; Hilbert, G; Pigneux, A; Reiffers, J; Texier, J; Vargas, F | 1 |
| Biondi, A; Coppi, MR; Liso, V; Mestice, A; Mininni, D; Palumbo, G; Pogliani, EM; Rossi, V; Specchia, G; Teruzzi, E | 1 |
| Bernasconi, C; Castagnola, C; Corso, A; Dabusti, M; Lazzarino, M; Lunghi, M; Tajana, M; Zappasodi, P | 1 |
| Baer, MR; Herzig, GP; Jenis, EH; Mookerjee, BK; Schriber, JR; Shah, M; Wetzler, M | 1 |
| Akan, H; Arat, M; Arslan, O; Beksaç, M; Gürman, G; Ilhan, O; Koç, H; Konuk, N; Ozcan, M; Uysal, A | 1 |
| Avanzini, P; Baldini, L; Brugiatelli, M; Carotenuto, M; Clò, V; Di Renzo, N; Dini, D; Federico, M; Gobbi, PG; Lombardo, M; Silingardi, V; Vallisa, D | 1 |
| Aulitzky, W; Huber, C; Peschel, C; Schneller, F; Schuler, M; Schumacher, K; Thaler, J | 1 |
| Feliu, E; Hernández, JA; Millá, F; Navarro, JT; Oriol, A; Pujol, M; Ribera, JM; Sancho, JM | 1 |
| Kirch, C; Schröder, JK; Schütte, J; Seeber, S | 1 |
| Deane, M; Foroni, L; Galactowicz, G; Hoffbrand, AV; Koh, M; Lawler, M; Prentice, HG; Secker-Walker, L | 1 |
| Estey, EH | 1 |
| Annino, L; Arcese, W; Giona, F; Mandelli, F; Meloni, G; Moleti, ML; Rondelli, R; Testi, AM | 1 |
| Engelhardt, R; Grotz, W; Lübbert, M; Rump, LC; Würthner, J | 1 |
| Aguado, MJ; Arrieta, R; Bustos, JG; Canales, MA; Hernández-García, C; Hernández-Navarro, F | 1 |
| Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P | 1 |
| Goa, KL; Whittington, R | 1 |
| Camera, A; Catalano, L; Picardi, M; Rotoli, B; Selleri, C | 1 |
| Andreeff, M; Beran, M; Cortes, J; Estey, EH; Freireich, E; Kantarjian, H; Keating, MJ; Pierce, S; Thall, PF | 1 |
| Mollee, PN; Rodwell, R; Taylor, D; Taylor, KM; Williams, B | 1 |
| Clarridge, J; Nachamkin, I; Osborne, J; Patel, JB; Schuster, MS; Waddington, M | 1 |
| Loy, BA; Martin, AW; Tecimer, C | 1 |
| Amadori, S; Archimbaud, E; Belhabri, A; De Cataldo, F; Fillet, G; Jehn, U; Martin, C; Peaud, PY; Thomas, X; Willemze, R | 1 |
| Cavaliere, M; Clavio, M; Gobbi, M; Miglino, M; Pierri, I; Pietrasanta, D | 1 |
| Ballerini, F; Beltrami, G; Canepa, L; Carrara, P; Cavaliere, M; Celesti, L; Clavio, M; Gatto, S; Gobbi, M; Lanza, L; Miglino, M; Pierri, I; Pietrasanta, D; Quintino, S; Varese, P | 1 |
| Benito, L; Delgado, I; García Alonso, L; García Vela, JA; Martin, M; Monteserin, MC; Oña, F; Somolinos, N | 1 |
| Kneisl, JS; Lipford, EH; Woodard, WL | 1 |
| Gherlinzoni, F; Isidori, A; Lemoli, R; Leopardi, G; Martinelli, G; Motta, M; Pastano, R; Piccaluga, P; Ricci, P; Rizzi, S; Testoni, N; Tosi, P; Tura, S; Visani, G | 1 |
| Bishop, JF; Bradstock, KF; Cobcroft, R; Eliadis, P; Enno, A; Gill, D; Herrmann, RP; Juneja, S; Lowenthal, RM; Manoharan, A; Matthews, JP; Page, FJ; Rooney, KF; Rosenfeld, D; Seldon, M; Taylor, KM; Wolf, MM; Young, GA | 1 |
| Kulkarni, S; Mehta, J; Min, T; Powles, R; Saso, R; Singhal, S; Swansbury, GJ; Treleaven, J | 1 |
| Avvisati, G; Biondi, A; Carlo-Stella, C; Diverio, D; Lo Coco, F; Mandelli, F; Martino, B; Meloni, G; Petti, MC; Pogliani, EM; Rossi, G; Selleri, C; Specchia, G | 1 |
| Filipits, M; Geissler, K; Jäger, U; Lechner, K; Pirker, R; Pohl, G; Scheper, RJ; Stranzl, T; Suchomel, RW | 1 |
| Diehl, V; Dimski, T; Lathan, B; Pantke, B; Schinköthe, T; Staib, P; Voliotis, D; Wiedenmann, S | 1 |
| Dias Wickramanayake, P; Diehl, V; Franklin, J; Glasmacher, A; Neufang, A; Scheid, C; Schulz, A; Staib, P; Steinmetz, HT; Tesch, H | 1 |
| Alaejos, I; Arbeteta, J; Balanzategui, A; Chillón, MC; García-Sanz, R; González, D; González, M; Hernández, JM; López-Pérez, R; Mateos, MV; Orfao, A; Rayón, C; San Miguel, J | 1 |
| Foss, HD; Keilholz, U; Knauf, W; Siehl, J; Szelényi, H; Thiel, E | 1 |
| Hinrichs, SH; Iwen, PC; Lackner, RP; McCarthy, DI; Rinaldi, MG; Sigler, L; Sutton, DA; Tarantolo, S | 1 |
| Minamikawa, K; Nakase, K; Shiku, H; Wakita, Y; Yamaguchi, T | 1 |
| Bueso-Ramos, CE; Glassman, AB; Hamoudi, WH; Medeiros, LJ; Townsend, G | 1 |
| Bergmann, L; Brack, N; Brockhaus, W; Fischer, JT; Fuhr, HG; Ganser, A; Heil, G; Hoelzer, D; Höffken, K; Hofmann, W; Ittel, TH; Knuth, P; Kolbe, K; Langer, W; Seipelt, G | 1 |
| Menéndez, B; Salar, A; Sierra, J; Sureda, A | 1 |
| Brun, M; D'Rozario, J; Scolyer, RA; Webb, M | 1 |
| Keung, YK; Kimbrough, RC; Sarria, JC; Vidal, AM | 1 |
| Devine, S; Heffner, LT; Jones, TW; Lonial, S; Smith, KJ; Waller, EK; Winton, EF; Yeager, AM | 1 |
| Aloe Spiriti, MA; Betrò, P; Breccia, M; D'Elia, GM; Latagliata, R; Luzi, G; Montefusco, E; Petti, MC; Pulsoni, A; Spadea, A | 1 |
| Belasco, JB; Bunin, NJ; Lange, BJ; Leahey, AM; Meek, R; Scher, C | 1 |
| Fujii, S; Fukushi, Y; Futagami, M; Higuchi, T; Saito, Y; Sakamoto, T; Sato, S; Takami, H; Yokoyama, Y | 1 |
| Cornelissen, JJ; Hagemeijer, A; Janssen, JJ; Nieuwint, AW; Ossenkoppele, GJ; Schuurhuis, GJ; Släter, R; van den Berg, E; van der Holt, B; van Rijn, RS; Vellenga, E; Verhoef, GE | 1 |
| Broxterman, HJ; Eekman, CA; Lankelma, J; Löwenberg, B; Ossenkoppele, GJ; Pinedo, HM; Schuurhuis, GJ; Sonneveld, P; van Putten, WJ | 1 |
| Boros, B; Egyed, M; Földi, J; Páldi-Haris, P; Rumi, G | 1 |
| Döhner, H; Döhner, K; Schlenk, RF; van der Reijden, BA | 1 |
| Kajiguchi, T; Miyata, Y; Saito, M; Takeyama, H | 1 |
| Ahn, YK; Cho, JG; Chung, IJ; Kim, HJ; Lee, JJ; Park, MR; Shin, DH | 1 |
| Clowes, C; Duarte, R; Pu, QQ; Wang, X | 1 |
| Avvisati, G; Barbui, T; Bernasconi, C; Bolufer, P; Colomer, D; Díaz-Mediavilla, J; Esteve, J; Ferrara, F; Fioritoni, G; González, JD; Gonzalez, M; Liso, V; Lo Coco, F; Mandelli, F; Martín, G; Petti, MC; Rayón, C; Ribera, JM; Rodeghiero, F; Sanz, MA | 1 |
| Arima, N; Fukushima, T; Kanamaru, A; Kishimoto, Y; Kusumoto, GS; Motoji, T; Ohno, R; Okamoto, T; Shimazaki, C; Takahashi, M; Takemoto, Y; Takeshita, A; Tsukuda, K; Uike, N; Yorimitsu, S | 1 |
| Acholonu, S; Anderlini, P; Andersson, B; Cabanillas, F; Champlin, RE; Cohen, A; Giralt, S; Hagemeister, F; Khouri, I; Körbling, MJ; Manning, J; Mclaughlin, P; Romaguera, J; Sarris, A; Ueno, NT | 1 |
| Huismans, DR; Pieters, R; Schuurhuis, GJ; Styczynski, J; Veerman, AJ; Wysocki, M | 1 |
| Aivado, M; Aul, C; Gattermann, N; Germing, U; Haas, R; Kobbe, G; Rieth, C; Rong, A | 1 |
| Dobie, D; Hastings, M; Mahendra, P; Richardson, G; Tauro, S | 1 |
| Beelen, DW; Brittinger, G; Flasshove, M; Kemmeries, G; Meusers, P; Noppeney, R; Roggenbuck, U; Scheulen, ME; Schütte, J; Seeber, S; Sohrab, S | 1 |
| Appelbaum, FR; Cassileth, PA; Forman, SJ; Harrington, DH; Head, DR; Kopecky, KJ; Mohamed, A; Paietta, E; Rowe, JM; Slovak, ML; Theil, KS; Willman, CL | 1 |
| Cavenagh, JD; Kelsey, SM; Lillington, DM; McBride, NC; Murrell, C; Newland, AC | 1 |
| Balduzzi, A; Biagi, E; De Lorenzo, P; Rovelli, A; Tagliabue, A; Uderzo, C | 1 |
| Chen, X; Greinix, HT; Haas, OA; Kalhs, P; Keil, F; Lechner, K; Loidolt, H; Louda, N; Mannhalter, C; Mitterbauer, G; Moser, K; Pirc-Danoewinata, H; Rabitsch, W; Worel, N | 1 |
| Adriansson, M; Arheden, K; Axelsson, P; Billström, R; Cervin, A; Fioretos, T; Johansson, B; Mitelman, F; Olofsson, T; Strömbeck, B; Tanke, HJ | 1 |
| Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA | 1 |
| al-Ramadi, B; Ellis, M; Gorka, W; Shamoon, A; Zwaan, F | 1 |
| Cheng, G; Chik, KW; Chui, CH; Lau, FY; Li, CK; Tsang, KS; Wong, R | 1 |
| Hatake, K; Komatsu, N; Matsumoto, Y; Mori, M; Muroi, K; Ohtsuki, T; Ozawa, K | 1 |
| Boos, J; Creutzig, U; Feldges, A; Gadner, H; Hermann, J; Kühl, J; Niemeyer, CM; Ritter, J; Sawatzki, DB; Schwabe, D; Selle, B; Zimmermann, M | 1 |
| Kim, S; Kim, SH; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Seol, M | 1 |
| Douglas, R; Michael, B; Nabil, S; Thomas, F | 1 |
| Baer, MR; Barone, S; Block, AW; Lawrence, D; Sait, SN; Wetzler, M | 1 |
| Cabrera, ME; Ducach, G; Etcheverry, R; Puga, BL; Toledo, H; Undurraga, MS; Vacarezza, R | 1 |
| Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T; Pedersen, B | 1 |
| Berthold, F; Creutzig, U; Gadner, H; Havers, W; Henze, G; Hermann, J; Jürgens, H; Kabisch, H; Kluba, U; Niggli, F; Reinhardt, D; Reiter, A; Ritter, J; Zimmermann, M | 1 |
| Cuneo, A; Liso, V; Mestice, A; Pannunzio, A; Rocchi, M; Specchia, G; Storlazzi, CT; Surace, C | 1 |
| Bernasconi, P; Boni, M; Castoldi, GL; Ciolli, S; Clavio, M; Cox, MC; Cuneo, A; Del Poeta, G; Dini, D; Falzetti, D; Fanin, R; Gobbi, M; Isidori, A; Leoni, F; Liso, V; Malagola, M; Mandelli, F; Martinelli, G; Mecucci, C; Petti, MC; Piccaluga, PP; Rondelli, R; Russo, D; Sessarego, M; Specchia, G; Testoni, N; Torelli, G; Tura, S; Visani, G | 1 |
| Ahmed, T; Feldman, EJ; Kancherla, R; Liu, D; Papageorgio, C; Pozzuoli, M; Seiter, K; Sreekantaiah, C; Weisberger, J; Weiss, M | 1 |
| Barbui, T; Bassan, R; Borleri, G; Broccia, G; Casula, P; Corneo, G; Cortelezzi, A; Coser, P; Fabris, P; Izzi, T; Lambertenghi-Deliliers, G; Lerede, T; Morandi, S; Pogliani, E; Rambaldi, A; Rossi, G; Spedini, P; Vespignani, M | 1 |
| Baccarani, M; Bertone, A; Bucalossi, A; De Vivo, A; Gobbi, M; Lauria, F; Marin, L; Mazza, P; Michelutti, A; Michieli, M; Pierri, I; Pricolo, G; Raspadori, D; Russo, D; Zaccaria, A; Zuffa, E | 1 |
| Bonifazi, F; Bonini, A; Castellani, S; Gugliotta, L; Isidori, A; Lemoli, RM; Malagola, M; Martinelli, G; Motta, MR; Piccaluga, PP; Rizzi, S; Tura, S; Visani, G | 1 |
| Bardy, P; Horvath, N; Hughes, T; Hui, CH; To, LB | 1 |
| Arthur, C; Bashford, J; Baxter, H; Bradstock, K; Brighton, T; Cannell, P; Dunlop, L; Durrant, S; Eliadis, P; Enno, A; Gill, D; Gillett, A; Gottlieb, D; Januszewicz, H; Joshua, D; Leahy, M; Lowenthal, R; Matthews, J; Schwarer, A; Taylor, K; Young, G | 1 |
| Dachselt, K; Deininger, M; Doepper, J; Dölken, G; Edel, E; Fiedler, F; Franke, A; Freund, M; Helbig, W; Herold, M; Hoffmann, FA; Kettner, E; Krahl, R; Lange, T; Leiblein, S; Niederwieser, D; Pasold, R; Pönisch, W; Richter, P; Schultze, W; Schwalbe, E; Schwarzer, A; Steglich, J; Subert, R; Uhle, R; von Grünhagen, U; Winkelmann, C | 1 |
| Bessho, M; Hirashima, K; Kawai, N; Kayano, H; Kusumoto, S; Matsuda, A; Sakata, T; Sugahara, Y; Suzuki, T; Yagasaki, F; Yoshida, K | 1 |
| Amadori, S; Archimbaud, E; Aul, C; Boogaerts, M; de Witte, T; Ferrant, A; Gratwohl, A; Hagemeijer, A; Jehn, U; Labar, B; Mandelli, F; Muus, P; Selleslag, D; Suciu, S; Verhoef, G; Wijermans, P; Willemze, R; Zittoun, R; Zwierzina, H | 1 |
| Beran, M; Cortes, J; Despa, S; Estey, EH; Faderl, S; Giles, FJ; Kantarjian, H; Koller, CA; O'Brien, S; Shen, Y; Thomas, DA | 1 |
| Faber, E; Hlusí, A; Hubácek, J; Indrák, K; Jarosová, M; Jebavý, L; Kmonícek, M; Knotková, R; Krahulová, M; Malý, J; Mayer, J; Penka, M; Szotkowski, T; Voglová, J; Zapletalová, J | 1 |
| Gotto, H; Hartmann, F; Jacobs, G; Pfreundschuh, M; Schwamborn, J | 1 |
| Banyai, A; Barta, A; Foldi, J; Gidali, J; Gopcsa, L; Kalasz, L; Pajor, L; Paloczi, K; Regeczy, N | 1 |
| Gadner, H; Mann, G; Trebo, MM | 1 |
| Aivado, M; Aul, C; Germing, U; Giagounidis, AA; Heinsch, M; Hildebrandt, B | 1 |
| Craddock, C; Garg, M; Lawler, M; Pawson, R; Potter, MN; Prentice, HG; Rassam, S; Rezvani, K; Theocharous, P; Yin, JA | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X | 1 |
| Hahn, JS; Jang, JH; Ko, YW; Lee, ST; Min, YH; Suh, HC | 1 |
| Anagnostopoulos, N; Androutsos, G; Galanopoulos, A; Kalmantis, T; Meletis, J; Paterakis, G; Rombos, Y; Sagriotis, A; Symeonidis, A; Tiniakou, M; Tsimberidou, AM; Yataganas, X; Zoumbos, N | 1 |
| Kamath, PS; Letendre, L; Tack, DK; Tefferi, A | 1 |
| Arcese, W; Cerretti, R; De Felice, L; Donato, V; Fenu, S; Guglielmi, C; Iori, A; Laurenti, L; Mengarelli, A; Micozzi, A; Romano, A; Torromeo, C | 1 |
| Alimena, G; Breccia, M; Cimino, G; De Carolis, S; Lo Coco, F; Mandelli, F | 1 |
| Kakishita, E; Mori, A; Okada, M; Okamoto, T; Takatsuka, H; Wakae, T | 1 |
| Bendix, K; Hokland, P; Kjeldsen, E; Kristensen, JS; Meyer, K; Nørgaard, JM; Olesen, G; Olesen, LH; Pedersen, B | 1 |
| Iwato, K; Kyo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suetsugu, Y; Sugihara, T; Wada, H; Yamada, O; Yata, K; Yawata, Y | 1 |
| Barbui, T; Bassan, R; Borleri, G; Buelli, M; Chiodini, B; Lerede, T; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Barbui, T; Bassan, R; Carter, M; Casula, P; Di Bona, E; Fabris, P; Lambertenghi-Deliliers, G; Lerede, T; Lister, TA; Morandi, S; Pogliani, E; Rambaldi, A; Rohatiner, AZ; Rossi, G | 1 |
| Kafka, M; Kapelushnik, J; Moser, A; Yermiahu, T | 1 |
| Alkotob, LM; Avery, RK; Chemaly, RF; Eliachar, I; Fox, SB; Procop, GW; Scharpf, J; Schmitt, SK; Smith, M; Sobecks, R | 1 |
| Anglaret, B; Archimbaud, E; Belhabri, A; Chelghoum, Y; Dhedin, N; Dombret, H; Fière, D; Michallet, M; Reman, O; Thomas, X; Vekhoff, A; Wattel, E | 1 |
| Akiba, T; Hatsumi, N; Karasawa, M; Maehara, T; Matsushima, T; Murakami, H; Nojima, Y; Saito, H; Shinonome, S; Suto, M; Tsukamoto, N; Uchiumi, H; Yokohama, A | 1 |
| Bernstein, SH; Jusko, WJ; Krzyzanski, W; Nichol, J; Wetzler, M | 1 |
| Beksac, M; Dalva, K; Hayran, M; Ilhan, O; Koc, H; Konuk, N; Ozcan, M; Sertkaya, D; Topcuoglu, P; Ustün, C | 1 |
| Clark, AD; Cook, G; Douglas, KW; Franklin, IM; McQuaker, IG; Mitchell, LD; Parker, AN; Tansey, PJ | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; Pierce, SA; Thall, PF; Thomas, DA; Wang, XM | 1 |
| Brito, G; Fernandez, T; Klumb, C; Land, MG; Maradei, S; Otero, L; Pombo-de-Oliveira, MS; Silva, ML; Veith, M | 1 |
| Fantasia, JE; Kaplan, R; Wu, J | 1 |
| Daenen, SM; Kluin-Nelemans, JC; van Spronsen, DJ | 1 |
| Giles, FJ | 1 |
| Aki, H; Baslar, Z; Ozguroglu, M; Tuzuner, N; Uygun, N | 1 |
| Batár, P; Kiss, A; Rák, K; Rejtó, L; Reményi, G; Telek, B; Udvardy, M | 1 |
| Arias, E; Baialardo, E; Benasayag, S; Bistmans, A; Reyes, M; Sapia, S; Slavutsky, I | 1 |
| Handa, H; Isozumi, K; Komatsumoto, S; Motohashi, S; Nara, M | 1 |
| Cortes, J; Davis, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; O'Brien, S; Thomas, D | 1 |
| Hoagland, HC; Hogan, WJ; Kaufmann, SH; Letendre, L; Litzow, MR; Pruthi, RK; Tefferi, A | 1 |
| Arcese, W; Aricò, M; Barisone, E; Basso, G; Biondi, A; Casale, F; Comis, M; Conter, V; Del Giudice, I; Dini, G; Giona, F; Ladogana, S; Lippi, A; Locatelli, F; Mandelli, F; Masera, G; Messina, C; Micalizzi, C; Micozzi, A; Moleti, ML; Mura, R; Pinta, MF; Rondelli, R; Santoro, N; Testi, AM; Valsecchi, MG | 1 |
| Barbui, T; Bassan, R; Buelli, M; Chiodini, B; Giussani, U; Lerede, T; Oldani, E; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Andreu, R; Benlloch, L; Cervera, J; de la Rubia, J; García, I; Jarque, I; Jiménez, C; Martín, G; Martínez, J; Mollá, S; Moscardó, F; Regadera, A; Sanz, G; Sanz, M | 1 |
| Aliff, TB; Frankel, SR; Jurcic, JG; Kalaycio, ME; Maslak, PG; Roma, TE; Scheinberg, DA; Tallman, MS; Weiss, MA | 1 |
| Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D | 1 |
| Bogdanovic, A; Colovic, M; Colovic, N; Jankovic, G; Miljic, P | 1 |
| Balduzzi, A; Biondi, A; Bonanomi, S; Dassi, M; Gaipa, G; Perseghin, P; Rovelli, A; Uderzo, C | 1 |
| Wood, RA | 1 |
| Amadori, S; Avvisati, G; Baccarani, M; Cantore, N; Di Bona, E; Ferrara, F; Fioritoni, G; Gallo, E; Invernizzi, R; Lazzarino, M; Liso, V; Lo-Coco, F; Mandelli, F; Mariani, G; Petti, MC; Ricciuti, F; Selleri, C; Sica, S; Vegna, ML; Veneri, D | 1 |
| Al-Ali, HK; Bumm, T; Deininger, MW; Franke, C; Friedrich, T; Hennig, E; Krahl, R; Krohn, K; Leiblein, S; Müller, C; Niederwieser, D; Schmidt, E; Shepherd, P | 1 |
| Beelen, D; Flasshove, M; Kasimir-Bauer, S; Noppeney, R; Scheulen, ME; Seeber, S | 1 |
| Aivado, M; Germing, U; Haas, R; Kobbe, G; Körfer, R; Pape, H; Schneider, P; Schubert, D; Storb, R; Strupp, C; Tenderich, G; Zohren, F | 1 |
| Douglas, RS; Goldstein, SM; Nichols, C | 1 |
| Alvarado, Y; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A | 1 |
| Alonzo, TA; Arceci, RJ; Bernstein, ID; Gerbing, RB; Lange, BJ; Loken, MR; Sievers, EL; Smith, FO; Woods, WG | 1 |
| Bolaños-Meade, J; Buddharaju, LN; Chen, TT; Guo, C; Karp, JE; Rapoport, AP; Sarkodee-Adoo, CB; Tidwell, ML | 1 |
| Dansako, H; Fujii, N; Fujita, S; Kaneda, K; Kojima, K; Shinagawa, K; Tanimoto, M; Yano, T; Yasukawa, M; Yoshida, C | 1 |
| Estey, EH; Thall, PF | 1 |
| Arber, DA; Dagis, A; Forman, SJ; Fung, HC; Krishnan, A; Molina, A; Nademanee, AP; Niland, JC; O'Donnell, MR; Parker, P; Rodriguez, R; Slovak, ML; Snyder, DS; Somlo, G; Spielberger, RT; Stein, AS; Vora, N; Wang, S | 1 |
| Disis, ML; Ginsburg, AS; Salazar, LG; True, LD | 1 |
| Barge, RM; Honders, MW; Spoelder, HE; Veuger, MJ; Willemze, R | 1 |
| Bacigalupo, A; Balleari, E; Ballerini, F; Beltrami, G; Canepa, L; Carella, AM; Carrara, P; Cerri, R; Clavio, M; Galbusera, V; Gatto, S; Ghio, R; Gobbi, M; Miglino, M; Pierri, I; Quintino, S; Risso, M; Sessarego, M; Varaldo, R; Venturino, C | 1 |
| Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA | 1 |
| Auvrignon, A; Bastard, C; Blaise, D; Castaigne, S; Dastugue, N; Delaunay, J; Dombret, H; Fenaux, P; Fière, D; Harousseau, JL; Lamy, T; Leblanc, T; Leverger, G; Mugneret, F; Pigneux, A; Reiffers, J; Rigal-Huguet, F; Van den Akker, J; Vey, N; Witz, F | 1 |
| Go, RS; Johnston, KL | 1 |
| Baer, MR; Barcos, M; Blumenson, L; Ferrone, S; Ford, LA; McElwain, BK; Mortazavi, A; Slack, JL; Stewart, CC; Wetzler, M | 1 |
| Buquicchio, C; Carluccio, P; Greco, G; Liso, A; Liso, V; Mestice, A; Pastore, D; Rizzi, R; Specchia, G | 1 |
| Pandit, SR; Raheem, MA | 1 |
| Berry, DA; Cortes, JE; Estey, EH; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; O'Brien, S; Thomas, DA; Verstovsek, S; Wathen, JK; Xiao, LC | 1 |
| Amadori, S; Anak, O; Aul, C; Beeldens, F; Belhabri, A; de Witte, T; Ferrant, A; Hess, U; Jehn, U; Labar, B; Mandelli, F; Muus, P; Oosterveld, M; Selleslag, D; Suciu, S; Verhoef, G; Wijermans, P; Willemze, R; Zittoun, R | 1 |
| Beyan, C; Cetin, T; Kaptan, K; Nevruz, O | 1 |
| Crum, NF; Fehl, FC; Graham, BS; Higginbottom, PA | 1 |
| Higa, T; Imai, A; Imamura, M; Kasai, M; Kiyama, Y; Kobayashi, N; Kondo, Y; Miyokawa, N; Ogasawara, M; Ogawa, T; Sato, K; Tanaka, J; Toubai, T | 1 |
| Chang, CS; Chung, CY; Horng, HC; Hsu, NC | 1 |
| Kumagawa, M; Nagano, M; Suzuki, K; Suzumiya, J; Takamatsu, Y; Tamura, K | 1 |
| Boogaerts, M; Daenen, S; de Greef, G; Ferrant, A; Fey, M; Gmür, J; Gratwohl, A; Huijgens, P; Kovacsovics, T; Löwenberg, B; Schouten, H; Sonneveld, P; Theobald, M; van Putten, W; Verdonck, L | 1 |
| Burnett, AK; Chopra, R; Clark, RE; Culligan, D; Hunter, A; Kell, WJ; Milligan, DW; Prentice, AG; Rohatiner, A; Yin, JA | 1 |
| Cabanillas, F; Cox, JD; Dabaja, BS; Ha, CS; Kyritsis, AP; Levin, V; McLaughlin, P; Meyers, CA; Preti, HA; Pro, B; Seabrooke, LF; Wilder, RB; Yung, WK | 1 |
| Ito, Y; Katagiri, T; Nakajima, A; Ohyashiki, K; Shimamoto, T | 1 |
| Mead, G; Woodcock, J; Young, C | 1 |
| Debatin, KM; Eckhoff, S; Meyer, LH; Mohr, A; Stahnke, K | 1 |
| Björkholm, M; Höglund, M; Juliusson, G; Karlsson, K; Löfgren, C; Möllgård, L; Paul, C; Tidefelt, U | 1 |
| Fuchigami, K; Fukushima, T; Hata, T; Honda, M; Jinnai, I; Kuriyama, K; Miyazaki, Y; Togami, K; Tomonaga, M; Yamasaki, J | 1 |
| Ahlgren, T; Billström, R; Brune, M; Hedenus, M; Höglund, M; Markevärn, B; Nilsson, B; Sallerfors, B; Simonsson, B; Stockelberg, D; Wahlin, A | 1 |
| Hoffbrand, AV; Koh, M; Mehta, A; Potter, M; Prentice, HG; Rankin, P; Virchis, A | 1 |
| Baccarani, M; Malagola, M; Martinelli, G; Piccaluga, PP; Ronconi, S; Rondoni, M; Visani, G | 1 |
| Fujii, S; Kikuchi, T; Miyata, A | 1 |
| Alonzo, TA; Aplenc, R; Arndt, C; Barnard, D; Dinndorf, P; Feig, S; Feusner, J; Gerbing, R; Lange, BJ; Seibel, N; Smith, FO; Weiman, M | 1 |
| Kondo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suemori, S; Suetsugu, Y; Sugihara, T; Tsujioka, T; Wada, H; Yamamori, S | 1 |
| Bolam, S; Child, JA; Davies, JM; Gilson, D; Howard, MR; Jalihal, SS; Mackie, MJ; McVerry, BA; Moreton, P; Morgan, GJ; Parapia, LA; Smith, GM; Williams, AT | 1 |
| Chang, YW; Cho, HC; Cho, HI; Hur, M; Kim, SH; Kim, YR; Lee, KM; Park, YI | 1 |
| Almqvist, A; Anttila, P; Elonen, E; Jantunen, E; Koistinen, P; Koivunen, E; Koponen, A; Mikkola, M; Nousiainen, T; Oksanen, K; Pelliniemi, TT; Pulli, T; Remes, K; Ruutu, T; Sarkkinen, R; Silvennoinen, R; Timonen, T; Vanhatalo, S | 1 |
| Giakoumi, X; Mantzouranis, M; Pangalis, GA; Vassilakopoulos, TP; Viniou, NA | 1 |
| Abe, Y; Choi, I; Inaba, S; Matsushima, T; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Ohtsuka, R; Tachikawa, Y | 1 |
| Arnold, R; Bergmann, L; Fiedler, W; Ganser, A; Heil, G; Hoelzer, D; Kirchner, H; Krauter, J; Lübbert, M; Noens, L; Raghavachar, A; Schlimok, G | 1 |
| Akercan, F; Cagirgan, S; Donmez, A; Mgoyi, L; Ozkinay, E; Vural, F; Yucebilgin, MS | 1 |
| Ault, K; Case, D; Damon, LE; Johnston, LJ; Linker, CA; Ries, CA; Rugo, HS | 1 |
| Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Hoeffken, K; Hoelzer, D; Hofmann, WK; Knuth, A; Koelbel, CB; Kolbe, K; Langer, W; Ottmann, OG; Schmoll, HJ; Westerhausen, M; Wiebe, S; Zander, C | 1 |
| Colburn, DE; Giles, FJ; Oladovich, D; Smith, JA | 1 |
| Arthur, C; Bashford, J; Baxter, H; Bradstock, KF; Brighton, T; Cannell, P; Catalano, J; Dunlop, L; Durrant, S; Eliadis, P; Enno, A; Gill, D; Gillett, A; Joshua, D; Juneja, S; Koutts, J; Leahy, M; Lowenthal, RM; Matthews, JP; Schwarer, AP; Szer, J; Taylor, K; Young, GA | 1 |
| Batlle, M; Besalduch, J; Brunet, S; Bueno, J; Carreras, E; Esteve, J; Feliu, E; Guàrdia, R; Julià, A; Llorente, A; Montserrat, E; Oriol, A; Pedro, C; Ribera, JM; Sánchez, JM; Sierra, J; Tormo, M; Vilà, JM; Vivancos, P | 1 |
| Dutcher, JP; Karbasian-Esfahani, M; Novik, Y; Paietta, E; Wiernik, PH | 1 |
| Anghilieri, M; Cairoli, R; Marbello, L; Minola, E; Morra, E; Nosari, A; Ricci, F | 1 |
| Brown, CA; Hashem, B; Lane, JE; Lesher, JL; Marzec, T | 1 |
| Avramis, V; Douglas, JG; Felgenhauer, J; Geyer, JR; Hawkins, DS; Holcenberg, J; Loken, MR; Meshinchi, S; Park, JR; Thomson, B | 1 |
| Addamo, B; Benner, A; Biedermann, HG; del Valle, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Glasmacher, A; Götze, K; Griesinger, F; Grimminger, W; Haas, R; Hartmann, F; Hensel, M; Kirchen, H; Koller, E; Kremers, S; Mergenthaler, HG; Pralle, H; Preiss, J; Salwender, H; Schlenk, RF; Schoch, R; Waterhouse, C | 1 |
| Burnett, AK; Milligan, DW; Wheatley, K | 1 |
| Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Hennessy, B; Kantarjian, H; O'brien, S; Ossa, G; Verstovsek, S | 1 |
| Creutzig, U; Dworzak, M; Lehrnbecher, T; Reinhardt, D; Stary, J; Zimmermann, M | 1 |
| Aleskog, A; Höglund, M; Larsson, R; Laurell, A; Lindhagen, E; Nilsson, K; Nygren, P; Roos, G; Rosenquist, R; Sundström, C; Thunberg, U; Tobin, G | 1 |
| Chalandon, Y; Helg, C; Stalder, M; Verholen, F | 1 |
| Komatsu, N; Mori, M; Nagai, T; Obara, Y; Ohmine, K; Ozawa, K; Toshima, M | 1 |
| Maruyama, Y; Satoh, Y; Takahashi, T; Tsujisaki, M; Yoshimoto, M | 1 |
| Benderra, Z; Chaoui, D; Faussat, AM; Legrand, O; Marie, JP; Perrot, JY; Sayada, L | 1 |
| Alymara, V; Bourantas, KL; Chaidos, A; Tsiara, S; Tzouvara, E; Vartholomatos, G | 1 |
| Bauer, KS; Garimella, TS; Karp, JE; Ross, DD; Tan, M; Wu, S | 1 |
| Balaian, L; Ball, ED | 1 |
| Bai, LY; Chao, TC; Chen, PM; Teng, HW; Wang, WS | 1 |
| Barulli, S; D'Adamo, F; Guiducci, B; Isidori, A; Leopardi, G; Malagola, M; Malerba, L; Mele, A; Nicolini, G; Piccaluga, P; Politi, P; Sparaventi, G; Stramigioli, S; Talevi, N; Visani, G | 1 |
| Benner, A; del Valle y Fuentes, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Germing, U; Glasmacher, A; Götze, K; Grimminger, W; Hartmann, F; Hensel, M; Nerl, C; Petzer, A; Pralle, H; Salwender, H; Schlenk, RF; Zick, L | 1 |
| Borkhardt, A; Bruch, J; Fuchs, U; Metzler, M; Perez, AV; Wilda, M; Woessmann, W | 1 |
| Karp, JE; Smith, BD | 1 |
| Albitar, M; Cortes, JE; Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Kornblau, S; Mattiuzzi, GN; O'Brien, SM; Thomas, D; Tsimberidou, AM; Verstovsek, S; Wierda, W | 1 |
| Creutzig, U; Diekamp, S; Dworzak, M; Fleischhack, G; Harbott, J; Langebrake, C; Ludwig, WD; Reinhardt, D; Ritter, J; Schrauder, A; Stary, J; Zimmermann, M | 1 |
| Creutzig, U; Diekamp, S; Dworzak, M; Reinhardt, D; Stary, J; Zimmermann, M | 1 |
| Chi, HS; Choi, SJ; Jang, S; Kim, S; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Lee, YS; Park, CJ; Ryu, SG; Seol, M | 1 |
| Ahmed, P; Anwar, M; Hashmi, KU; Hussain, I; Iqbal, H; Khan, B; Mahmood, A; Malik, HS; Raza, S | 1 |
| Carluccio, P; Ciuffreda, L; Liso, A; Liso, V; Mestice, A; Pastore, D; Pietrantuono, G; Rizzi, R; Specchia, G | 1 |
| Bousquet, M; Brousset, P; Dastugue, N; De Mas, V; Delsol, G; Duchayne, E; Laurent, G; Quelen, C; Roquefeuil, B | 1 |
| Armata, J; Balcerska, A; Balwierz, W; Chybicka, A; Dluzniewska, A; Kowalczyk, J; Matysiak, M; Ochocka, M; Radwanska, U; Rokicka-Milewska, R; Sonta-Jakimczyk, D; Wachowiak, J; Wysocki, M | 1 |
| Lamm, RD; McCarthy, PM; Sade, RM | 1 |
| Horácek, JM; Jebavý, L; Malý, J; Praus, R; Pudil, R; Strasová, A; Tichý, M; Zák, P | 1 |
| Alpay, R; Disel, U; Paydas, S; Tuncer, I; Yavuz, S | 1 |
| Avanzini, P; Baccarani, M; Bocchia, M; Bonini, A; Candoni, A; Castelli, M; Damiani, D; de Vivo, A; Fanin, R; Fiacchini, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Michielutti, A; Ottaviani, E; Piccaluga, PP; Pricolo, G; Raspadori, D; Rondoni, M; Russo, D; Testoni, N; Visani, G; Zaccaria, A; Zuffa, E | 1 |
| Glasmacher, A; Gorschlüter, M; Mey, U; Schmidt-Wolf, IG; Schwerdtfeger, R | 1 |
| Disel, U; Paydas, S; Yavuz, S | 1 |
| Hayashi, Y; Kanazawa, T; Morikawa, A; Ogawa, C; Taketani, T; Taki, T | 1 |
| Asou, N; Emi, N; Honda, S; Kishimoto, Y; Matsuda, S; Matsushima, T; Mitani, K; Miyawaki, S; Miyazaki, Y; Ogawa, Y; Ohno, R; Ohtake, S; Sakamaki, H; Takahashi, M; Yagasaki, F | 1 |
| Döhner, H; Döhner, K; Eiwen, K; Fröhling, S; Schlenk, RF; Scholl, C | 1 |
| Escherich, G; Hassenpflug, WA; Horstmann, MA; Janka, G; Kabisch, H; zur Stadt, U | 1 |
| Apostolidis, I; Arvanitopoulou, E; Asprogeraka, T; Bakiri, M; Giannakoulas, N; Kotsianidis, I; Marinakis, T; Matsouka, P; Pagoni, M; Papaioannou, M; Skandali, A; Spanoudakis, E; Tsatalas, K; Viniou, N; Yataganas, X; Zikos, P | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Pierce, S; Plunkett, W; Shan, J | 1 |
| Caballero, D; Mateos, JJ; Perez, E; San Miguel, JF; Sanz-Rodriguez, C; Vazquez, L | 1 |
| Gould, PA; Hengel, CL; Kaye, DM; Russell, PA | 1 |
| Hanada, R; Horibe, K; Kobayashi, R; Tawa, A; Tsuchida, M; Tsukimoto, I | 1 |
| Belloc, F; Lacombe, F; Pigneux, A; Praloran, V; Tabrizi, R; Vial, JP | 1 |
| Baldini, L; Balzarotti, M; Bernardi, M; Bobbio, F; Brandes, AA; Caligaris Cappio, F; Corazzelli, G; Dell'Oro, S; Ferreri, AJ; Foppoli, M; Ilariucci, F; Montanari, M; Picozzi, P; Ponzoni, M; Reni, M; Spina, M; Stelitano, C; Tosoni, A; Zaja, F | 1 |
| Belch, A; Gluck, S; Larratt, L; Robinson, KS; Sheridan, D; Shustik, C; Stewart, K; Van Der Jagt, R; Wells, G; Yetisir, E | 1 |
| Abruzzo, LV; Al-Quran, SZ; Lin, P; Medeiros, LJ; Olivares, A; Stephens, TW | 1 |
| Antonioli, E; Baccini, M; Bosi, A; Gianfaldoni, G; Leoni, F; Mannelli, F | 1 |
| Rokicka, M | 1 |
| Adamo, F; Amadori, S; Beeldens, F; Berneman, Z; de Witte, T; Fazi, P; Fillet, G; Jehn, U; Lefrère, F; Leone, G; Mandelli, F; Marie, JP; Montanaro, M; Muus, P; Nobile, F; Ricciuti, F; Rizzoli, V; Suciu, S; Thomas, X; Willemze, R | 1 |
| Hatoum, HA; Hudaib, AR; Mahfouz, RA; Otrock, ZK; Shamseddine, AI; Taher, AT | 1 |
| Creutzig, U; Dworzak, M; Graf, N; Hermann, J; Lehrnbecher, T; Niemeyer, CM; Reinhardt, D; Reiter, A; Ritter, J; Stary, J; Zimmermann, M | 1 |
| Li, JY; Qian, SX; Qiu, HR; Shen, RL; Wu, YJ; Zhang, JF; Zhang, SJ; Zhou, HF | 1 |
| Meehan, SA; Polsky, D; Scharf, S; Srivastava, M | 1 |
| Avvisati, G; Breccia, M; Carmosino, I; Cimino, G; Iorio, N; Latagliata, R; Lo-Coco, F; Mandelli, F; Minni, A; Petti, MC; Testi, A | 1 |
| Baek, JH; Kim, DH; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Sohn, SK; Yang, DH | 1 |
| Appelbaum, FR; Banker, DE; Beran, M; Chen, W; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Jackson, CE; Kornblau, SM; Lemker, E; Shen, D; Stirewalt, D; Verstovsek, S | 1 |
| Alvarez, C; Bolufer, P; Brunet, S; Colomer, D; Díaz-Mediavilla, J; Escoda, L; Esteve, J; González San Miguel, JD; González, M; Martín, G; Rivas, C; Rubio, V; Sánchez Godoy, P; Sanz, MA; Sayas, MJ; Tomás, JF; Tormo, M | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Albitar, M; Borthakur, G; Cortes, J; Faderl, S; Ferrajoli, A; Giles, FJ; Kantarjian, H; Kornblau, S; Pierce, S; Ravandi, F; Thomas, D; Verstovsek, S; Wierda, W | 1 |
| Baratè, C; Cafro, AM; Camaggi, CM; Intropido, L; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Strocchi, E; Tedeschi, A; Tresoldi, E | 1 |
| Du, X; Ke, XY; Liu, Y; Lu, ZS; Lv, JQ; Ma, J; Shen, ZX; Xu, XH; Zeng, XY; Zhan, ZM; Zhang, XH; Zhao, YM | 1 |
| Alimara, V; Bourantas, KL; Tsabouri, S; Tsiara, S; Vassiou, A | 1 |
| Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Ravandi, F; Thomas, D; Wierda, W | 1 |
| Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kirito, K; Mano, H; Matsuo, Y; Odgerel, T; Sato, Y; Tsunoda, S; Vu, HA | 1 |
| Amadori, S; Broccia, G; de Witte, T; Feremans, W; Fillet, G; Jehn, U; Leone, G; Meloni, G; Rio, B; Suciu, S; Thomas, X; Vignetti, M | 1 |
| Alfaro, EM; Alonso, CN; Baro, C; Corral, Mdel P; Felice, MS; Gallego, MS; Rossi, J; Solé, F; Villa, O | 1 |
| Amadori, S; Buccisano, F; Consalvo, MI; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Fraboni, D; Maurillo, L; Mazzone, C; Neri, B; Ottaviani, L; Panetta, P; Sarlo, C; Spagnoli, A; Tamburini, A; Venditti, A | 1 |
| Capelli, D; Discepoli, G; Leoni, P; Montanari, M; Offidani, M; Olivieri, A; Poloni, A; Troiani, E | 1 |
| Albarello, A; Bacigalupo, A; Balleari, E; Balocco, M; Carella, AM; Catania, G; Clavio, M; Gobbi, M; Manna, A; Michelis, G; Miglino, M; Pierri, I; Sessarego, M; Van Lint, MT; Varaldo, R; Vignolo, L | 1 |
| Boveri, E; Castagnola, C; Castello, A; Magrini, U | 1 |
| Breda, L; Chiarelli, F; De Sanctis, S; Di Marzio, D; La Barba, G; Rollo, V | 1 |
| Genev, ED; Grudeva-Popova, JG; Lazarova, A; Mumdjiev, IN; Spasova, MI; Stoyanova, AA | 1 |
| Amin, HM; Harb, AJ; Quintás-Cardama, A; Verstovsek, S | 1 |
| Caracciolo, F; Focosi, D; Galimberti, S; Papineschi, F; Petrini, M | 1 |
| Abruzzo, LV; Bobadilla, D; Cortes, J; Gibbons, DL; Kantarjian, H; Quintás-Cardama, A; Slovak, ML | 1 |
| Dastugue, N; Huguet, F; Ifrah, N; Jourdan, E; Perreau, V; Pigneux, A; Reiffers, J; Salmi, LR; Sotto, JJ; Vey, N | 1 |
| Chang, HJ; Cho, MS; Choi, MY; Kong, JH; Kwon, JM; Lee, KE; Lee, SM; Lee, SN; Mun, YC; Nam, E; Nam, SH; Seong, CM; Yoo, SH | 1 |
| Fujiwara, M; Higashimura, M; Izumi, N; Koike, T; Satou, N; Shibasaki, Y; Tsukada, N | 1 |
| Dölken, G; Flieger, D; Glasmacher, A; Hahn-Ast, C; Kirchner, H; von Lilienfeld-Toal, M | 1 |
| Büchner, T; Creutzig, U; Döhner, H; Reinhardt, D; Sauerland, MC; Schlenk, RF; Zimmermann, M | 1 |
| Beham-Schmid, C; Leithner, A; Linkesch, W; Radl, R; Ranner, G; Scheipl, S; Windhager, R | 1 |
| Asai, T; Chiba, S; Hangaishi, A; Kurokawa, M; Suzuki, HI; Tamaki, Z | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; D'Amato, F; De Angelo, DJ; Galinsky, I; Levine, J; McAfee, S; Miller, KB; Neuberg, D; Schenkein, D; Sirulnik, A; Stone, RM; Supko, JG; Trehu, EG; Wadleigh, M; Zahrieh, D | 1 |
| Hwang, SY; Kim, HJ; Kim, SH; Kim, TS; Song, JH | 1 |
| Adams, DJ; Giles, F; Jacobsen, TF; Myhren, F; Rizzieri, DA; Sandvold, ML | 1 |
| Craig, CM; Schiller, GJ | 1 |
| Hayakawa, M; Ichihashi, T; Iida, H; Iino, M; Kiyoi, H; Naoe, T; Narimatsu, H; Sawamoto, A; Sugiura, I; Suzuki, R; Takeo, T; Tsuzuki, M; Yanada, M; Yokozawa, T | 1 |
| Kulpraneet, M; Panichchob, P; Prayongratana, K; Tantisiriwat, W | 1 |
| Baker, N; Bosi, A; Dansey, R; Herrmann, R; Kassis, J; Lazzarino, M; Noga, SJ; Sierra, J; Szer, J; Thomas, X | 1 |
| Alptekin, M; Erkutlu, I; Kilciksiz, S; Okan, V; Pehlivan, M; Sari, I; Yilmaz, M | 1 |
| Candoni, A; Chiarvesio, A; Damiani, D; Fanin, R; Malagola, M; Martinelli, G; Michelutti, A; Piccaluga, PP; Russo, D; Simeone, E; Tiribelli, M; Toffoletti, E | 1 |
| Brandt, M; Estey, E; Freireich, EJ; Kantarjian, HM; Keating, MJ; Medeiros, LJ; O'Brien, S; Pierce, S; Tsimberidou, AM; Wen, S | 1 |
| Ito, T; Nakazawa, H; Saida, T; Uhara, H | 1 |
| Fladmark, KE; Gjertsen, BT; Hovland, R; Oveland, E; Selheim, F; Wergeland, L | 1 |
| Borowitz, MJ; Camitta, BM; Carroll, WL; Devidas, M; Gaynon, PS; Hunger, SP; Linda, SB; Raetz, EA; Winick, NJ | 1 |
| Borthakur, G; Estrov, Z; Faderl, S; Ferrajoli, A; Huang, X; Kantarjian, HM; Kwari, M; Ravandi, F; Verstovsek, S; Wierda, W | 1 |
| Asagoe, K; Matsuzawa, Y; Sakoda, H; Sugahara, H; Togashi, Y | 1 |
| Corallo, CE; Coutsouvelis, J | 1 |
| Belloc, F; Jeanneteau, M; Lacombe, F; Mahon, FX; Milpied, N; Pigneux, A; Reiffers, J; Uhalde, M | 1 |
| Borthakur, G; Estey, EH; Faderl, S; Gandhi, VV; Garcia-Manero, G; Kantarjian, H; Pierce, S; Plunkett, WK; Ravandi, F; Wang, X | 1 |
| López Carrizosa, MC; Ortiz Cruz, E; Rodríguez Pérez, A; Samper Ots, PM; Villalón Blanco, L | 1 |
| Fujita, N; Inaba, T; Nakatani, T; Nishimura, H; Saito, J; Uchiyama, H; Yamamoto, M; Yamane, Y | 1 |
| Ando, K; Kawada, H; Murayama, H; Nakamura, N; Ogawa, Y; Ohmachi, K; Suzuki, R; Tsuboi, K | 1 |
| Jones, RL; Kulkarni, S; Mehta, J; Morgan, G; Potter, M; Powles, R; Saso, R; Singhal, S; Sirohi, B; Smith, K; Swansbury, GJ; Treleaven, J | 1 |
| Berlanga, JJ; Besalduch, J; Brunet, S; Bueno, J; Esteve, J; Gallardo, D; Guardia, R; Heras, I; Hoyos, M; Llorente, A; Nomdedeu, J; Pérez-García, A; Ribera, JM; Sierra, J; Tormo, M | 1 |
| Chen, SG; Li, GY; Liu, JZ; Wang, CB; Wang, LX; Zhang, B | 1 |
| Alexander, C; Bashford, J; Jefferies, PD; Lee, GA; Whitehead, K | 1 |
| Demir, M; Oztürk, E; Pamuk, GE; Taşçi, M | 1 |
| Bellaaj, H; Elloumi, M; Kallel, C; Kammoun, H; Kassar, O; Sandi, HS | 1 |
| Cafro, AM; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Nosari, AM; Ricci, F; Tedeschi, A | 1 |
| Bae, SH; Joo, YD; Kim, H; Lee, JH; Lee, KH; Lee, WS; Mo Ryoo, H; Park, JH | 1 |
| Bandieri, E; Forghieri, F; Luppi, M; Maccaferri, M; Morselli, M; Potenza, L; Torelli, G; Volzone, F | 1 |
| Chen, LJ; Li, JY; Lu, H; Lu, RN; Qian, SX; Qiu, HX; Sheng, RL; Wu, HX; Xu, W | 1 |
| Brown, AW; McGregor, BA; Osswald, MB; Savona, MR | 1 |
| Buyukasik, Y; Goker, H; Ozcebe, OI; Sayinalp, N; Serefhanoglu, S | 1 |
| Hong, M; Li, JY; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, R | 1 |
| Bommana, V; Irani, F; Kasmani, R; Kumar, B; Mahajan, K; Mian, A | 1 |
| Cho, D; Kim, HJ; Kim, SH; Kim, TS; Lee, IK; Song, JH | 1 |
| Abebe, L; Einzig, A; Lee, SH; Paietta, E; Wiernik, PH | 1 |
| Borthakur, G; Cortes, J; Jones, D; Kantarjian, HM; Luthra, R; Rios, MB; Verma, D; Verstovsek, S | 1 |
| Ahn, JS; Chae, YS; Cho, YY; Choi, YJ; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Lee, SR; Shin, HJ; Sohn, SK; Yang, DH | 1 |
| Bargetzi, M; Dudler, C; Gratwohl, A; Passweg, JR; Tichelli, A; Wernli, M | 1 |
| Bhartia, S; Proctor, SJ; Sieniawski, M; Wilkinson, J | 1 |
| Altman, JK; Andreeff, M; Borthakur, G; Brandwein, J; Carter, BZ; Estey, EH; Hedley, DW; Jacob, C; Jolivet, J; Karp, JE; Kassis, J; LaCasse, E; Mak, DH; Morris, SJ; Schiller, GJ; Schimmer, AD; Tallman, MS; Xu, W | 1 |
| Candoni, A; Fanin, R; Malagola, M; Russo, D; Simeone, E; Tiribelli, M | 1 |
| Hara, T; Kitagawa, J; Moriwaki, H; Oyama, M; Tsurumi, H | 1 |
| Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P | 1 |
| Abboud, CN; Augustin, KM; Cashen, AF; Dipersio, JF; Goyal, S; Hladnik, L; Martin, MG; Monahan, RS; Reichley, RM; Stockerl-Goldstein, K; Tiwari, D; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Amadori, S; Baila, L; de Witte, T; Di Raimondo, F; Fazi, P; Ferrara, F; Labar, B; Liso, V; Mandelli, F; Marie, JP; Marmont, F; Meloni, G; Muus, P; Petti, MC; Stasi, R; Suciu, S; Thomas, X; Vignetti, M; Willemze, R; Zittoun, R | 1 |
| Cotta, CV; Khan, G; Pohlman, B; Sweetenham, J; Wesolowski, R | 1 |
| Agha, M; Boyiadzis, M; Foon, KA; Luong, TM; McHayleh, W; Natale, J; Raptis, A; Redner, RL; Schlesselman, JJ; Sehgal, R | 1 |
| Matsumura, I | 1 |
| Miyazaki, Y | 1 |
| Kakimoto, T; Matsuzawa, M; Mihara, A; Nakazato, T; Sanada, Y; Suzuki, K; Takahashi, Y; Watanabe, H; Yoshida, S | 1 |
| Hong, M; Li, JY; Lu, H; Qian, SX; Wu, HX; Xu, W | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y | 1 |
| Imanishi, D; Imoto, S; Kanamaru, A; Kobayashi, T; Kuriyama, K; Miyazaki, Y; Morita, Y; Naoe, T; Ohnishi, K; Ohno, R; Tanimoto, M; Yagasaki, F | 1 |
| Ahn, HS; Cho, B; Chung, NG; Hwang, TJ; Im, HJ; Kang, HJ; Kim, HK; Koo, HH; Kook, H; Lee, DH; Park, HJ; Seo, JJ; Shin, HY; Sung, KW; Yoo, KH | 1 |
| Asou, N; Handa, H; Kageyama, S; Kishimoto, Y; Kiyoi, H; Maeda, Y; Matsuda, S; Miyawaki, S; Miyazaki, Y; Nagai, T; Naoe, T; Ohnishi, K; Ohno, R; Ohtake, S; Okada, M; Okumura, H; Takahashi, M; Takeuchi, J; Yagasaki, F | 1 |
| Asano, H; Hangaishi, A; Hosoi, M; Kurokawa, M; Takahashi, T; Yamamoto, G | 1 |
| Dessalvi, P; Di Tucci, AA; Emanuele, A; Pettinau, M; Romani, C | 1 |
| Cho, EK; Lee, JH; Park, J; Shin, DB; Sym, SJ; Yi, HS | 1 |
| Bencini, S; Bosi, A; Gianfaldoni, G; Longo, G; Mannelli, F; Ponziani, V; Vannucchi, AM | 1 |
| Li, Y; Zhang, R; Zhang, XH | 1 |
| Cetin, CB; Ergene, U; Ozbalci, D | 1 |
| Aziz, A; Gosbell, IB; Sanghavi, R; Varghese, B | 1 |
| Andreeff, M; Bekele, BN; Borthakur, G; Brandt, M; Byrd, A; Cortes, JE; Estrov, Z; Faderl, S; Garcia-Manero, G; Jones, D; Kantarjian, HM; Konopleva, MY; Levis, M; Luthra, R; O'Brien, S; Pierce, SR; Pratz, K; Ravandi, F; Thomas, D | 1 |
| Arslan, M; Erkut, M; Erkut, N; Ersoz, S; Sonmez, M | 1 |
| Adiguzel, U; Erkayhan, G; Sari, A; Unal, S | 1 |
| Tallman, MS | 1 |
| Kato, J; Mori, T; Murata, M; Okamoto, S; Ono, Y; Shimizu, T; Sugita, K; Yamane, A | 1 |
| Betts, DR; Bourquin, JP; Bradtke, J; Creutzig, U; Dworzak, MN; Haas, OA; Reinhardt, D; Sander, A; Stary, J; von Neuhoff, C; Zemanova, Z; Zimmermann, M | 1 |
| Bene, MC; Berthou, C; Cahn, JY; Dreyfus, F; Escoffre-Barbe, M; Fegueux, N; Harousseau, JL; Himberlin, C; Hunault-Berger, M; Ifrah, N; Jourdan, E; Lioure, B; Lissandre, S; Luquet, I; Milpied, N; Pigneux, A; Recher, C; Reiffers, J; Sauvezie, M; Witz, F | 1 |
| Choi, MJ; Kim, HO; Kim, HS; Park, YM | 1 |
| Blinder, R; Chang, P; Galinsky, I; Ho, VT; Housman, E; Kesari, S; Lane, SW; Mullally, A; Stone, RM | 1 |
| Bakir, T; Bektaş, A; Cakar, B; Turgut, M; Ustaoğlu, M | 1 |
| Elonen, E; Itälä-Remes, M; Jantunen, E; Kinnunen, U; Koistinen, P; Nousiainen, T; Ohtonen, P; Räty, R; Remes, K; Silvennoinen, R; Syrjälä, H | 1 |
| Bourke, B; Cortelazzo, S; Piccin, A; Rovigatti, U; Smith, OP | 1 |
| Hsu, CH; Liu, CI | 1 |
| Bae, JY; Kim, BK; Kim, HK; Kim, I; Koh, Y; Lee, DS; Park, MH; Park, S; Park, SS; Song, EY; Yoon, SS | 1 |
| Andresen, S; Bolwell, B; Chan, J; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sproat, L; Sweetenham, J; Tench, S | 1 |
| Fong, C; Tong, M | 1 |
| Amadori, S; Avvisati, G; Borlenghi, E; Bosi, A; Breccia, M; Carella, AM; Cimino, G; Di Bona, E; Di Raimondo, F; Diverio, D; Fabbiano, F; Fazi, P; Ferrara, F; Fioritoni, G; Gallo, E; Lo-Coco, F; Mandelli, F; Martinelli, G; Paoloni, F; Peta, A; Petti, MC; Pogliani, EM; Rambaldi, A; Specchia, G; Vignetti, M | 1 |
| Celentano, M; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Riccardi, C | 1 |
| Aytac, S; Balci, YI; Cetin, M; Gumruk, F; Gurgey, A; Kuskonmaz, B; Tavil, B; Tuncer, M; Uckan, D; Unal, S; Yetgin, S | 1 |
| Allen, S; Galinsky, I; Hurd, D; Kolitz, JE; Larson, RA; Marcucci, G; Moser, B; Sanford, B; Schulman, P; Stock, W; Stone, RM; Vij, R | 1 |
| Asou, N; Fujieda, A; Fujita, H; Handa, H; Honda, S; Kimura, Y; Kiyoi, H; Miyamura, K; Miyawaki, S; Miyazaki, Y; Nagai, T; Nakaseko, C; Naoe, T; Ohnishi, K; Ohno, R; Ohtake, S; Okumura, H; Sakamaki, H; Shinagawa, K; Takahashi, M; Taniwaki, M; Usui, N; Yagasaki, F; Yamane, T | 1 |
| Altman, J; Kuzel, T; Parajuli, R; Perdekamp, M; Tallman, M | 1 |
| Jeraj, R; Juckett, MB; Nickles, RJ; Perlman, SB; Vanderhoek, M | 1 |
| Andreeff, M; Borthakur, G; Byrd, AL; Carter, BZ; Estey, E; Kantarjian, H; Konopleva, M; Mak, DH; Morris, SJ | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Thomas, DA; Verstovsek, S; Wright, JJ | 1 |
| Carrascosa, JM; Ferrándiz, C; Guinovart, RM | 1 |
| Appelbaum, FR | 1 |
| Ancliff, P; Darbyshire, P; Goulden, N; Green, N; Hancock, J; Leighton, C; Love, S; Masurekar, A; Moorman, AV; Morgan, M; Parker, C; Révész, T; Saha, V; Sutton, R; Waters, R | 1 |
| Farah, RA; Farhat, HZ; Jalkh, KS; Kadri, AM; Sayad, PE | 1 |
| Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Marui, Y; Sawa, N; Sumida, K; Suwabe, T; Takaichi, K; Takemoto, F; Tsuchiya, Y; Ubara, Y; Yamanouchi, M | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Foon, KA; Hou, JZ; Luong, TM; Mehta, DR; Raptis, A; Redner, RL; Schlesselman, JJ | 1 |
| Akiyama, N; Ayabe, T; Kawasugi, K; Nishi, R; Oka, Y; Shirafuji, N; Shirasaki, R; Shirota, M; Taguchi, A; Tashiro, H; Umezawa, K | 1 |
| Amri, A; Arguello, M; Borden, K; Cormack, G; Kraljacic, BC | 1 |
| Andrews, C; Baer, MR; Barcos, M; Baumann, H; Block, AW; Ford, LA; Nowak, NJ; Sait, SN; Tighe, S; Wang, ES; Wetzler, M | 1 |
| de Meis, E; Dobbin, JA; Emerenciano, M; Macedo-Silva, ML; Marschalek, R; Meyer, C; Pombo-de-Oliveira, MS | 1 |
| Baer, MR; Barcos, M; Block, AW; Ford, LA; Hyland, AJ; Licht, AS; Sait, SN; Varadarajan, R; Wang, ES; Wetzler, M | 1 |
| Bastida, J; Carretero, G; Medina, C; Santana, N; Valerón-Almazán, P; Vilar, J | 1 |
| Broome, HE; Curtin, PT; Dell'Aquila, ML; Rashidi, HH; Thorson, JA; Wang, HY | 1 |
| Baer, MR; Ball, ED; Borthakur, G; Cortes, J; Dipersio, J; Fernandez, HF; Goodman, M; Kantarjian, H; Kolitz, JE; Wetzler, M | 1 |
| Bozoglan, H; Ergene, U; Yoleri, L | 1 |
| Avvisati, G; Breccia, M; Candoni, A; Cimino, G; Di Raimondo, F; Fazi, P; Kropp, MG; Latagliata, R; Lo-Coco, F; Mandelli, F; Martinelli, G; Melillo, L; Petti, MC; Rupoli, S; Salvi, F; Sborgia, M; Tonso, A; Venditti, A; Vignetti, M; Vincelli, D | 1 |
| Solis, EC | 1 |
| Aoki, A; Miyazono, T; Saito, S; Sugiyama, T; Yoneda, N; Yoneda, S | 1 |
| Katayama, Y; Murayama, SY; Myoken, Y; Sugata, T | 1 |
| Abril, C; Al-Kali, A; Brandt, M; Cortes, J; Faderl, S; Jones, D; Kantarjian, H; Pierce, S; Ravandi, F | 1 |
| Baer, MR; Barcos, M; Block, AW; Ford, LA; Hyland, AJ; Lee, HJ; Licht, AS; Sait, SN; Wang, ES; Wetzler, M | 1 |
| Baro, J; Bermúdez, A; Colorado, M; Conde, E; Díez-Gallarreta, Z; Gutiérrez, ML; Insunza, A; Iriondo, A; López-Duarte, M; Olalla, I; Pérez-Vázquez, G; Richard, C; Sanroma, P; Yañez, L | 1 |
| Andreeff, M; Brandt, M; Cortes, J; Faderl, S; Garcia-Manero, G; Kadia, T; Kantarjian, H; Konopleva, M; Kornblau, S; Luthra, R; Patel, K; Pierce, S; Ravandi, F; Wang, X | 1 |
| Brizard, F; Canioni, D; Chomel, JC; Mayeur-Rousse, C; Randriamalala, E; Sorel, N; Turhan, AG; Voldoire, M | 1 |
| Cho, JH; Hur, M; Kim, WS; Ko, YS; Lee, MH; Moon, HW; Yun, YM | 1 |
| Fang, LW; Hu, NB; Pan, LJ; Qin, TJ; Wang, JZ; Xiao, ZJ; Xu, ZF; Zhang, HL; Zhang, Y | 1 |
| Giles, F; Jacobsen, TF; O'Brien, S; Ravandi, F; Rizzieri, D; Swords, R | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Cheong, JW; Kim, JS; Kim, SJ; Kim, Y; Min, YH; Yoon, S | 1 |
| Huang, TS; Lin, HW; Shih, SR; Yao, M | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Abbenante, MC; Astolfi, A; Baccarani, M; Candoni, A; Cattina, F; Damiani, D; Fanin, R; Ferrari, A; Formica, S; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Lonetti, A; Malagola, M; Martinelli, G; Michelutti, A; Ottaviani, E; Papayannidis, C; Parisi, S; Russo, D; Sazzini, M; Simeone, E | 1 |
| Ahn, KS; Kim, IW; Kim, KI; Kim, TK; Oh, JM; Shin, WG; Yoon, SS | 1 |
| Avery, S; Coutsouvelis, J; Lee, D; Low, M; Opat, S; Patil, S; Salem, H; Schwarer, A; Spencer, A; Walker, P; Wei, A | 1 |
| Rashidi, A; Roullet, MR | 1 |
| de Revel, T; Eddou, H; Foissaud, V; Konopacki, J; Malfuson, JV; Thepenier, C | 1 |
| Creutzig, U; Reinhardt, D; Sander, A; Von Neuhoff, C | 1 |
| Chi, M; Estey, E; Lin, A; McQuary, A; Othus, M | 1 |
| Chang, CS; Cho, SF; Liu, TC | 1 |
| Huh, J; Jung, CW; Kim, DH; Kim, H; Kim, HJ; Kim, SH; Kim, YK; Lee, WS; Min, WS; Moon, JH; Mun, YC; Park, J; Shin, MG; Sohn, SK; Won, JH | 1 |
| Ahn, HK; Jung, CW; Kim, DH; Kim, H; Kim, HJ; Kim, KH; Kim, SH; Kim, YK; Lee, KO; Lee, WS; Min, WS; Moon, JH; Mun, YC; Park, CH; Park, J; Sohn, SK | 1 |
| Chen, SN; Dai, HP; Gong, YL; Pan, JL; Wu, DP; Wu, LL; Wu, YF; Xue, YQ; Zhang, J | 1 |
| Agresta, S; Amrein, PC; Attar, EC; Ballen, KK; Borger, DR; Burke, M; Chen, YB; Edmonds, KM; Emadi, A; Fathi, AT; Foster, J; Hill, C; Iafrate, AJ; Lopez, HU; Matulis, CR; Neuberg, DS; Sadrzadeh, H; Schenkein, DP; Stone, RM; Straley, KS; Yen, KE | 1 |
| Cheong, JW; Hong, DS; Joo, YD; Kim, BK; Kim, CS; Kim, DY; Kim, H; Kim, I; Kim, MK; Kim, SH; Koh, Y; Lee, HK; Lee, JH; Lee, KH; Lee, SM; Min, YH; Park, E; Park, MR; Park, S; Park, SK; Sohn, SK; Won, JH; Yoon, SS | 1 |
| Garcia-Manero, G | 1 |
| Bacher, U; Bokemeyer, C; Fiedler, W; Haalck, T; Janjetovic, S; Janning, M | 1 |
| Abrahamsson, J; Forestier, E; Gustafsson, B; Ha, SY; Hasle, H; Heilmann, C; Heldrup, J; Jahnukainen, K; Jónsson, ÓG; Lausen, B; Palle, J; Wareham, NE; Zeller, B | 1 |
| Gisselbrecht, C | 1 |
| Chen, F; Fan, Z; Feng, R; Guo, X; Huang, F; Liu, X; Meng, F; Shi, P; Xu, B; Zha, J | 1 |
| Attal, M; Bérard, E; Bertoli, S; Dastugue, N; Delabesse, E; Demur, C; Dobbelstein, S; Duchayne, E; Huguet, F; Huynh, A; Laurent, G; Lauwers-Cances, V; Mansat-De Mas, V; Récher, C; Sarry, A; Tavitian, S; Vergez, F | 1 |
| Andre, V; Andreeff, M; Brandt, JT; Callies, S; Erba, HP; Juckett, M; Kadam, S; Lahn, M; Sayar, H; Schmidt, S; Van Bockstaele, D | 1 |
| Audisio, E; D'Ardia, S; Di Bello, C; Di Celle, PF; Frairia, C; Inghirami, G; Marmont, F; Messa, E; Pich, A; Riera, L; Sismondi, F; Toppino, D; Vitolo, U | 1 |
| Arioka, Y; Funato, T; Hara, T; Kawasoe, M; Markey, SP; Matsunami, H; Moriwaki, H; Okawa, K; Saito, K; Takeda, M; Takemura, M; Tsurumi, H; Yamamoto, Y | 1 |
| Cao, X; Cen, J; Chen, Z; Gu, W; Li, M; Liu, Y; Xiang, L; Xie, X; Zhen, X | 1 |
| Chen, B; Ouyang, J; Wang, J; Xu, JY; Yang, YG; Zhang, QG; Zhou, M; Zhou, RF | 1 |
| Li, XY; Li, Y; Wang, X | 1 |
| Aquino, S; Avenoso, D; Ballerini, F; Bergamaschi, M; Clavio, M; Colombo, N; Cruciani, F; De Astis, E; Ghiggi, C; Gobbi, M; Grasso, R; Guolo, F; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G | 1 |
| Creutzig, U; Dworzak, MN; Reinhardt, D; Ritter, J; Schellong, G; Zimmermann, M | 1 |
| Abe, T; Arihara, Y; Fujii, S; Fujita, M; Hirako, T; Jyomen, W; Kato, J; Kuroda, H; Maeda, M; Sakurai, T; Yamada, M | 1 |
| Falk, IJ; Fyrberg, A; Gréen, H; Hermanson, M; Höglund, M; Lotfi, K; Nahi, H; Palmqvist, L; Paul, E; Rosenquist, R; Stockelberg, D; Wei, Y | 1 |
| Andreeff, M; Borthakur, G; Brandt, M; Choi, S; Cortes, J; Daver, N; Du, M; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; Kornblau, S; Nazha, A; Pemmaraju, N; Ravandi, F | 1 |
| Dailey, ME; Gorgan, MA; Mar, N; Vredenburgh, JJ | 1 |
| Burnett, AK; Gibson, BE; Hills, RK; Hunter, AE; Kjeldsen, L; Milligan, D; Russell, NH; Wheatley, K; Yin, J | 1 |
| Ichikawa, M; Kobayashi, T; Kurokawa, M; Nannya, Y | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Handa, H; Hatsumi, N; Jimbo, T; Miyawaki, S; Nojima, Y; Saitoh, T; Sakura, T; Shimizu, H; Takada, S | 1 |
| Chen, XH; Gao, L; Gong, Y; Zhang, C; Zhang, X | 1 |
| Chang, CS; Hsiao, HH; Hsu, JF; Lin, SF; Liu, TC; Liu, YC; Lu, PL; Wu, CH | 1 |
| Fernández-Sojo, J; Oliveras Vilà, T; Ribera, JM; Vives, S | 1 |
| Asou, N; Emi, N; Horikawa, K; Iwanaga, M; Kimura, Y; Kishimoto, Y; Kiyoi, H; Matsuda, M; Monma, F; Nakaseko, C; Naoe, T; Ohtake, S; Okada, M; Ono, T; Shinagawa, K; Takahashi, M; Takeshita, A; Yamauchi, T | 1 |
| Bergeland, T; Blau, IW; Gianella-Borradori, A; Gjertsen, BT; Huguet-Rigal, F; Jacobsen, TF; Johansen, M; Kindler, T; Krauter, J; Krug, U; Rizzieri, D; Schlenk, RF; Thomas, X; Vey, N | 1 |
| Cui, J; Gao, S; Han, W; Li, W; Liu, X; Su, L; Tan, Y; Yu, P | 1 |
| Abraham, R; Barkoh, BA; Luthra, R; Medeiros, LJ; Mehrotra, M; Mishra, BM; Patel, KP; Ravandi, F; Sargent, RL | 1 |
| Andreeff, M; Arana Yi, C; Borthakur, G; Brandt, M; Cortes, JE; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Konopleva, M; Levis, M; Luthra, R; O'Brien, S; Pierce, S; Pratz, K; Ravandi, F; Thomas, D | 1 |
| Chung, NG; Jang, W; Kim, M; Lee, JW | 1 |
| Tohyama, K | 1 |
| Miyawaki, S | 1 |
| Jang, JH; Jung, CW; Jung, HA; Kim, K; Kim, SJ; Maeng, CH; Park, S | 1 |
| Bae, SH; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, KH; Lee, WS; Park, JH; Ryoo, HM | 1 |
| Cen, J; Li, C; Liu, X; Ma, Y; Mei, K; Qian, L; Shen, J; Wang, Y; Zhao, D | 1 |
| Baldini, L; Balzarotti, M; Bobbio, F; Brandes, AA; Ciceri, F; Corazzelli, G; Ferreri, AJ; Ilariucci, F; Montanari, M; Reni, M; Spina, M; Stelitano, C; Zaja, F | 1 |
| Cabrera, JR; de Laiglesia, A; de Pablo, R; Dorado, N; Forés, R; García-Marco, JA; Lario, A; Piris, M; Regidor, C; Vilches, C | 1 |
| Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Hong, SK; Kim, EC; Sung, JY | 1 |
| Brossart, P; Brugger, W; Derigs, HG; Döhner, H; Döhner, K; Gaidzik, VI; Göttlicher, M; Götze, K; Greil, R; Heil, G; Held, G; Horst, HA; Kirchen, H; Köhne, CH; Koller, E; Kremers, S; Matzdorff, A; Nachbaur, D; Paschka, P; Raghavachar, A; Ringhoffer, M; Schlenk, RF; Tassara, M; Wattad, M; Wulf, G | 1 |
| Iland, HJ; Seymour, JF; Wei, A | 1 |
| Desjonqueres, A; Eveillard, M | 1 |
| Adachi, S; Hamamoto, K; Hanada, R; Hayashi, Y; Horibe, K; Imaizumi, M; Kobayashi, R; Kudo, K; Miyamura, T; Morimoto, A; Moritake, H; Nakayama, H; Shimada, A; Tabuchi, K; Taga, T; Tawa, A; Tomizawa, D; Tsuchida, M; Tsukimoto, I; Yabe, H | 1 |
| Barber, L; Clay, J; Devlia, V; Feliu, J; Mufti, G; Pagliuca, A; Raj, K; Shaw, B | 1 |
| Adlard, K; Alonzo, TA; Ballard, J; Gamis, AS; Gerbing, RB; Horton, TM; Howard, DS; Jenkins, G; Kelder, A; Moscow, JA; Perentesis, JP; Schuurhuis, GJ; Smith, FO | 1 |
| Akhtari, M; Armitage, JO; Bhatt, VR; Bociek, RG; Dave, BJ; Kessinger, A; Sanger, WG; Sanmann, JN; Yuan, J | 1 |
| Bae, SH; Bang, SM; Cheong, JW; Han, BR; Jo, DY; Joo, YD; Kim, DY; Kim, HJ; Kim, KH; Kim, SJ; Kim, SY; Kim, YK; Kwak, JY; Lee, JH; Lee, JO; Lee, KH; Lee, MH; Lee, NR; Lee, WS; Maeng, CH; Min, YH; Moon, JH; Park, J; Ryoo, HM; Sohn, SK; Song, IC; Won, JH; Yoon, HJ; Zang, DY | 1 |
| Aldayel, AS; Konoplev, S; Medeiros, LJ; Rich, A; Sun, J; Yin, CC | 1 |
| Advani, AS; Appelbaum, FR; Copelan, E; List, AF; McDonough, S; Mulford, DA; Othus, M; Sekeres, MA; Willman, C | 1 |
| Bradstock, KF; Collins, M; Cull, G; Di Iulio, J; Enno, A; Hahn, U; Lewis, ID; Link, E; Marlton, P; Schwarer, A; Seymour, JF; Szer, J | 1 |
| Avvisati, G; Breccia, M; Carmosino, I; Chisini, M; Cimino, G; Colafigli, G; Finsinger, P; Foà, R; Girmenia, C; Latagliata, R; Lo-Coco, F; Minotti, C; Montagna, C; Petti, MC; Romano, A; Volpicelli, P; Vozella, F | 1 |
| Chen-Liang, TH; Florensa, L; Jerez, A; Ortuño, FJ | 1 |
| Chen, J; Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Wei, J; Yu, W | 1 |
| Drokov, MIu; Galstian, GM; Kessel'man, SA; Kliasova, GA; Kulikov, SM; Kuz'mina, LA; Obukhova, TN; Paramonova, EV; Parovichnikova, EN; Savchenko, VG; Sokolov, AN; Troitskaia, VV; Vasil'eva, VA | 1 |
| Gan, SL; Liu, YF; Sun, H; Tian, DH; Xie, XS; Xing, HZ | 1 |
| Basso, G; Beqiri, V; Bisio, V; Buldini, B; Fagioli, F; Locatelli, F; Manara, E; Masetti, R; Pession, A; Pigazzi, M; Putti, MC; Rizzari, C; Rondelli, R; Tregnago, C | 1 |
| Kotsianidis, I; Tsatalas, C | 1 |
| Ho, A; Lao, Z; Wong, GC; Yiu, R | 1 |
| Grimwade, D; Kayser, S; Schlenk, RF; Walter, RB; Yosuico, VE | 1 |
| Becker, PS; Chen, TL; Dean, C; Estey, EH; Hendrie, PC; Mawad, R; Pagel, JM; Sandhu, V; Scott, BL; Shadman, M; Shannon-Dorcy, K; Walter, RB | 1 |
| Brunet, S; Clapés, V; Guardia, R; Oriol, A; Piernas, S; Ribera, JM; Sierra, J; Subirà, M; Vives, S | 1 |
| Borthakur, G; Brandt, M; Cortes, J; Daver, N; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Wang, X | 1 |
| Bao, L; Huang, X; Jia, J; Jiang, B; Jiang, H; Jiang, Q; Lu, J; Wang, J; Yang, S; Zhang, Y; Zhao, T; Zhu, H | 2 |
| Menon, MP; Vidholia, A | 1 |
| Fan, X; Hu, J; Tang, W; Wang, L | 1 |
| Bae, SH; Choi, Y; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, KH; Lee, WS; Ryoo, HM | 1 |
| Bourquin, JP; Creutzig, U; Dworzak, M; Fleischhack, G; Graf, N; Gruhn, B; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Stray, J; von Neuhoff, C; von Stackelberg, A; Zimmermann, M | 1 |
| Boissel, N; Cluzeau, T; Devillier, R; Dombret, H; Kiladjian, JJ; Lengline, E; Raffoux, E; Rey, J; Robin, M; Ronchetti, AM; Sebert, M; Vey, N | 1 |
| Su, YZ; Sun, NT; Wang, CB; Zhou, Y | 1 |
| Brunet, S; Castro, N; Chillón, MC; Díez-Campelo, M; González, M; Herrera, P; López, J; Mateo, M; Mateos, MV; Montesinos, P; Ocio, EM; Olave, MT; Oriol, A; Pérez-Simón, JA; Prieto-Conde, MI; San Miguel, JF; Sanz, MÁ; Vidriales, MB | 1 |
| Anacak, Y; Aydinok, Y; Balkan, C; Delcastello, BE; Kamer, SA; Karadaş, N; Karapinar, DY; Kavakli, K | 1 |
| Baty, J; Chang, GS; Christopher, M; Demeter, RT; DiPersio, JF; Duncavage, EJ; Fronick, C; Fulton, R; Graubert, TA; Griffith, M; Griffith, OL; Heath, SE; Helton, NM; Hundal, J; Ketkar-Kulkarni, S; Klco, JM; Kulkarni, S; Lamprecht, TL; Larson, DE; Ley, TJ; Link, DC; Magrini, V; Mardis, ER; Miller, CA; O'Laughlin, M; Ozenberger, BA; Payton, JE; Petti, A; Radich, JP; Shen, D; Spencer, DH; Walter, MJ; Wartman, LD; Welch, JS; Westervelt, P; Wilson, RK | 1 |
| Blanco-Prieto, MJ; Castello-Cros, R; Cirauqui, C; Estella-Hermoso de Mendoza, A; Imbuluzqueta, E; Odero, MD; Pippa, R | 1 |
| Bezerra, MA; Bezerra, MF; de Assis, RA; de Mello, MR; Duarte, BK; Fernandes, E; Lima, AS; Lorand-Metze, I; Lucena-Araujo, AR; Machado, CG; Oliveira, MM; Pagnano, K; Ramos, CF; Souto, FR | 1 |
| Horinek, A; Korabecna, M; Koutova, L; Lysak, D; Pazourkova, E; Pospisilova, S; Sterbova, M; Svobodova, I | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Amadori, S; Baron, F; Bron, D; de Witte, T; Halkes, C; Meert, L; Muus, P; Selleslag, D; Suciu, S; Willemze, R | 1 |
| Boulinguez, S; Gadaud, N; Gladieff, L; Guenounou, S; Lamant, L; Masson Regnault, M; Recher, C; Roche, H; Sibaud, V; Tournier, E | 1 |
| Ahn, MS; Choi, JH; Choi, YW; Jeong, SH; Kang, SY; Lee, HW; Park, JS | 1 |
| Chen, J; Liu, Y; Shen, Y; Wu, D | 1 |
| Jamy, O; Martin, MG; Wiedower, E | 1 |
| Gou, H; Hu, X; Lu, X; Peng, W; Shang, M; Song, X; Ye, Y; Ying, B; Zhang, J; Zhao, Z; Zhou, J; Zhou, Y | 1 |
| Ardeshna, K; Badat, M; Cheesman, S; D'Sa, S; Joshi, R; Lambert, J; Linch, D; Maciocia, P; Mohamedbhai, S; Pule, M | 1 |
| Bochennek, K; Creutzig, U; Gilfert, J; Hassler, A; Lehrnbecher, T; Perner, C; Reinhardt, D; Schöning, S | 1 |
| Fang, L; Hu, N; Lin, Y; Pan, L; Qin, T; Qu, S; Ru, K; Wang, J; Xiao, Z; Xing, R; Xu, Z; Zhang, H; Zhang, Y | 1 |
| Çelik, Y; Maden, M; Pamuk, G; Ünlü, E | 1 |
| Cen, J; Qian, L; Shen, J; Yin, W; Zhou, C | 1 |
| Appelbaum, FR; Erba, H; Estey, E; Godwin, J; Mukherjee, S; Othus, M; Petersdorf, S; Sekeres, MA | 1 |
| Bacigalupo, A; Ballerini, F; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Miglino, M; Minetto, P; Pastori, G; Rebesco, B; Sessarego, M | 1 |
| Amador-Barciela, ML; Barrios, M; Benavente, C; Bergua, JM; Fernández-Abellán, P; García, R; García-Huerta, AJ; Herrera-Puente, P; Martinez-Cuadrón, D; Martínez-Sánchez, MP; Montesinos, P; Pérez-Encinas, M; Prieto-Fernandez, J; Riaza-Grau, R; Rodríguez-Macias, G; Rodríguez-Veiga, R; Sanz, MA; Sayas, MJ; Serrano, J; Simiele, A | 1 |
| Adam, H; Colle, J; Costello, R; Fanciullino, R; Farnault, L; Ivanov, V; Labiad, Y; Mercier, C; Suchon, P; Venton, G | 1 |
| Carrión Campo, R; Martínez Rubio, M; Moya Moya, MA; Rico Sergado, L; Saldaña Garrido, JD | 1 |
| Aoi, M; Kitamura, K; Sakurada, H; Sugimura, Y; Tachi, T; Teramachi, H; Yamamura, M; Yuge, M | 1 |
| Chen, Y; Hu, J; Liu, T; Yang, T; Yang, X; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Suo, SS; Tong, HY; Wei, JY; Yao, XM; Yu, WJ; Zhang, Y; Zhu, SL | 1 |
| Andreeff, M; Borthakur, G; Brandt, M; Cortes, J; Daver, N; DiNardo, C; Estrov, Z; Garcia-Manero, G; Huang, X; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, H; Konoplev, S; Konopleva, M; Pierce, S; Ravandi, F; Wang, S; Wang, X | 1 |
| Ding, K; Fu, R; Li, L; Liu, H; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wu, Y | 1 |
| Fridle, C; Manz, MG; Medinger, M; Pabst, T; Passweg, J; Seipel, K; Wilk, MC | 1 |
| Andreeff, M; Borthakur, G; Piya, S | 1 |
| Beltrão, EI; Benicio, MT; Bezerra, MA; Bezerra, MF; Coelho-Silva, JL; Lucena-Araujo, AR; Machado, CG; Nascimento, JC; Rego, EM; Rocha, CR | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; Bergeron, M; Blonquist, TM; Brunner, AM; Burke, M; Chen, YB; Connolly, C; Fathi, AT; Fishman, KM; Foster, J; Graubert, TA; Hermance, NM; Hobbs, G; Joseph, C; Manning, AL; McGregor, KL; Neuberg, DS; Perry, AM; Ramos, AY; Sadrzadeh, H; Silver, R; Som, TT; Supko, J; Wander, SA | 1 |
| Fischer, M; Fleischmann, M; Hilgendorf, I; Hochhaus, A; Schnetzke, U; Scholl, S; Spies-Weisshart, B; Walther, M | 1 |
| Non, LR; Pande, A; Romee, R; Santos, CA | 1 |
| Hu, C; Jin, J; Lin, P; Lou, Y; Luo, Y; Ma, L; Mai, W; Mei, C; Meng, H; Qian, J; Qian, W; Ren, Y; Tong, H; Wei, J; Xie, L; Xu, G; Xu, W; Ye, L; Ye, X; Zhou, X | 1 |
| Clavio, M; Gobbi, M; Guolo, F; Lemoli, RM; Miglino, M; Minetto, P | 1 |
| Braun, JT; Freter, CE; Lionberger, JM; Petruska, PJ; Ramlal, R; Schoen, MW; Woelich, SK | 1 |
| Heisel, RW; Lim, SH; Mascara, GP; Oleksiuk, LM; Sutton, RR; Weber, DR; Winger, DG | 1 |
| Ang, AL; Ho, LP; Ng, HJ; Ong, SY; Yeo, PM | 1 |
| Koyama, T; Shinki, H; Tsunaka, M | 1 |
| Balakrishnan, VS | 1 |
| Chen, P; Dong, X; Gu, L; Li, D; Shao, J; Xu, L; Yang, Y; Zhao, H | 1 |
| Bosi, A; Coltro, G; Guglielmelli, P; Mannelli, F; Pacilli, A; Vannucchi, AM | 1 |
| Brierley, CK; Eyre, TA | 1 |
| Borthakur, G; Brandt, M; Cortes, JE; Daver, NG; DiNardo, CD; Estrov, Z; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Konopleva, M; O'Brien, SM; Pemmaraju, N; Plunkett, W; Ravandi, F; Sasaki, K; Short, NJ; Wierda, WG; Xiao, L | 2 |
| Blijlevens, NMA; Kox, M; Leijte, GP; Pickkers, PP; Scheffer, GJ; Timmermans, K | 1 |
| Billingham, L; Brock, K; Copland, M; Siddique, S; Sirovica, M; Yap, C | 1 |
| Aqel, N; Ayto, R; Camilleri, M; Griffin, JC; Siow, W | 1 |
| Chen, K; Deng, M; Deng, S; Li, J; Li, P; Li, Y; Wang, Y; Xu, B; Zhang, L; Zhou, Y | 1 |
| Gu, MJ; Kim, MJ; Kim, MK; Kim, YK | 1 |
| Cen, J; Chen, S; Pan, J; Shao, H; Wu, C; Yang, Q | 1 |
| Albano, F; Carluccio, P; Casieri, P; Delia, M; Mestice, A; Pasciolla, C; Pastore, D; Ricco, A; Rossi, AR; Specchia, G | 1 |
| Damiani, D; Fanin, R; Michelutti, A; Tiribelli, M | 1 |
| Al Harthy, M; Gondek, LP; Murray, JC; Pallazola, VA; Webster, J; Zimmerman, SL | 1 |
| Evans, AG; Goorha, S; Hobbs, ALV; Leonard, JM; Mills, EL; Seligson, ND | 1 |
| Ballerini, F; Cagnetta, A; Carminati, E; Cea, M; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Matarese, S; Miglino, M; Minetto, P; Raiola, AM | 1 |
| Benavente, C; Bergua, J; Boluda, B; Cordón, L; Díaz-Beyá, M; Esteve, J; Garrido, A; Jiménez-Ubieto, A; Martínez, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Pérez-Simón, JA; Prieto-Delgado, J; Rodríguez-Veiga, R; Salamero, O; Sanz, MA; Sempere, A; Serrano, J; Vidriales, B; Vives, S | 1 |
| Baccarani, M; Candoni, A; Fanin, R; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Martinelli, G; Papayannidis, C; Simeone, E; Visani, G | 1 |
| Advani, AS; Appelbaum, FR; Erba, HP; Li, H; Liedtke, M; List, AF; Medeiros, BC; Michaelis, LC; O'Dwyer, K; Othus, M | 1 |
| Aragon-Miguel, R; Burillo-Martinez, S; Calleja-Algarra, A; Ortiz-Romero, PL; Prieto-Barrios, M; Rodriguez-Peralto, JL; Tous-Romero, F; Velasco-Tamariz, V; Zarco-Olivo, C | 1 |
| Barghout, SH; Chan, SM; Claudio, J; Gronda, M; Gupta, V; Heath, E; Hurren, R; Kamel-Reid, S; Kavanagh, S; Khalaf, D; Liyanage, SU; Lutynski, A; Maze, D; Minden, MD; Rostom, A; Rydlewski, A; Schimmer, AD; Schuh, AC; Sibai, H; Siriwardena, TP; Stockley, TL; Sukhai, M; Yee, K; Zhang, T | 1 |
| Amrolia, P; Breslin, P; Cummins, M; De La Fuente, J; Gassas, A; Gibson, B; Hiwarkar, P; Hough, R; James, B; Lawson, S; Patrick, K; Petterson, T; Potter, M; Shenton, G; Sivaprakasam, P; Skinner, R; Slatter, M; Veys, P; Vora, A; Wynn, R | 1 |
| Braun, JT; Fesler, MJ; Freter, CE; Lionberger, JM; Petruska, PJ; Reddy, DV; Schoen, MW; Woelich, SK | 1 |
| Cheng, Y; Guo, L; Ma, X; Yu, C; Zhang, Y; Zhu, S | 1 |
| Baer, MR; El Chaer, F; Law, JY; Mohindra, P; Singh, ZN; Zou, Y | 1 |
| Huang, WB; Li, MW; Lin, P; Wang, W; Yang, XN; Yao, HY | 1 |
| Andreeff, M; Bueso-Ramos, C; Cortes, JE; Coyle, M; Daver, N; DiNardo, CD; Futreal, PA; Garcia-Manero, G; Gumbs, C; Issa, GC; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, HM; Konopleva, M; Little, L; Morita, K; Patel, KP; Pemmaraju, N; Ravandi, F; Sasaki, K; Song, X; Takahashi, K; Thornton, R; Tippen, S; Wang, F; Wang, S; Yan, Y; Zhang, J | 1 |
| Arellano, M; Carlisle, JW | 1 |
| Ali, A; Burnett, AK; Cahalin, P; Freeman, S; Hills, RK; Hunter, A; Nielsen, OJ; Russell, NH; Thomas, IF | 1 |
| Della Pepa, R; Giordano, C; Grimaldi, F; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, P; Sirignano, C; Trastulli, F; Zacheo, I | 1 |
| Haack, K; Henderson, PT; Jonas, BA; Malfatti, MA; Pan, CX; Scharadin, TM; Turteltaub, KW | 1 |
| Dührsen, U; Hanoun, M; Noppeney, R; Westhus, J | 1 |
| Gourd, E | 1 |
| Aymerich, M; Bataller, A; Camós, M; Colomer, D; Díaz-Beyá, M; Esteve, J; Garrote, M; López-Guerra, M; Oliver-Caldés, A; Vega-García, N | 1 |
| Becker, H; Döhner, H; Döhner, K; Fiedler, W; Gaidzik, VI; Ganser, A; Götze, KS; Greil, C; Heuser, M; Janning, M; Kebenko, M; Könecke, C; Krauter, J; Lübbert, M; Neuhaus, B; Papkalla, A; Paschka, P; Reimer, P; Schlenk, RF; Thol, F; Verbeek, M; Wattad, M | 1 |
| Chen, B; Chen, D; Guan, C; Peng, M; Shao, X; Xie, P; Xu, P; Yuan, C | 1 |
| Ballesteros, J; Bergua, J; Colorado, M; García-Boyero, R; Gil, C; Gorrochategui, J; Hernández-Campo, P; Herrera, P; Jiménez-Bravo, S; Lavilla, E; Linares Gómez, M; López, JA; Martínez-Cuadrón, D; Martínez-López, J; Montesinos, P; Moscardó, F; Pérez-Oteyza, J; Pérez-Simón, JA; Primo, D; Rodríguez, G; Rojas, JL; Sanz, M; Serrano, J; Tormo, M; Troconiz, I; Vidriales, MB; Villoria, J; Vives, S | 1 |
| Abdalla, K; Abrar, MB; AlAzmi, AA; Elimam, N; Jastaniah, W; Mustafa, O | 1 |
| Alfayez, M; Boddu, PC; Borthakur, G; Cortes, J; Daver, NG; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Kadia, TM; Kantarjian, HM; Konopleva, M; Naqvi, K; Pierce, S; Ravandi, F; Short, NJ; Yilmaz, M | 1 |
| Ashizawa, M; Fujiwara, SI; Hatano, K; Kako, S; Kanda, Y; Kawaguchi, SI; Kawasaki, Y; Kimura, SI; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nagayama, T; Nakano, H; Ochi, SI; Oh, I; Ohmine, K; Sato, K; Shirato, Y; Toda, Y; Yamamoto, C; Yamasaki, R | 1 |
| Baskhaeva, GA; Davidiva, JO; Drokov, MY; Dvirnik, VN; Fidarova, ZT; Galtseva, IV; Gavrilina, OA; Kokhno, AV; Kulikov, SM; Kuzmina, LA; Kuznetsova, SA; Lobaova, TI; Loukianova, IA; Obukhova, TN; Parovichnikova, EN; Savchenko, VG; Sokolov, AN; Sudarikov, AB; Troitskaya, VV; Vasilyeva, VA | 1 |
| Cook, JR; Nomani, L; Rogers, HJ | 1 |
| Arnold, AJ; Gilmour, GS; Koch, MW | 1 |
| Choi, EJ; Jeon, M; Kang, YA; Lee, JH; Lee, KH; Lee, YS; Park, HS; Seol, M; Woo, JM | 1 |
| Farooq, A; Farooq, MU; Khan, DH; Mir, MA; Mushtaq, F | 1 |
| Guo, X; Zhang, X | 2 |
| Audisio, E; Boccadoro, M; Bruno, B; Candoni, A; Cerrano, M; Crisà, E; D'Ardia, S; Dubbini, MV; Ferrero, D; Zannier, ME | 1 |
| Abou Dalle, I; Andreeff, M; Borthakur, G; Bose, P; Cortes, J; Daver, N; DiNardo, C; Garcia-Manero, G; Kadia, T; Kantarjian, H; Konopleva, M; Loghavi, S; Naqvi, K; Nogueras González, GM; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Short, NJ; Yalniz, F; Yilmaz, M | 1 |
| Chen, Y; Cheng, N; Feng, Y; Lai, W; Liu, J; Zhang, L | 1 |
| Adès, L; Fenaux, P; Sébert, M | 1 |
| Barbon Gauro, J; Heng, MS; Thomas, J; Yaxley, A | 1 |
| Chung, W; Cui, J; Han, J; Heo, JY; Jang, Y; Ju, X; Kim, SJ; Kweon, GR; Lee, MJ; Lee, YL; Ryu, MJ; Son, JH; Song, IC | 1 |
| Alonso Domínguez, JM; Arquero, T; Atance, M; Chamizo, C; Piris, MA; Prieto-Torres, L; Requena, L; Rodriguez-Pinilla, SM; Salgado, RN; Soto, C | 1 |
| Aragüés, M; Chicharro, P; Fraga, J; Llamas-Velasco, M; Reolid, A; Rodríguez-Jiménez, P | 1 |
| Bian, Y; Huang, C; Ma, S; Ma, W; Miao, L; Miao, M; Xia, F; Yu, D | 1 |
| Abu Samra, M; Basara, N; Benner, A; Bentz, M; Döhner, H; Döhner, K; Fiedler, W; Gaidzik, VI; Ganser, A; Girschikofsky, M; Götze, K; Greil, R; Hertenstein, B; Heuser, M; Horst, HA; Kapp-Schwoerer, S; Kindler, T; Koller, E; Krauter, J; Krzykalla, J; Leis, C; Lübbert, M; Martens, U; Mayer, K; Nachbaur, D; Paschka, P; Schleicher, J; Schlenk, RF; Schroeder, T; Thol, F; Wattad, M; Weber, D; Wulf, G | 1 |
| Bang, SM; Byun, JM; Hong, J; Kim, I; Koh, Y; Lee, J; Lee, JO; Shin, DY; Suh, KJ; Yoon, SS | 1 |
| Brossart, P; Glasmacher, A; Hahn-Ast, C; Mayer, K; Schmidt-Wolf, IGH; Schwab, K; von Lilienfeld-Toal, M | 1 |
| Gong, L; Huang, X; Jia, J; Jiang, H; Jiang, Q; Lai, Y; Liu, K; Liu, X; Lu, R; Lu, S; Ruan, G; Shi, H; Wang, J; Wang, Y; Wu, Y; Xu, L; Yan, C; Zhang, X; Zhao, X | 1 |
| Bashey, A; Holland, HK; Morris, LE; Solh, MM; Solomon, SR; Zhang, X | 1 |
| Bohannon, L; Brander, D; Chan, C; Chao, N; de Castro, C; Diehl, L; Dillon, LW; Erba, H; Gadi, VK; Galal, A; Hourigan, CS; Jauhari, S; LeBlanc, T; Li, Z; Lyu, J; Meyer, E; Nixon, AB; Rao, AV; Rizzieri, DA; Shelby, R; Siamakpour-Reihani, S; Staats, J; Stefanovic, A; Sung, AD; Wong, HY; Xie, J | 1 |
| Aplenc, R | 1 |
| Chan, SY; Dang, CC; Guan, YK; Lau, NS | 1 |
| Capelli, D; Chiarucci, M; Discepoli, G; Fiorentini, A; Leoni, P; Menotti, D; Olivieri, A; Poloni, A; Saraceni, F | 1 |
| Angelov, D; Cotter, AG; Fay, M; Lambert, JS; McGettrick, P; McGinty, T; O'Kelly, B; Sheehan, G | 1 |
| Shi, T; Xie, W; Yang, X; Ye, X; Zhao, S; Zhu, J; Zhu, L | 1 |
| Kanaya, M; Kondo, T | 1 |
| Amberg, S; Bokemeyer, C; Christine Wilke, A; Chromik, J; Deppermann, U; Fiedler, W; Ganser, A; Heuser, M; Janning, M; Kebenko, M; Kranich, AL; Modemann, F; Schlipfenbacher, V; Serve, H; Theile, S; Thol, F | 1 |
| Deeren, D | 1 |
| Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X | 1 |
| Cheong, JW; Chung, H; Hyun, SY; Jang, JE; Kim, JS; Kim, SJ; Kong, JH; Lee, JI; Min, YH; Na, EJ; Shim, KY | 1 |
| Oniashvilli, N; Pasvolsky, O; Raanani, P; Rozovski, U; Rubinstein, M; Sela-Navon, M; Shargian-Alon, L; Wolach, O; Yahav, D; Yeshurun, M | 1 |
| Bankar, A; Bolster, L; Brandwein, JM; Hallett, D; Hamilton, M; Karkhaneh, M; Liew, E; Patterson, J; Saini, L; Taparia, M; Van Slyke, T; Wu, C; Zhu, N | 1 |
| Azar, MM; Pischel, L; Ringer, M | 1 |
| Deng, XH; Hu, YG; Lei, W; Li, XL | 1 |
| He, J; Wang, L; Yan, X | 1 |
| Anderson, LD; Awan, F; Bergstrom, CP; Chen, W; Chung, S; Collins, R; Dahiya, S; Kansagra, A; Madanat, Y; Patel, P; Ramakrishnan, P; Rizvi, S; Vusirkala, M; Yan, J; Zhang, CC; Zhu, H | 1 |
| Chen, XJ; Chen, YM; Guo, Y; Liu, F; Liu, LP; Liu, TF; Liu, XM; Quan Qi, B; Ruan, M; Yang, WY; Zhang, AL; Zhang, L; Zhu, XF; Zou, Y | 1 |
| Benitez, LL; Bixby, DL; Boyer, D; Burke, PW; Lee, W; Marini, BL; Perissinotti, AJ; Pettit, K; Reid, JH | 1 |
| Abedi, M; Hoeg, RT; Jonas, BA; Krishnan, R; Moskoff, BN; Rosenberg, AS; Tenold, ME; Tuscano, JM | 1 |
| Acuña-Cruz, E; Barragán, E; Bergua, JM; Boluda, B; Cano-Ferri, I; Martín-Herreros, B; Martínez Sánchez, MP; Martínez-Cuadrón, D; Martínez-López, J; Megías-Vericat, JE; Montesinos, P; Rodríguez-Veiga, R; Sanz, M; Sargas, C; Sempere, A; Serrano, A; Suárez-Varela, S; Torrent, A; Torres-Miñana, L; Vives, S | 1 |
| Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M | 1 |
| Davainis, L; Griskevicius, L; Maneikis, K; Peceliunas, V; Pileckyte, R; Staras, V; Trociukas, I; Vaitekenaite, V; Zucenka, A; Zvirblis, T | 1 |
| Chen, Q; Chen, Y; Hu, J; Li, J; Li, X; Mao, Y; Shen, Y; Sheng, Y; Wang, L; Weng, X; Wu, J; Wu, M; You, J; Zhang, Y; Zhao, H; Zheng, Y | 1 |
| Kuo, DJ; Le Floch, N; Spies, JM; Wong, V | 1 |
| Michaelis, LC | 1 |
| Burnett, A; Dennis, M; Hills, R; Kjeldsen, L; Russell, N | 1 |
| Ali, S; Burnett, AK; Cahalin, P; Clark, RE; Hills, RK; Kjeldsen, L; Russell, NH; Thomas, IF | 1 |
| Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Bravo, GM; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, SA; Xiao, L; Yilmaz, M | 1 |
| Elonen, E; Huhtala, H; Itälä-Remes, M; Jantunen, E; Kairisto, V; Kauppila, M; Koistinen, P; Koivunen, E; Kolonen, A; Kuittinen, T; Nousiainen, T; Ollikainen, H; Pelliniemi, TT; Penttilä, K; Porkka, K; Pyörälä, M; Räty, R; Rauhala, A; Rimpiläinen, J; Rintala, H; Ruutu, T; Säily, M; Sankelo, M; Silvennoinen, R; Sinisalo, M; Volin, L | 1 |
| Jiang, Y; Ye, Z | 1 |
| Al-Kali, A; Alkhateeb, H; Begna, KH; Chen, D; Elliott, MA; Gangat, N; Hogan, WJ; Hook, CC; Ketterling, RP; Litzow, MR; Mangaonkar, A; Pardanani, A; Patnaik, MS; Shah, M; Tefferi, A; Viswanatha, D | 1 |
| Ahn, MJ; Bae, SH; Bang, SM; Cho, EK; Choi, JH; Chong, SY; Hyun, MS; Jo, DY; Kim, B; Kim, BS; Kim, CS; Kim, DY; Kim, H; Kim, HJ; Kim, HS; Kim, I; Kim, SH; Kwon, H; Lee, JH; Lee, KH; Lee, MH; Lee, WS; Min, YJ; Moon, HN; Mun, YC; Nam, SH; Oh, D; Park, JH; Park, KT; Park, SY; Park, YH; Ryoo, HM; Seo, JJ; Seong, CM; Yoon, HJ; Yoon, SS; Zang, DY | 1 |
| Agrawal, N; Ahmed, R; Bansal, N; Bhurani, D; Halder, R; Mehta, P; Rainchwar, S; Singh, R; Verma, M | 1 |
| Alvarado, Y; Borthakur, G; Brandt, M; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, H; Ohanian, M; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Wang, X | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Chang, YJ; Gong, LZ; Huang, XJ; Jia, JS; Jiang, H; Jiang, Q; Liu, XH; Qin, YZ; Ruan, GR; Tang, FF; Wang, J; Wang, Y; Yu, WJ; Zhao, XS; Zhu, XL | 1 |
| Albano, F; Attolico, I; Carluccio, P; Contento, C; Delia, M; Di Gennaro, D; Gagliardi, VP; Musto, P | 1 |
| Bhojwani, D; Dao, J; Doan, A; Freyer, DR; Gaynon, P; Hadar, AJ; Huang, HKT; Kovach, AE; Malvar, J; Orgel, E; Parekh, C; Posch, LC; Raca, G; Rushing, T; Stokke, J | 1 |
| Feng, B; Fu, JF; Kan, WJ; Li, J; Li, JN; Liu, MM; Luo, GH; Song, N; Tu, YT; Wang, HL; Wei, G; Wu, WB; Xu, GY; Xu, R; Zhou, YB | 1 |
| Cenin, DA; Donald Harvey Iii, R; Kovacsovics, T; Kurish, HP; Lee, JS; Li, BKT; Lo, M; Patel, S; Prelewicz, S; Schlafer, D; Wagner, CB; Walchack, R; Wasef, B; Ying, J | 1 |
| Cao, J; Chen, Y; Dong, QF; Hu, JD; Li, F; Luo, LT; Sang, YQ; Wang, J; Wang, SL; Yang, T; Ye, YZ; Zhang, L; Zheng, J; Zheng, XY | 1 |
| Fredman, D; Gafter-Gvili, A; Raanani, P; Sherban, A; Shimony, S; Stahl, M; Wolach, O; Yeshurun, M | 1 |
| Bataller, A; Borthakur, G; Bose, P; Champlin, R; Daver, N; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Islam, R; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Marx, KR; Molica, M; Pemmaraju, N; Rausch, CR; Ravandi, F; Shpall, E; Tidwell, RS; Wang, S; Ylimaz, M | 1 |
| Abe, Y; Ishida, T; Kasai, Y; Kasuya, Y; Kikuchi, T; Nomura, M; Norihama, Y; Oda, Y; Ogura, M; Sato, K; Takei, T; Tsukada, N | 1 |
65 review(s) available for idarubicin and cytarabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Aggressive chemotherapy for acute leukemia relapsed after bone marrow transplantation: a second chance?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Time Factors; Vincristine | 1992 |
Idarubicin: an anthracycline antineoplastic agent.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Cytarabine; Drug Labeling; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1992 |
New drugs in acute myelogenous leukemia: a review.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Isomerism; Leukemia, Myeloid, Acute; Mitoxantrone; Remission Induction; Survival Rate; Tretinoin | 1992 |
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vidarabine | 1992 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
Idarubicin: a second-generation anthracycline.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Drug Evaluation; Humans; Idarubicin; Leukemia; Neoplasms; Remission Induction | 1991 |
Treatment of relapsed and refractory acute myeloid leukemia in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Remission Induction | 1989 |
Mobilisation of Ph-negative peripheral blood stem cells in CML with idarubicin and cytarabine.
Topics: Cell Separation; Cytarabine; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Transplantation, Autologous | 1994 |
Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results.
Topics: Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Survival Rate | 1995 |
Primary extramedullary leukemia of the prostate: case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Diagnostic Errors; Doxorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prostatectomy; Prostatic Neoplasms; Radioisotope Teletherapy; Remission Induction; Urinary Retention; Vincristine | 1996 |
New strategies for the treatment of acute promyelocytic leukaemia.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Remission Induction; Treatment Outcome; Tretinoin | 1997 |
A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
Topics: Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis | 1998 |
Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Glomerulosclerosis, Focal Segmental; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Proteinuria | 1998 |
Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Humans; Idarubicin; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Topotecan; Vidarabine | 1998 |
Idarubicin: a pharmacoeconomic evaluation of its use in adult patients with acute myeloid leukaemia.
Topics: Adult; Aged; Bone Marrow Transplantation; Cost-Benefit Analysis; Cytarabine; Drug Therapy, Combination; Drug Tolerance; Economics, Pharmaceutical; Formularies as Topic; Health Care Costs; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Treatment Outcome | 1993 |
Bilateral breast relapse in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine | 2001 |
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosome Inversion; Chromosomes, Human; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatomegaly; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Retrospective Studies; Splenomegaly; Survival Analysis; Translocation, Genetic; Treatment Outcome | 2001 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Etoposide; Female; Humans; Idarubicin; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin | 2001 |
AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Cytarabine; Disseminated Intravascular Coagulation; Female; Gestational Age; Humans; Idarubicin; Infant, Newborn; Leukemia, Promyelocytic, Acute; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Complications, Neoplastic; Remission Induction; Risk; Tretinoin | 2002 |
[Acute myelogenous leukemia associated with severe esophageal stricture after chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Esophageal Stenosis; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2002 |
Troxacitabine-based therapy of refractory leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Cytosine; Dioxolanes; Humans; Idarubicin; Leukemia; Remission Induction; Topotecan | 2002 |
Primary granulocytic sarcoma of the urinary bladder: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Doxorubicin; Fatal Outcome; Humans; Idarubicin; Male; Methotrexate; Sarcoma, Myeloid; Urinary Bladder Neoplasms; Vinblastine | 2002 |
[Experience with fludarabine treatment and review of the literature].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Remission Induction; Treatment Outcome; Vidarabine | 2002 |
Central nervous system relapse in acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Methotrexate; Tretinoin | 2002 |
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Clinical Trials as Topic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; France; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2003 |
Acute myelogenous leukemia in an adult with thrombocytopenia with absent radii syndrome.
Topics: Abnormalities, Multiple; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cytarabine; Cytokines; Female; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Menorrhagia; Neoplasm Proteins; Platelet Count; Proto-Oncogene Proteins; Radius; Receptors, Cytokine; Receptors, Thrombopoietin; Recurrence; Remission Induction; Risk; Syndrome; Thrombocytopenia | 2003 |
Non-hodgkins lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Idarubicin; Ifosfamide; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Prednisolone; Prednisone; Vincristine | 2003 |
Acute myeloblastic leukemia in pregnancy: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third | 2004 |
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cladribine; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Piperazines; Prospective Studies; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2004 |
Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Remission Induction | 2007 |
Long-term propylthiouracil use and acute myeloid leukemia: a case report and review of the literature.
Topics: Adult; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 21; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Iodide Peroxidase; Leukemia, Myeloid, Acute; Peroxidase; Propylthiouracil; Remission Induction; Time Factors; Translocation, Genetic; Transplantation, Homologous | 2008 |
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
Acute monoblastic leukemia with t(10;11)(p12;q23) presenting with pulmonary involvement: a case report and literature review.
Topics: Adult; Antibiotics, Antineoplastic; Antifungal Agents; Antimetabolites, Antineoplastic; Aspergillosis, Allergic Bronchopulmonary; Bronchoalveolar Lavage; Caspofungin; Cytarabine; Echinocandins; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Monocytic, Acute; Lipopeptides; Lung Neoplasms; Male; Pyrimidines; Thailand; Triazoles; Voriconazole | 2008 |
[Klinefelter syndrome and acute myeloblastic leukaemia].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 8; Cytarabine; Cytogenetics; Genetic Predisposition to Disease; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Karyotyping; Klinefelter Syndrome; Leukemia, Myeloid, Acute; Male; Trisomy | 2009 |
The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Etoposide; Fatal Outcome; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Mitoxantrone; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Remission Induction; Reoperation; Salvage Therapy; Vidarabine; Vincristine; Young Adult | 2009 |
Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Time Factors; Young Adult | 2009 |
[Standard therapies for acute myeloid leukemia].
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenites; Cytarabine; Daunorubicin; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Remission Induction | 2009 |
[Acute myeloid leukemia trials by Japan Adult Leukemia Study Group (JALSG)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Evidence-Based Medicine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Young Adult | 2009 |
Granulocytic sarcoma of abdomen in acute myeloid leukemia patient with inv(16) and t(6;17) abnormal chromosome: case report and review of literature.
Topics: Abdominal Neoplasms; Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 6; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Remission Induction; Sarcoma, Myeloid; Translocation, Genetic | 2010 |
[Acute myelogenous leukemia developed at the 26th week of gestation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Cytarabine; Female; Humans; Idarubicin; Infant, Low Birth Weight; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pregnancy Trimester, Second; Remission Induction | 2011 |
Therapy-related acute leukemia with mixed phenotype and t(9;22)(q32;q11.2): a case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Back; Benzamides; Bone Marrow; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Endometrial Neoplasms; Female; Gene Rearrangement; Genes, abl; Humans; Idarubicin; Imatinib Mesylate; Immunophenotyping; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Soft Tissue Neoplasms; Submandibular Gland Neoplasms; Translocation, Genetic | 2012 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
Relapse of acute myeloid leukemia at the pituitary gland: a case report and review of literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Diabetes Insipidus; Etoposide; Female; Humans; Hypopituitarism; Idarubicin; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Methotrexate; Pituitary Neoplasms; Radiotherapy; Recurrence; Remission Induction; Vision Disorders | 2012 |
High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gastrointestinal Tract; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Cytarabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Idarubicin; Leukemia, Myeloid, Acute; Vorinostat | 2012 |
Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Therapy; Etoposide; Gene Expression Profiling; Humans; Idarubicin; Lymphoma, Large B-Cell, Diffuse; Medical Oncology; Prognosis; Recurrence; Rituximab; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2012 |
Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Publication Bias; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Development of a curative treatment within the AML-BFM studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Methotrexate; Multicenter Studies as Topic; Prednisone; Randomized Controlled Trials as Topic; Survival Rate; Thioguanine; Vincristine | 2013 |
[Acute promyelocytic leukemia presenting with central nervous system involvement at initial diagnosis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Central Nervous System Neoplasms; Cytarabine; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Invasiveness; Treatment Outcome; Tretinoin | 2013 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
[Current therapy for acute myeloid leukemia and acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Discovery; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Molecular Targeted Therapy; Mutation; Recurrence; Tretinoin; Vincristine | 2014 |
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Hydroxyurea; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Platelet Transfusion; Practice Guidelines as Topic; Remission Induction; Risk Assessment; Thioguanine; Treatment Outcome; Tretinoin | 2014 |
Myelomastocytic leukemia with aberrant CD25 expression: case report and review of the literature.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Brain; Cerebral Hemorrhage; Cytarabine; Fatal Outcome; Humans; Hydroxamic Acids; Idarubicin; Interleukin-2 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mast Cells; Middle Aged; Neoplasms, Second Primary; Neoplastic Stem Cells; Opportunistic Infections; Prostatectomy; Prostatic Neoplasms; Vorinostat | 2014 |
Minimal residual disease-directed therapy in acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Oncogene Proteins, Fusion; RUNX1 Translocation Partner 1 Protein | 2015 |
Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Eruptions; Female; Humans; Hyperpigmentation; Idarubicin; Lomustine; Male; Middle Aged; Paclitaxel; Vincristine | 2015 |
Pseudozyma and other non-Candida opportunistic yeast bloodstream infections in a large stem cell transplant center.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cryptococcus; Cytarabine; Dermatomycoses; Echinocandins; Exanthema; Fever; Fungemia; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipopeptides; Male; Micafungin; Opportunistic Infections; Retrospective Studies; Saccharomyces; Salvage Therapy; Trichosporon; Ustilaginales; Vidarabine; Voriconazole; Yeasts | 2017 |
How I treat older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous | 2018 |
Leukemic Vasculitis: Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow Transplantation; Colitis, Ulcerative; Cytarabine; Diagnosis, Differential; Erythema; Female; Humans; Idarubicin; Immunohistochemistry; Leg Dermatoses; Leukemia, Myeloid, Acute; Leukemic Infiltration; Mesalamine; Skin Neoplasms; Transplantation Conditioning; Treatment Outcome; Vasculitis | 2019 |
Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cladribine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2020 |
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Safety; Survival Analysis; Topoisomerase II Inhibitors; Treatment Outcome; United States; Young Adult | 2020 |
Clinical characteristics and management of primary granulocytic sarcoma of the oral cavity: A case report and literature review.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Idarubicin; Middle Aged; Mouth; Mouth Neoplasms; Remission Induction; Sarcoma, Myeloid | 2020 |
Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Asian People; Consolidation Chemotherapy; Cytarabine; Decitabine; Drug Therapy, Combination; Female; Hospitalization; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Treatment Outcome; Tretinoin | 2020 |
Is there an optimal adjunct therapy to traditional cytotoxic induction?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction | 2021 |
Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2023 |
239 trial(s) available for idarubicin and cytarabine
| Article | Year |
|---|---|
Intensive induction chemotherapy in elderly patients. The BGMT Group.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged | 1992 |
Autologous bone marrow transplantation vs intensive chemotherapy in first complete remission: interim results of GOELAM study in AML.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; France; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Analysis; Transplantation, Autologous | 1992 |
Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience.
Topics: Age Factors; Aged; Aged, 80 and over; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Daunorubicin; Drug Administration Schedule; Feasibility Studies; Humans; Idarubicin; Infusions, Intravenous; Italy; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Thioguanine | 1992 |
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome | 1992 |
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocytosis; Male; Middle Aged; Remission Induction | 1992 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine | 1991 |
Idarubicin plus ARA-C followed by allogeneic or autologous bone marrow transplantation in advanced acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Humans; Idarubicin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Remission Induction; Transplantation, Autologous; Transplantation, Homologous | 1991 |
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Probability | 1991 |
Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Humans; Idarubicin; Infant; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 1990 |
Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1989 |
A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Remission Induction | 1989 |
Idarubicin in acute leukaemia. GIMEMA Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Multicenter Studies as Topic; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1989 |
Idarubicin in acute leukemia: results of US trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute | 1989 |
Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Random Allocation; Remission Induction | 1989 |
A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Remission Induction | 1989 |
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1989 |
Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatmen
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Europe; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pilot Projects; Prognosis; Prospective Studies; Survival Analysis | 1995 |
Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR- cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged | 1994 |
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Vidarabine | 1993 |
Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; HLA-DR Antigens; Humans; Idarubicin; Interferon-alpha; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Treatment Outcome | 1994 |
Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Interleukin-2; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1993 |
Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results.
Topics: Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Survival Rate | 1995 |
Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marrow Diseases; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Neoplasms; Prospective Studies; Radiotherapy; Remission Induction; Salvage Therapy; Treatment Outcome | 1994 |
Pre-treatment with all-trans retinoic acid accelerates polymorphonuclear recovery after chemotherapy in patients with acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hematopoiesis; Humans; Idarubicin; Immunologic Factors; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytosis; Male; Middle Aged; Neutrophils; Platelet Count; Premedication; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin | 1994 |
MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: an update.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cytarabine; Daunorubicin; Drug Resistance; Female; Follow-Up Studies; Gene Expression; Humans; Idarubicin; Leukemia, Myeloid; Male; Membrane Glycoproteins; Middle Aged; Prognosis; Remission Induction; RNA, Neoplasm; Survival Rate; Treatment Outcome | 1993 |
Comparison of survival. Chemotherapeutically treated and untreated older patient with acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Sex Factors; Survival Rate; Thioguanine | 1994 |
[Results of induction treatment with idarubicin for acute nonlymphoblastic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome | 1994 |
Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Survival Analysis | 1994 |
Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Drug Therapy; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Time Factors; Tretinoin | 1994 |
[A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Electrocardiography; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1993 |
Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid; Male; Remission Induction; Thioguanine | 1994 |
Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Rate | 1993 |
Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction; Survival Analysis | 1993 |
Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Remission Induction; Survival Analysis | 1993 |
[Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1993 |
Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Survival Analysis; Vincristine | 1993 |
Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neutropenia; Pilot Projects; Remission Induction; Survival Rate | 1996 |
The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. GIMEMA Cooperative Group, Italy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Male; Methotrexate; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Analysis; Survival Rate | 1996 |
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Topics: Acute Disease; Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged | 1996 |
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Rate | 1996 |
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Prognosis; Proportional Hazards Models; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous | 1996 |
Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor. (GM-CSF).
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Drug Synergism; Drug Therapy, Combination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Risk Factors | 1996 |
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome | 1996 |
Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Interleukin-3; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Philadelphia Chromosome | 1996 |
Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Risk Factors; Salvage Therapy | 1996 |
Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.
Topics: Adult; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cerebral Hemorrhage; Cohort Studies; Cytarabine; Disseminated Intravascular Coagulation; Fatal Outcome; Female; Germinoma; Hemorrhage; Humans; Idarubicin; Incidence; Infarction; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Melanoma; Middle Aged; Myocardial Infarction; Neoplasms, Multiple Primary; Remission Induction; Retrospective Studies; Spleen; Thrombosis; Treatment Outcome; Tretinoin | 1996 |
Anthracycline drugs and MDR expression in human leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
Topics: Adolescent; Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Data Interpretation, Statistical; Daunorubicin; Electrocardiography; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1996 |
Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction | 1996 |
Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction | 1996 |
Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Taiwan | 1996 |
Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Réflexion en Hématologie.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Prospective Studies; Remission Induction | 1997 |
Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Prospective Studies | 1997 |
Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Agranulocytosis; Antibiotics, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Nausea; Remission Induction; Thrombocytopenia; Treatment Outcome; Vomiting | 1997 |
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Filgrastim; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1997 |
Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prospective Studies; Recurrence; Survival Analysis; Survival Rate; Treatment Outcome | 1997 |
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Prognosis; Remission Induction | 1997 |
ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Infant; Leukocyte Count; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prospective Studies; Recurrence; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 1997 |
Peripheral blood progenitor cell mobilisation in patients with multiple myeloma following oral idarubicin and dexamethasone (Z-Dex) induction therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Male; Mesna; Middle Aged; Multiple Myeloma; Remission Induction | 1997 |
Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hematologic Neoplasms; Humans; Idarubicin; Lymphoproliferative Disorders; Male; Middle Aged | 1998 |
[Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
Topics: Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1998 |
A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1998 |
A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Over Studies; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence | 1998 |
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Chemotherapy, Adjuvant; Creatinine; Cyclosporine; Cytarabine; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Treatment Outcome | 1998 |
IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Remission Induction; Vidarabine | 1998 |
Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gene Rearrangement; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome | 1998 |
Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease Progression; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 1998 |
Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis | 1998 |
Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Heart Diseases; Hematologic Diseases; Humans; Idarubicin; Italy; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Proportional Hazards Models; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Survival Rate | 1998 |
Management of advanced acute lymphoblastic leukemia in children and adults: results of the ALL R-87 protocol. AIEOP and GIMEMA Cooperative Groups.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Infant; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1998 |
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Probability; Prognosis; Survival Rate; Time Factors; Tretinoin; Vidarabine | 1999 |
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with
Topics: Acute Disease; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Double-Blind Method; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Pilot Projects; Transplantation, Autologous | 1999 |
GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Analysis; Vidarabine | 1999 |
A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Survival Rate | 1999 |
The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Middle Aged; Multivariate Analysis; Remission Induction; Treatment Outcome | 1999 |
Therapy of molecular relapse in acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Middle Aged; Mitoxantrone; Neoplasm Proteins; Oncogene Proteins, Fusion; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Survival Analysis; Time Factors; Tretinoin | 1999 |
Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index Ci.
Topics: Adult; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cell Survival; Cytarabine; Danazol; Drug Screening Assays, Antitumor; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Predictive Value of Tests; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Analysis; Tamoxifen; Vidarabine | 1999 |
Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Fever of Unknown Origin; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Recombinant Proteins; Recurrence; Vidarabine | 1999 |
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Immunotherapy; Interleukin-2; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate | 2000 |
High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Salvage Therapy; Survival Analysis | 2000 |
Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
Topics: Adolescent; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Marrow Transplantation; Central Nervous System Neoplasms; Child; Child, Preschool; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Injections, Spinal; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Vincristine | 2000 |
Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Transplantation, Autologous | 2000 |
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Predictive Value of Tests; Recurrence; Risk; Thioguanine; Tretinoin | 2000 |
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Idarubicin; Immunosuppressive Agents; Immunotherapy, Adoptive; Male; Melphalan; Pilot Projects; Transplantation Conditioning; Vidarabine | 2000 |
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
Topics: Acute Disease; Adolescent; Adult; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Chromosomes, Human; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Remission Induction; Risk; Survival Analysis; Translocation, Genetic; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2000 |
Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Prospective Studies; Survival Rate; Treatment Outcome | 2000 |
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Treatment Outcome | 2001 |
High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Remission Induction; Survival Rate; Treatment Outcome | 2001 |
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Risk Factors; Survival Rate | 2001 |
Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Melphalan; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Factors; Transplantation, Homologous; Whole-Body Irradiation | 2001 |
Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Pancytopenia; Pilot Projects; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Vidarabine | 2001 |
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2001 |
Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
Topics: Acute Disease; Adjuvants, Immunologic; Adult; Cost-Benefit Analysis; Cytarabine; Female; Glycosylation; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Recombinant Proteins; Survival Rate | 2001 |
Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Interferon-alpha; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome | 2001 |
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous; Transplantation, Homologous | 2001 |
[Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75) (a prospective multicenter randomized study conducted 1998-2000].
Topics: Acute Disease; Aged; Antineoplastic Agents; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prospective Studies; Remission Induction; Survival Rate | 2001 |
Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Platelet Count; Survival Rate | 2001 |
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine | 2001 |
Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Male; Maximum Tolerated Dose; Middle Aged; Salvage Therapy; Treatment Outcome | 2002 |
All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Therapeutic Equivalency; Treatment Outcome; Tretinoin | 2002 |
Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Platelets; Cell Count; Cytarabine; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Megakaryocytes; Middle Aged; Thrombopoietin; Time Factors | 2002 |
Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Recombinant Proteins; Survival Rate; Treatment Outcome | 2002 |
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Cytarabine; Drug Therapy, Combination; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Infusions, Parenteral; Interleukin-11; Leukemia, Myeloid; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Therapeutic Equivalency | 2002 |
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Amifostine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome | 2002 |
A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate | 2002 |
FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infections; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Vidarabine | 2002 |
A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cognition; Conjunctivitis; Cytarabine; Dose-Response Relationship, Drug; Female; Fever; Heart; Hematemesis; Humans; Idarubicin; Male; Middle Aged; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Analysis; Treatment Outcome | 2002 |
Peripheral blood stem cell collection in children with acute leukemia: effectiveness of the 'DIAVE' mobilizing regimen.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Child; Child, Preschool; Cytarabine; Dexamethasone; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia; Peripheral Blood Stem Cell Transplantation; Vincristine | 2002 |
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow
Topics: Adolescent; Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Child; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hemorrhage; Humans; Idarubicin; Infections; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Middle Aged; Remission Induction; Treatment Outcome; Vomiting | 2002 |
Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Tretinoin | 2003 |
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 2003 |
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2003 |
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytosine; Dioxolanes; Female; Humans; Idarubicin; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Survival; Treatment Outcome | 2003 |
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis | 2003 |
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aminoglycosides; Amsacrine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cohort Studies; Cytarabine; Doxorubicin; Etoposide; Feasibility Studies; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Pilot Projects; Remission Induction; Thioguanine; Vidarabine | 2003 |
Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Bromodeoxyuridine; Central Nervous System Neoplasms; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Infusions, Intravenous; Lymphoma; Male; Methotrexate; Middle Aged; Treatment Outcome | 2003 |
Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Child; Cytarabine; Etoposide; fas Receptor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Leukocytes, Mononuclear; Lymphocyte Depletion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Treatment Outcome | 2003 |
Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Rate | 2003 |
More efficient mobilisation of peripheral blood stem cells with HiDAC+AMSA+G-CSF than with mini-ICE+G-CSF in patients with AML.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Caspase 14; Caspases; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Transplantation, Autologous | 2003 |
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Thioguanine; Treatment Outcome | 2004 |
The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Idarubicin; Lymphoma; Male; Methotrexate; Middle Aged; Pilot Projects; United Kingdom | 2004 |
Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Patient Selection; Recurrence; Statistics, Nonparametric; Survival Rate; Thioguanine; Time Factors | 2004 |
Risk-adapted induction and consolidation therapy in adults with de novo AML aged
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Risk Assessment; Stem Cell Transplantation; Survival Analysis | 2004 |
Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Humans; Idarubicin; Middle Aged; Mouth Mucosa; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2004 |
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Survival Rate; Treatment Outcome | 2004 |
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Treatment Outcome | 2005 |
Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Mitoxantrone; Proportional Hazards Models; Remission Induction; Transplantation, Autologous | 2004 |
Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Thrombocytopenia | 2004 |
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacteremia; Bone Marrow Neoplasms; Child; Child, Preschool; Cytarabine; Dexamethasone; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Ifosfamide; Infant; Infusions, Intravenous; Leucovorin; Male; Mesna; Methotrexate; Mouth Mucosa; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Stomatitis; Thioguanine; Treatment Outcome; Vincristine | 2004 |
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous; Tretinoin | 2004 |
A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Drug Interactions; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Leukemia; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2005 |
Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2005 |
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Remission Induction; Tretinoin | 2005 |
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Interleukin-11; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Analysis | 2005 |
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Survival Rate; Treatment Outcome | 2005 |
Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Bone Marrow Transplantation; Cause of Death; Child; Child, Preschool; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Poland; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2005 |
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult L
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Probability; Remission Induction; Risk Assessment; Treatment Outcome; Vincristine; Vindesine | 2005 |
Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Data Interpretation, Statistical; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Greece; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Societies, Medical; Survival Analysis; Treatment Outcome | 2006 |
Remission induction chemotherapy induces in vivo caspase-dependent apoptosis in bone marrow acute myeloid leukemia blast cells and spares lymphocytes.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Marrow Transplantation; Caspases; Cell Count; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Leukocyte Common Antigens; Leukocyte Count; Lymphocytes; Male; Middle Aged; Prognosis; Remission Induction | 2006 |
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Female; Hematologic Diseases; Humans; Idarubicin; Life Tables; Lymphoma, Non-Hodgkin; Male; Meningeal Neoplasms; Methotrexate; Middle Aged; Radiotherapy, Adjuvant; Remission Induction; Stroke; Survival Analysis; Thiotepa | 2006 |
Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Time Factors | 2006 |
Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Intravenous; Length of Stay; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Pancytopenia; Patient Compliance; Risk Factors | 2006 |
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cranial Irradiation; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Infections; Leukemia, Myeloid; Male; Mitoxantrone; Neutropenia; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Remission Induction; Survival Analysis | 2007 |
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholesterol; Cytarabine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pravastatin; Safety | 2007 |
Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Oncogene Proteins, Fusion; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Time Factors; Treatment Outcome; Tretinoin | 2007 |
High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Survival Analysis | 2007 |
[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cyclophosphamide; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mucositis; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Treatment Outcome; Vincristine | 2006 |
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Recombinant Proteins; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison
Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Survival Analysis; Treatment Outcome; Vidarabine | 2007 |
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lomustine; Male; Middle Aged; Survival Rate; Treatment Outcome | 2007 |
A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Retrospective Studies; Time Factors | 2007 |
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cohort Studies; Cytarabine; Female; Gene Expression Profiling; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Pyrazines; Tissue Distribution; Treatment Outcome | 2008 |
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Recovery of Function; Remission Induction | 2008 |
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Vidarabine; Young Adult | 2008 |
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Sarcoma, Myeloid; Survival Rate; Treatment Outcome | 2008 |
Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Central Nervous System Neoplasms; Child; Child, Preschool; Cytarabine; Dexamethasone; Doxorubicin; Female; Flow Cytometry; Humans; Idarubicin; Infant; Leukemia, T-Cell; Leukemic Infiltration; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction | 2008 |
Clofarabine combinations as acute myeloid leukemia salvage therapy.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Salvage Therapy | 2008 |
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Vidarabine | 2008 |
Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome | 2008 |
CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
Topics: 3' Untranslated Regions; Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; CTLA-4 Antigen; Cytarabine; Disease-Free Survival; Etoposide; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Polymorphism, Single Nucleotide; Proportional Hazards Models; Recurrence; Remission Induction; Young Adult | 2009 |
Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Cyclosporine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Dyes; Humans; Idarubicin; Inhibitory Concentration 50; K562 Cells; Leukemia, Myeloid, Acute; Male; Rhodamine 123; Time Factors; Treatment Outcome; Verapamil | 2009 |
Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate; Tretinoin; Vidarabine | 2009 |
Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2009 |
[Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2009 |
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2009 |
DV-ICE, intensive induction and early transplantation for adult patients with acute lymphoblastic leukemia: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Early Termination of Clinical Trials; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Idarubicin; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Treatment Failure; Vincristine; Young Adult | 2009 |
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Oligonucleotides; Peripheral Nervous System Diseases; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Treatment Outcome; X-Linked Inhibitor of Apoptosis Protein | 2009 |
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Remission Induction; Vidarabine; Young Adult | 2009 |
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
[FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2009 |
Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2010 |
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Drug Administration Schedule; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Precision Medicine; Prognosis; Remission Induction; Treatment Outcome; Young Adult | 2010 |
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Confidence Intervals; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Male; Probability; Proportional Hazards Models; Radiotherapy, Adjuvant; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2010 |
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
Topics: Adolescent; Adult; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Middle Aged; Remission Induction; Tretinoin; Young Adult | 2010 |
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cohort Studies; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Treatment Outcome | 2011 |
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Survival Analysis; Young Adult | 2011 |
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.
Topics: Aged; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cytarabine; Drug Administration Schedule; Drug Dosage Calculations; Female; Gene Expression; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Progenitor Cells; Oligonucleotides; Recurrence; RNA, Messenger; X-Linked Inhibitor of Apoptosis Protein | 2011 |
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Age of Onset; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoadjuvant Therapy; Neoplasm Staging; Quinolones; Remission Induction; Risk; Young Adult | 2011 |
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Assessment; Treatment Outcome; United Kingdom; Vidarabine; Vincristine | 2010 |
Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Down-Regulation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; STAT3 Transcription Factor | 2011 |
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Genes, p53; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Recurrence; Treatment Failure | 2012 |
GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hemorrhage; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Opportunistic Infections; Prognosis; Remission Induction; Survival Analysis; Tretinoin | 2011 |
[Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Young Adult | 2011 |
Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cytarabine; Female; Half-Life; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Young Adult | 2012 |
High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gastrointestinal Tract; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Proto-Oncogene Proteins c-kit; Survival Rate; Time Factors; Vidarabine | 2013 |
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demography; Female; Humans; Idarubicin; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Recurrence; Survivin; Treatment Outcome | 2013 |
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Drug Eruptions; Follow-Up Studies; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Nausea; Pilot Projects; Remission Induction; Survival Analysis; Young Adult | 2013 |
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Platelet Count; Prognosis; Prospective Studies; Remission Induction; Treatment Outcome; Tretinoin; Young Adult | 2014 |
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Equilibrative Nucleoside Transporter 1; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2014 |
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Treatment Failure; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Fatigue; Female; Gastrointestinal Diseases; Humans; Hydroxyurea; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Treatment Outcome | 2014 |
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Critical Care; Cytarabine; Disease-Free Survival; Drug Synergism; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Survival Rate; Tretinoin; Valproic Acid | 2014 |
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Rabbits; Salvage Therapy; Treatment Outcome; Young Adult | 2014 |
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pravastatin; Recurrence; Time Factors; Treatment Outcome; Young Adult | 2014 |
A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Fibroblast Growth Factor 7; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Stomatitis | 2014 |
[Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Mitoxantrone; Russia | 2014 |
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pravastatin; Risk Factors; Survival Rate | 2015 |
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Databases, Factual; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Risk Assessment; Survival Rate; United Kingdom | 2015 |
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 2016 |
Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Prognosis; Survival Rate | 2015 |
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Idarubicin; Indoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Neoplasm, Residual; Panobinostat; Prognosis; Recurrence; Treatment Outcome | 2015 |
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
Topics: Adolescent; Adult; Aged; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate | 2015 |
Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Infections; Leukemia, Myeloid, Acute; Male; Mitoxantrone | 2016 |
Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Disease-Free Survival; Female; Humans; Idarubicin; Immunotherapy; Injections, Spinal; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Pilot Projects; Rituximab; Treatment Outcome; Young Adult | 2016 |
[Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Remission Induction | 2016 |
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Cytarabine; Female; Humans; Idarubicin; Immunohistochemistry; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome | 2017 |
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Vidarabine; Young Adult | 2017 |
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Implementing the EffTox dose-finding design in the Matchpoint trial.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Blast Crisis; Cytarabine; Humans; Idarubicin; Imidazoles; Models, Statistical; Outcome Assessment, Health Care; Pyridazines; Research Design; Vidarabine | 2017 |
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Vidarabine; Young Adult | 2018 |
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Topics: Adolescent; Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Topics: Adult; Aged; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Cholesterol; Cohort Studies; Combined Modality Therapy; Cytarabine; Cytogenetic Analysis; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pravastatin; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction | 2018 |
Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2019 |
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Retrospective Studies; Sorafenib; Survival Rate; Tandem Repeat Sequences | 2019 |
Gemtuzumab Ozogamicin in
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Progression-Free Survival; Prospective Studies; Tretinoin; Young Adult | 2020 |
Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.
Topics: Aged; Allografts; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Risk Factors | 2020 |
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Recurrence; Salvage Therapy; Triazoles | 2020 |
Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Retrospective Studies; Survival Rate; Vidarabine; Vincristine | 2021 |
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Triazoles; Vidarabine | 2021 |
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Sulfonamides; Survival Rate; Vidarabine; Young Adult | 2021 |
Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2022 |
Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Remission Induction; Vidarabine | 2022 |
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Clofarabine; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; United Kingdom; Vidarabine | 2022 |
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Finland; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Prospective Studies; Remission Induction; Thioguanine | 2022 |
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderso
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prospective Studies; Retrospective Studies; Vidarabine | 2022 |
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Sorafenib | 2023 |
474 other study(ies) available for idarubicin and cytarabine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1992 |
High interleukin-6 plasma levels in acute promyelocytic leukemia.
Topics: Cytarabine; Drug Therapy, Combination; Humans; Idarubicin; Interleukin-6; Leukemia, Promyelocytic, Acute; Osmolar Concentration; Time Factors | 1992 |
Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Combined Modality Therapy; Cyclosporins; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Philadelphia Chromosome; Transplantation, Autologous | 1991 |
Granulocyte-macrophage colony-stimulating factor in acute non-lymphocytic leukemia before and after chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Time Factors | 1991 |
Idarubicin plus attenuated high-dose cytosine arabinoside in the treatment of relapsed and refractory acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local | 1990 |
[Acute myeloid leukemia with poor prognosis: treatment with oral 4-demethoxydaunorubicin (idarubicin) and low-dose cytarabine via subcutaneous route].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1990 |
Alpha-2 antiplasmin in acute nonlymphoblastic leukemia.
Topics: alpha-2-Antiplasmin; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Cytarabine; Disseminated Intravascular Coagulation; Fibrinolysis; Humans; Idarubicin; Leukemia, Myeloid, Acute; Plasminogen; Prognosis; Remission Induction | 1989 |
Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1989 |
Idarubicin in combination with etoposide and cytarabine in adult acute non-lymphoblastic leukaemia (ANLL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction | 1989 |
4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1989 |
Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Remission Induction | 1989 |
Oral idarubicin in combination with cytosine-arabinoside in previously untreated patients with acute non-lymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1986 |
4-Demethoxydaunorubicin (idarubicin) in relapsed and refractory acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male | 1987 |
Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1987 |
Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1987 |
Idarubicin in refractory acute leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Parenteral; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
Idarubicin alone or in combination with cytarabine and etoposide (3 + 3 + 5 protocol) in acute non-lymphoblastic leukaemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1985 |
Therapeutic activity of 4-demethoxydauno-rubicin (idarubicin) in adult acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged; Time Factors | 1983 |
Complete remission in prolymphocytic leukemia with 4-demethoxydaunorubicin and arabinosyl cytosine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Humans; Idarubicin; Leukemia, Lymphoid; Leukocyte Count; Male; Middle Aged; Prednisone; Splenomegaly; Vincristine | 1984 |
High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Remission Induction | 1993 |
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Blood Cell Count; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Female; Flow Cytometry; Gene Expression; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Prognosis; Prospective Studies; Quinine; Remission Induction; Risk; Salvage Therapy; Treatment Outcome | 1995 |
Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Mercaptopurine; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Remission Induction; Thioguanine; Translocation, Genetic | 1995 |
Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Blood Transfusion, Autologous; Cell Separation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Remission Induction; RNA, Messenger; RNA, Neoplasm; Time Factors; Treatment Outcome | 1993 |
Aggressive chemotherapy for acute leukemia relapsed after transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Female; Humans; Idarubicin; Italy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Tretinoin; Vincristine | 1994 |
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Differentiation; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Immunologic Factors; Leukemia, Promyelocytic, Acute; Life Tables; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Neutropenia; Nuclear Proteins; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Analysis; Transcription Factors; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins | 1995 |
Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Rhodamine 123; Rhodamines; Survival Analysis | 1995 |
Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Aspartate-Ammonia Ligase; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Incidence; Methotrexate; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy | 1994 |
Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Associazione Italiana Ematologìa ed Ocologia Pediatrica.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Recurrence | 1994 |
Daunorubicin (DNR) accumulation in fresh leukemic cells: correlation with clinical and biological features.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Stimulation, Chemical; Treatment Failure; Verapamil | 1994 |
[The comparative evaluation of the efficacy of different therapeutic plans in acute nonlymphocytic leukemias].
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Drug Evaluation; Hematopoiesis; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Prednisolone; Remission Induction; Time Factors; Vincristine | 1993 |
[The current chemotherapy of acute myeloid leukemias in adults].
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Mitoxantrone; Prognosis; Remission Induction; Time Factors | 1993 |
Idarubicin in the therapy of acute myeloid leukemia: final analysis in 57 previously untreated patients.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis | 1993 |
Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Drug Administration Schedule; Drug Resistance; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1993 |
Sick sinus syndrome in a teenager treated with idarubicin.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arrhythmia, Sinus; Bradycardia; Cytarabine; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Sick Sinus Syndrome | 1993 |
New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cyclosporine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mathematical Computing; Monitoring, Physiologic; Probability; Remission Induction; Research Design | 1996 |
Idarubicin in combination with cytarabine and VP-16 in the treatment of post myelodysplastic syndrome acute myeloblastic leukemia (MDS-AML).
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1995 |
Cutaneous eruption of lymphocyte recovery mimicking mycosis fungoides in a patient with acute myelocytic leukemia.
Topics: CD4 Antigens; Cytarabine; Diagnosis, Differential; Drug Therapy, Combination; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Mycosis Fungoides; Skin | 1995 |
Translocation (12;15)(p13;q13) in a patient with relapsed acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 15; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Recurrence; Translocation, Genetic | 1996 |
Trisomy 21 in acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Down Syndrome; Humans; Hydroxyurea; Idarubicin; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Acute; Male; Mitoxantrone | 1996 |
All-trans-retinoic acid (ATRA) responsive skin relapses of acute promyelocytic leukaemia followed by ATRA-induced pseudotumour cerebri.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Blotting, Southern; Cytarabine; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Molecular Sequence Data; Polymerase Chain Reaction; Pseudotumor Cerebri; Skin Neoplasms; Tretinoin | 1996 |
Collection, analysis and transplantation of Ph-negative blood precursor cells in chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Recurrence; Remission Induction; Transplantation, Autologous | 1996 |
Late relapse after autologous BMT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Time Factors | 1996 |
[Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Screening Assays, Antitumor; Female; Idarubicin; Leukemia P388; Mice; Neoplasm Transplantation; Tumor Cells, Cultured | 1996 |
Marked bone marrow eosinophilia at the time of relapse of acute myeloblastic leukaemia in association with the appearance of translocation t(12;20)(q24;q11).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Eosinophilia; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Remission Induction; Translocation, Genetic | 1996 |
Isolated leukemia cutis and CNS involvement in combination with cytogenetic findings of trisomy 8--two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Central Nervous System Neoplasms; Chromosomes, Human, Pair 8; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Skin Neoplasms; Trisomy; Vidarabine | 1995 |
Cutaneous monoblastic leukemia as a first sign of relapse six years after autologous bone marrow transplantation for acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Female; Humans; Idarubicin; Leukemia, Monocytic, Acute; Middle Aged; Recurrence; Skin; Skin Neoplasms; Time Factors; Transplantation, Autologous | 1996 |
Autologous peripheral blood stem cell transplantation in a patient with previous invasive middle ear mucormycosis.
Topics: Acute Disease; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Facial Paralysis; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mastoid; Middle Aged; Mitoxantrone; Mucormycosis; Myringoplasty; Neutropenia; Otitis Media, Suppurative; Remission Induction; Transplantation Conditioning; Transplantation, Autologous | 1996 |
Acute abdomen due to endometriosis as a diagnostic and therapeutic challenge in the treatment of acute myelocytic leukemia.
Topics: Abdomen, Acute; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Endometriosis; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged | 1997 |
Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells.
Topics: Adult; Cytarabine; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Transplantation Conditioning; Transplantation, Autologous | 1997 |
CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; CD3 Complex; CD56 Antigen; Cell Nucleus; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Female; Femoral Neoplasms; Herpesvirus 4, Human; Humans; Idarubicin; Immunophenotyping; Killer Cells, Natural; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methylprednisolone; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Pelvic Neoplasms; Prednisone; Quinine; Vincristine | 1997 |
Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cytarabine; Daunorubicin; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Idarubicin; Kinetics; Leukemia; Mitoxantrone | 1997 |
Angioimmunoblastic lymphadenopathy with disseminated human herpesvirus 6 infection in a patient with acute myeloblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Cytarabine; DNA, Viral; Fatal Outcome; Fever; Herpesviridae Infections; Herpesvirus 6, Human; Humans; Hypergammaglobulinemia; Idarubicin; Immunoblastic Lymphadenopathy; Immunophenotyping; Leukemia, Myeloid, Acute; Lymph Nodes; Male; Middle Aged; Pericarditis; Polymerase Chain Reaction; Remission Induction; Tumor Virus Infections | 1997 |
Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Blast Crisis; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lupus Erythematosus, Systemic; Methotrexate; Prednisone; Remission Induction; Transplantation, Autologous; Vincristine | 1997 |
Early transformation to acute myeloblastic leukaemia with the acquisition of inv(16) in Ph positive chronic granulocytic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Chromosome Inversion; Chromosome Mapping; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Fatal Outcome; Humans; Idarubicin; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Philadelphia Chromosome | 1997 |
Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cytarabine; Daunorubicin; Ear Canal; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Mercaptopurine; Middle Aged; Mitoxantrone; Neoplasm Proteins; Oncogene Proteins, Fusion; Radiotherapy; Recurrence; Remission Induction; Salvage Therapy; Tretinoin; Vindesine | 1997 |
Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prognosis; Prospective Studies; Remission Induction; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Tretinoin | 1997 |
Bayesian interim analysis of phase II cancer clinical trials.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid; Models, Statistical; Research Design; Vidarabine | 1997 |
[IL-2 post-autologous transplant of hematopoietic stem cells].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Interleukin-2; Leukemia, Myeloid, Acute; Remission Induction; Transplantation, Autologous | 1997 |
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 1995 |
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Coloring Agents; Cyclosporine; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Platelet Count; Survival Rate; Treatment Outcome; Vidarabine | 1997 |
Effective mobilization of Philadelphia-chromosome-negative cells in chronic myelogenous leukaemia patients using a less intensive regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Pilot Projects | 1998 |
Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Lenograstim; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Recombinant Proteins; Treatment Outcome | 1998 |
Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Salvage Therapy; Secondary Prevention; Treatment Outcome | 1998 |
Successful fetal outcome after exposure to idarubicin and cytosine-arabinoside during the second trimester of pregnancy--a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Fetal Growth Retardation; Humans; Idarubicin; Infant, Newborn; Infant, Premature; Leukemia, Monocytic, Acute; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prenatal Exposure Delayed Effects | 1998 |
Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Argentina; Bone Marrow Cells; Child, Preschool; Cytarabine; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Karyotyping; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Treatment Outcome | 1998 |
[Successful treatment with idarubicin in a pediatric case of t(8;21) acute myelogenous leukemia with additional chromosomal abnormalities at relapse].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Translocation, Genetic; Treatment Outcome | 1998 |
[Successful emergency operation for massive hemorrhage due to jejunal angiodysplasia after intensive chemotherapy in a patient with refractory anemia with excess of blasts].
Topics: Anemia, Refractory, with Excess of Blasts; Angiodysplasia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Therapy, Combination; Emergencies; Enterocolitis; Gastrointestinal Hemorrhage; Humans; Idarubicin; Jejunal Diseases; Male; Mercaptopurine; Middle Aged; Neutropenia; Prednisolone; Vincristine | 1998 |
Severe infection caused by Stomatococcus mucilaginosus in a neutropenic patient: case report and review of the literature.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gram-Positive Bacterial Infections; Humans; Idarubicin; Leukemia, Myeloid; Micrococcaceae; Mouth; Neutropenia; Opportunistic Infections; Pneumonia, Bacterial; Sepsis | 1998 |
Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Female; Gene Amplification; Gene Rearrangement; Humans; Idarubicin; Immunophenotyping; Leukemia, Promyelocytic, Acute; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Skin Neoplasms; Translocation, Genetic; Tretinoin | 1998 |
Management of acute promyelocytic leukemia relapse in the ATRA era.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Thioguanine; Treatment Outcome; Tretinoin | 1998 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Hemorrhage; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Pancytopenia; Platelet Count; Platelet Transfusion; Retrospective Studies; Spain; Thrombocytopenia | 1998 |
Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blotting, Southern; Cytarabine; Cytidine Deaminase; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mutation; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction | 1998 |
FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Transplantation, Homologous; Treatment Outcome; Vidarabine | 1998 |
Management of acute myeloid leukaemia following myelodysplastic syndrome in a kidney graft recipient.
Topics: Acute Disease; Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cytarabine; Etoposide; Female; Humans; Idarubicin; Imipenem; Kidney Transplantation; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Postoperative Complications; Thienamycins | 1999 |
A single apheresis to achieve a high number of peripheral blood CD34+ cells in a lithium-treated patient with acute myeloid leukaemia.
Topics: Adult; Antigens, CD34; Antimanic Agents; Antineoplastic Combined Chemotherapy Protocols; Bipolar Disorder; Blood Cell Count; Cytarabine; Daunorubicin; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Idarubicin; Leukapheresis; Leukemia, Monocytic, Acute; Lithium Carbonate; Mitoxantrone; Recombinant Proteins; Remission Induction; Thioguanine | 1999 |
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Humans; Idarubicin; Immunocompromised Host; Infections; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; N-Formylmethionine Leucyl-Phenylalanine; Neutropenia; Neutrophils; Phagocytosis; Respiratory Burst; Retrospective Studies; Risk Factors; Thioguanine; Vidarabine | 1999 |
Early detection by ultrasound scan of severe post-chemotherapy gut complications in patients with acute leukemia.
Topics: Acute Disease; Adult; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dilatation, Pathologic; Enterocolitis; Etoposide; Female; Gallbladder Diseases; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Intubation, Gastrointestinal; Leukemia; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Ultrasonography | 1999 |
Long-term molecular remission in promyelocytic transformation of myeloproliferative disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Daunorubicin; Disease Progression; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Polycythemia Vera; Preleukemia; Prognosis; Remission Induction; Thrombocythemia, Essential; Thrombophilia; Translocation, Genetic; Tretinoin | 1999 |
Bacteremia caused by a novel isolate resembling leptotrichia species in a neutropenic patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cytarabine; Gram-Negative Anaerobic Straight, Curved, and Helical Rods; Gram-Negative Bacterial Infections; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Microscopy, Electron; Middle Aged; Neutropenia; Phylogeny | 1999 |
Acute myeloblastic leukemia (M0) with an unusual chromosomal abnormality: translocation (1;14)(p13;q32).
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 14; Cytarabine; Female; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Peroxidase; Translocation, Genetic | 1999 |
GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged | 1999 |
Acute myeloid leukemia M2 and t(8;21)(q22;q22) with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-), and CD33(-).
Topics: Adult; Antibiotics, Antineoplastic; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Bone Marrow Cells; CD13 Antigens; Cell Adhesion Molecules; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Lipopolysaccharide Receptors; Male; Membrane Glycoproteins; Peroxidase; Phenotype; Sialic Acid Binding Ig-like Lectin 3; Translocation, Genetic | 1999 |
Isolated granulocytic sarcoma of the humerus.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Cytarabine; Diagnosis, Differential; Fatal Outcome; Humans; Humerus; Idarubicin; Leukemia, Myeloid; Magnetic Resonance Imaging; Male; Pain; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 1999 |
Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Topics: Acute Disease; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Transplantation; Clinical Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Evaluation Studies as Topic; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Time Factors; Transplantation, Autologous; Treatment Outcome | 1999 |
The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Idarubicin; Immunohistochemistry; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Survival Rate; Tretinoin; Vault Ribonucleoprotein Particles | 1999 |
Two new 3' PML breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Exons; Fatal Outcome; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic; Tretinoin | 2000 |
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Immunization, Passive; Interleukin-2; Male; Melphalan; Middle Aged; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Pulmonary infection caused by Gymnascella hyalinospora in a patient with acute myelogenous leukemia.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Ascomycota; Cytarabine; Drug Resistance, Microbial; Female; Humans; Idarubicin; Itraconazole; Leukemia, Myeloid, Acute; Lung Diseases, Fungal; Midwestern United States; Mycological Typing Techniques | 2000 |
Acute promyelocytic leukemia with del(6)(p23).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 6; Cytarabine; Humans; Idarubicin; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Neoplasm Proteins; Oncogene Proteins, Fusion; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2000 |
Acute myelomonocytic leukemia with histologic features resembling sarcomatoid carcinoma in bone marrow.
Topics: Biomarkers, Tumor; Bone Marrow; Bone Marrow Neoplasms; Carcinosarcoma; Cytarabine; Cytogenetics; Diagnosis, Differential; Fatal Outcome; Humans; Idarubicin; Immunohistochemistry; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Muramidase | 2000 |
Mini-ICE regimen allows mobilization of peripheral blood progenitor cells in a patient with chronic myelogenous leukemia failing the ICE protocol.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Ifosfamide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2000 |
Acute basophilic leukemia presenting with abnormal liver function tests and the absence of blast cells in the peripheral blood.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Cytoplasmic Granules; Diagnosis, Differential; Drug Therapy, Combination; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Karyotyping; Leukemia, Basophilic, Acute; Leukemic Infiltration; Liver; Liver Function Tests; Male; Middle Aged; Neoplastic Stem Cells | 2000 |
Anaerobic bacteremia in a neutropenic patient with oral mucositis.
Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacteria, Anaerobic; Cytarabine; Eubacterium; Fusobacterium necrophorum; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Male; Mouth Mucosa; Neutropenia; Stomatitis | 2000 |
Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs induction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction | 2000 |
Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Liver Neoplasms; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Prednisolone; Remission Induction; Reoperation | 2000 |
P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Male; Middle Aged; Treatment Outcome | 2000 |
Interferon may reduce minimal residual disease of acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Interferons; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Recurrence; Remission Induction; Tretinoin | 2000 |
Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; DNA-Binding Proteins; Etoposide; Gene Deletion; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Mitoxantrone; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Prognosis; Prospective Studies; Recurrence; Remission Induction | 2000 |
[In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Myelodysplastic Syndromes; Tumor Cells, Cultured | 2000 |
Life-threatening paroxysmal supraventricular tachycardia developed during granulocyte transfusion therapy for neutropenia-related infection.
Topics: Adult; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Citrates; Cytarabine; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Idarubicin; Infections; Leukapheresis; Leukemia, Erythroblastic, Acute; Leukocyte Transfusion; Male; Neutropenia; Sodium Citrate; Tachycardia, Supraventricular | 2000 |
Serum ICAM-1 concentrations following conventional dose consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell rescue.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Intercellular Adhesion Molecule-1; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Neutrophils; Recombinant Proteins; Solubility | 2000 |
Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Humans; Idarubicin; Japan; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate | 2000 |
In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Asparaginase; Bone Marrow Cells; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Infant; Leukemia, Prolymphocytic; Leukemia, T-Cell; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Statistics, Nonparametric; Teniposide; Thioguanine; Vincristine | 2000 |
Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Dosage Compensation, Genetic; Female; Follow-Up Studies; Hematopoiesis; Humans; Idarubicin; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Retrospective Studies; Thioguanine; Time Factors | 2000 |
Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor (MUD) transplantation for refractory T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Carmustine; Cefotaxime; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Idarubicin; Immunocompromised Host; Immunosuppressive Agents; Levofloxacin; Lymphoma, T-Cell; Male; Melphalan; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Prednisone; Recurrence; Rifampin; Splenectomy; Streptococcus pneumoniae; Transplantation Conditioning; Vincristine | 2000 |
Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Rate | 2000 |
TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Idarubicin; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Whole-Body Irradiation | 2000 |
PBPC mobilization with chemotherapy and G-CSF in patients with chronic myeloid leukemia: quantification of bcr/abl-positive cells by interphase fluorescence in situ hybridization and competitive PCR.
Topics: Adult; Cell Nucleus; Chronic Disease; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Interphase; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oncogene Proteins; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr | 2001 |
Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity?
Topics: Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosomes, Human, Pair 7; Cytarabine; Female; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Isochromosomes; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Remission Induction; Thioguanine | 2001 |
Severe hepatic injury associated with lipid formulations of amphotericin B.
Topics: Adolescent; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Liver; Liver Diseases | 2001 |
Transfusion of peripheral blood stem cells from donor homozygous for a shared HLA-haplotype: avoiding fatal transfusion-associated graft-versus-host disease while preserving anti-leukemic effect.
Topics: Acute Disease; Adult; Blood Transfusion; Cytarabine; Fatal Outcome; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; HLA Antigens; Homozygote; Humans; Idarubicin; Leukemia, Myeloid; Male | 2001 |
[Outcome of acute myelogenous leukemia in 41 patients treated with idarubicin: the prognosis of t(8;21) cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome | 2001 |
Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia; Leukocyte Transfusion; Male; Recurrence; Survival Rate; Transplantation, Homologous | 2001 |
Topoisomerase II inhibitor induced leukemia in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Homosexuality, Male; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, AIDS-Related; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Neoplasm Metastasis; Neoplasms, Second Primary; Topoisomerase II Inhibitors | 2001 |
[Acute myeloid leukemia in the adult. Results of the National Antineoplastic Drug Protocol at the Hospital del Salvador, 1990-1998].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Immunophenotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Retrospective Studies; Treatment Outcome | 2000 |
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; Tumor Cells, Cultured | 2001 |
Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Cytarabine; Humans; Idarubicin; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Kidney Transplantation; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Polycystic Kidney Diseases; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2001 |
Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Recombinant Proteins; Recurrence; Salvage Therapy; Transplantation, Homologous; Vidarabine | 2001 |
[CD7(+) acute myeloid leukemia (M0) associated with a mediastinal bulky mass lesion].
Topics: Adult; Antigens, CD7; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Neoplasms, Multiple Primary; Remission Induction | 2001 |
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Survival Analysis; Topotecan; Vidarabine | 2001 |
Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia with different clinical stages.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Purging; Caspase 14; Caspases; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Recombinant Proteins; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2001 |
And the sun keeps shining.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Etoposide; Female; Hair Follicle; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2001 |
Acute basophilic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Coloring Agents; Cytarabine; Cytoplasmic Granules; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Karyotyping; Leukemia, Basophilic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Periodic Acid-Schiff Reaction; Peroxidase; Recurrence; Tolonium Chloride; Translocation, Genetic | 2001 |
Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Filgrastim; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Reoperation; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Salvage Therapy; Survival Rate; Topotecan; Treatment Outcome | 2001 |
Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; Calcium Channel Blockers; Carbocyanines; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluoresceins; Fluorescent Dyes; Genistein; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Probenecid; Prognosis; Prospective Studies; Rhodamine 123; Survival Analysis; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Verapamil | 2002 |
Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia.
Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Idarubicin; Immunotherapy; Infusions, Intravenous; Leukemia, Monocytic, Acute; Recurrence; Tomography, X-Ray Computed; Transplantation, Autologous | 2001 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Infant; Leukemia; Life Tables; Male; Methylprednisolone; Middle Aged; Premedication; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2002 |
Secondary acute promyelocytic leukemia in a patient with non-Hodgkin's lymphoma treated with VP-16 and MST-16.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Piperazines; Prednisolone; Remission Induction; Tretinoin; Vincristine | 2002 |
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cohort Studies; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Lipopolysaccharide Receptors; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplastic Stem Cells; Thioguanine; Treatment Outcome | 2001 |
Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Life Tables; Male; Melphalan; Mercaptopurine; Middle Aged; Neoplasm Proteins; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Retrospective Studies; Teniposide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2000 |
Automated differential counts in acute promyelocytic leukemia patients may be misleading.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cytarabine; Diagnostic Errors; Eosinophils; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Leukocyte Count; Tretinoin | 2002 |
A case of zygomycosis and invasive candidiasis involving the epiglottis and tongue in an immunocompromised patient.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Candida; Candidiasis; Cytarabine; Epiglottis; Fungi; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid, Acute; Male; Neutropenia; Tongue; Tongue Diseases; Zygomycosis | 2002 |
Acute basophilic leukemia lacking basophil-specific antigens: the importance of cytokine receptor expression in differential diagnosis.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Diagnosis, Differential; Humans; Idarubicin; Leukemia, Basophilic, Acute; Male; Mast Cells; Middle Aged; Receptors, Cytokine; Receptors, IgE | 2002 |
In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Cytarabine; Drug Resistance, Multiple; Etoposide; Female; Fluorescent Dyes; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Rhodamine 123; Treatment Outcome; Tretinoin | 2002 |
Translocation (11;11)(p13- p15;q23) in a child with therapy-related acute myeloid leukemia following chemotherapy with DNA-topoisomerase II inhibitors for Langerhans cell histiocytosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Chromosomes, Human, Pair 11; Cytarabine; Drug Therapy, Combination; Enzyme Inhibitors; Etoposide; Fatal Outcome; Histiocytosis, Langerhans-Cell; Humans; Idarubicin; Karyotyping; Leukemia, Myelomonocytic, Acute; Male; Neoplasms, Second Primary; Nuclear Pore Complex Proteins; Prednisolone; Topoisomerase II Inhibitors; Translocation, Genetic; Vinblastine | 2002 |
Oral manifestations of acute myelomonocytic leukemia: a case report and review of the classification of leukemias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fatal Outcome; Gingival Hemorrhage; Gingival Overgrowth; Humans; Idarubicin; Leukemia; Leukemia, Myelomonocytic, Acute; Male; Middle Aged | 2002 |
[Diagnostic image (92). A man with fever during chemotherapy. Invasive pulmonary mycosis].
Topics: Amphotericin B; Antibiotics, Antineoplastic; Antifungal Agents; Antimetabolites, Antineoplastic; Cytarabine; Fever; Humans; Idarubicin; Leukemia; Lung; Lung Diseases, Fungal; Male; Middle Aged; Radiography | 2002 |
Inv(4)(p14q27) in a case with de novo acute nonlymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Inversion; Chromosomes, Human, Pair 4; Cytarabine; Fatal Outcome; Humans; Idarubicin; Karyotyping; Leukemia, Myelomonocytic, Acute; Male; Mitoxantrone | 2002 |
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Topics: Acute Disease; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Fatal Outcome; Humans; Idarubicin; Killer Cells, Natural; Leukemia, Myeloid; Leukemic Infiltration; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mitoxantrone; Myeloid Cells; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma, Myeloid; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colitis; Cytarabine; Female; Humans; Idarubicin; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Retrospective Studies; Treatment Outcome | 2002 |
Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; Disease-Free Survival; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Headache; Humans; Idarubicin; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Neoplastic Stem Cells; Patient Compliance; Pilot Projects; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Failure; Tretinoin | 2002 |
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine | 2002 |
Enterocolitis as initial presentation of acute myelogenous leukemia exacerbated by induction chemotherapy with idarubicin-cytosine arabinoside.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colitis; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia | 2002 |
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Benzamides; Blood Cells; Bone Marrow Cells; Clone Cells; Cohort Studies; Cytarabine; Dosage Compensation, Genetic; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Idarubicin; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Receptors, Androgen; Remission Induction | 2003 |
Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression; Genes, bcl-2; Genes, MDR; Genes, p53; Heat-Shock Proteins; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Heart Transplantation; Humans; Idarubicin; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Postoperative Complications; Stem Cell Transplantation | 2002 |
Acute myelogenous leukaemia presenting as a conjunctival lesion and red eye.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Conjunctiva; Conjunctival Neoplasms; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2002 |
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Female; Gemtuzumab; Hepatic Veno-Occlusive Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Recurrence | 2003 |
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; California; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Infant; Leukemia, Myeloid; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Single-Blind Method; Survival Analysis; Thioguanine; Treatment Outcome | 2003 |
A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13).
Topics: Acetyltransferases; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 16; Cytarabine; Female; Gene Rearrangement; Histone Acetyltransferases; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Reverse Transcriptase Polymerase Chain Reaction; Saccharomyces cerevisiae Proteins; Sequence Analysis, DNA; Translocation, Genetic | 2003 |
New designs for phase 2 clinical trials.
Topics: Acute Disease; Adenine Nucleotides; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bayes Theorem; Bias; Biomarkers; Clinical Trials, Phase II as Topic; Clofarabine; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Drug Carriers; False Negative Reactions; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Middle Aged; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Thalidomide; Topotecan; Treatment Outcome | 2003 |
Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Interleukin-2; Leukemia, Myeloid; Male; Middle Aged; Stem Cell Transplantation | 2003 |
Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacillaceae Infections; Bacillus cereus; Cytarabine; Enterocolitis; Fatal Outcome; Humans; Idarubicin; Leukemia, Myeloid, Acute; Liver Diseases; Male; Neutropenia; Sepsis | 2003 |
Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.
Topics: 2-Chloroadenosine; Alternative Splicing; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Biological Transport; Buthionine Sulfoximine; Calcium Channel Blockers; Cytarabine; Daunorubicin; Decitabine; Deoxyadenosines; Deoxycytidine Kinase; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Humans; Idarubicin; Leukemia; Methotrexate; Neoplasm Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Verapamil | 2003 |
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Recombinant Proteins; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2002 |
HLA-DR antigen-negative acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Female; Flow Cytometry; HLA-DR Antigens; Humans; Idarubicin; Immunophenotyping; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Prospective Studies; Recurrence; Treatment Outcome | 2003 |
Mucormycosis in acute myeloid leukaemia.
Topics: Acute Disease; Amphotericin B; Antifungal Agents; Combined Modality Therapy; Cytarabine; Frozen Sections; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Mucormycosis; Thoracic Wall | 2003 |
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIM
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Histocompatibility Testing; Humans; Idarubicin; Leukemia, Myeloid; Living Donors; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2003 |
Severe hyperglycemia as a complication of big ICE chemotherapy in a patient with acute myeloblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cytarabine; Etoposide; Female; Humans; Hyperglycemia; Idarubicin; Insulin; Leukemia, Myeloid, Acute; Recurrence; Time Factors | 2002 |
Sweet's syndrome masquerading as facial cellulitis.
Topics: Antineoplastic Agents; Cellulitis; Cytarabine; Diagnosis, Differential; Face; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Sweet Syndrome; Treatment Outcome | 2003 |
A case of leukemia of the appendix presenting as acute appendicitis.
Topics: Aged; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendicitis; Appendix; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mercaptopurine; Sarcoma, Myeloid | 2003 |
Successful treatment for multiple cerebral hemorrhage in a newly diagnosed patient with acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebral Hemorrhage; Cytarabine; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Reverse Transcriptase Polymerase Chain Reaction; Tomography, X-Ray Computed; Treatment Outcome; Tretinoin | 2003 |
[High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16)(p13q22)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bradycardia; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2003 |
Myeloid/natural killer cell precursor acute leukemia accompanied by homozygous protein C deficiency.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Anticoagulants; Antimetabolites, Antineoplastic; Cytarabine; Heparin, Low-Molecular-Weight; Homozygote; Humans; Idarubicin; Killer Cells, Natural; Leukemia, Myeloid; Male; Myeloid Cells; Neoplastic Stem Cells; Pedigree; Protein C Deficiency | 2003 |
[Intensive multi-drug chemotherapy for acute myeloid leukemia in a renal allograft recipient].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Kidney Transplantation; Leukemia, Myeloid, Acute; Male; Middle Aged; Postoperative Complications | 2003 |
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Salvage Therapy; Transplantation, Autologous | 2003 |
[Acute myelogenous leukemia complicated with severe tumor lysis syndrome after a single day of idarubicin/cytarabine chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Tumor Lysis Syndrome | 2003 |
MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Cytarabine; Daunorubicin; Enzyme Inhibitors; Etoposide; Fatal Outcome; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 2003 |
Protein 4.1 deficiency and deletion of chromosome 20q are associated with acquired elliptocytosis in myelodysplastic syndrome.
Topics: Aged; Anemia, Refractory; Antibiotics, Antineoplastic; Chromosome Deletion; Chromosomes, Human, Pair 20; Cytarabine; Cytoskeletal Proteins; Elliptocytosis, Hereditary; Erythrocytes; Humans; Idarubicin; Immunosuppressive Agents; Male; Membrane Proteins; Myelodysplastic Syndromes; Pancytopenia | 2004 |
Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recombinant Proteins; Salvage Therapy; Treatment Outcome; Vidarabine | 2004 |
Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Combined Modality Therapy; Cyclosporine; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pneumonia; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin.
Topics: Acute Disease; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Caspofungin; Cytarabine; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Drug Interactions; Echinocandins; Humans; Idarubicin; Itraconazole; Leukemia, Myeloid; Lipopeptides; Mycoses; Peptides; Peptides, Cyclic; Substrate Specificity | 2004 |
Aggressive systemic mastocytosis mimicking sclerosing cholangitis.
Topics: Abdominal Pain; Adrenal Cortex Hormones; Adult; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow; Budd-Chiari Syndrome; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Clone Cells; Cytarabine; Diagnosis, Differential; Diarrhea; Fatal Outcome; Female; Flushing; Histamine H1 Antagonists; Humans; Idarubicin; Liver; Lymphoma; Mast Cells; Mastocytosis, Systemic; Mutation, Missense; Point Mutation; Prednisone; Proto-Oncogene Proteins c-kit; Recurrence | 2004 |
Pressure-induced bullae and sweat gland necrosis following chemotherapy induction.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blister; Cytarabine; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Humans; Idarubicin; Leukemia, Myeloid; Male; Necrosis; Remission Induction; Sweat Gland Diseases; Sweat Glands | 2004 |
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Myelodysplastic Syndromes; Vidarabine | 2004 |
Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chi-Square Distribution; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Incidence; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Logistic Models; Male; Mitoxantrone; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Survival Rate | 2004 |
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cladribine; Cyclophosphamide; Cytarabine; DNA Mutational Analysis; Doxorubicin; Drug Resistance, Neoplasm; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Idarubicin; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Melphalan; Prednisolone; Survival Analysis; Vidarabine; Vincristine | 2004 |
Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion.
Topics: ABO Blood-Group System; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Group Incompatibility; Blood Transfusion; Combined Modality Therapy; Cytarabine; Drug Resistance; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Killer Cells, Natural; Leukemia, Myelomonocytic, Acute; Leukocyte Transfusion; Male; Middle Aged; Plasmapheresis; Red-Cell Aplasia, Pure; Remission Induction; Rituximab; Transplantation, Homologous | 2004 |
[Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cytarabine; Ecthyma; Female; gamma-Globulins; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Pseudomonas aeruginosa; Pseudomonas Infections; Scalp; Sepsis; Treatment Outcome | 2004 |
Complex t(8;14;21)(q22;q13;q22), a variant of t(8;21), with t(15;21)(q15;p11) in a patient with acute myelogenous leukemia (M1).
Topics: Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Drug Therapy, Combination; Female; Genetic Variation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Middle Aged; Oncogene Proteins, Fusion; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Secondary Prevention; Transcription Factors; Translocation, Genetic | 2004 |
Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Proliferation; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Rate | 2004 |
A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome; Tretinoin | 2004 |
Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
Topics: Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Line, Tumor; Cell Survival; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Sialic Acid Binding Ig-like Lectin 3; Signal Transduction | 2005 |
Acute pancreatitis during all-trans-retinoic acid treatment for acute promyelocytic leukemia in a patient without overt hypertriglyceridemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hypertriglyceridemia; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Pancreatitis; Tretinoin | 2005 |
Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA-Binding Proteins; Etoposide; GTPase-Activating Proteins; Histone-Lysine N-Methyltransferase; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Proto-Oncogenes; RNA, Messenger; Transcription Factors | 2005 |
Trying to improve clinical outcome in AML: lessons from negative trials.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Idarubicin; Interleukin-11; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Megakaryoblastic, Acute; Male; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2005 |
Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukocyte Transfusion; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Tissue Donors; Transplantation, Homologous; Treatment Outcome | 2005 |
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine | 2005 |
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukocyte Count; Liver; Male; Middle Aged; Mucositis; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Autoantigens; Cell Cycle Proteins; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Cytarabine; Fatal Outcome; Genetic Variation; Humans; Hydroxyurea; Idarubicin; In Situ Hybridization, Fluorescence; Janus Kinase 2; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oncogene Proteins, Fusion; Open Reading Frames; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Secondary Prevention; Sequence Analysis, RNA; Translocation, Genetic; Treatment Outcome | 2005 |
Medical ethics collides with public policy: LVAD for a patient with leukemia.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cost-Benefit Analysis; Cytarabine; Health Care Rationing; Heart-Assist Devices; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Public Policy; United States | 2005 |
The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Creatine Kinase, MB Form; Cytarabine; Echocardiography; Female; Heart Diseases; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Troponin T | 2005 |
Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Ear, External; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Methylprednisolone; Neutropenia; Recombinant Proteins; Recurrence; Sweet Syndrome; Vidarabine | 2006 |
Acute myeloid leukemia with near-triploid karyotype and extramedullary involvement of mediastinum.
Topics: Adult; Antineoplastic Agents; Bone Marrow Cells; Central Nervous System; Cytarabine; Disease Progression; Etoposide; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Mediastinum; Polyploidy; Prognosis; Stem Cell Transplantation; Tomography, X-Ray Computed | 2005 |
Feasibility of FLAG-IDA regimen in cases with relapsed/refractory acute leukemia cases.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Liver Diseases; Male; Mucositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine | 2006 |
TLS/FUS-ERG fusion gene in acute lymphoblastic leukemia with t(16;21)(p11;q22) and monitoring of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosome Mapping; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Cytarabine; Etoposide; Exons; Humans; Idarubicin; Infant; Male; Neoplasm, Residual; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA-Binding Protein FUS; Translocation, Genetic; Treatment Outcome | 2005 |
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin | 2005 |
Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Drug Evaluation; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia-Lymphoma, Adult T-Cell; Male; Methylprednisolone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thiotepa; Topotecan; Treatment Outcome; Vidarabine; Vinblastine | 2005 |
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Analysis; Topotecan; Vidarabine | 2006 |
Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Caspofungin; Combined Modality Therapy; Cytarabine; Debridement; Diplopia; Drug Therapy, Combination; Echinocandins; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid, Acute; Lipopeptides; Male; Middle Aged; Mitoxantrone; Opportunistic Infections; Orbital Diseases; Peptides, Cyclic; Sinusitis; Zygomycosis | 2005 |
Subacute anthracycline cardiotoxicity.
Topics: Adult; Antibiotics, Antineoplastic; Cardiomyopathies; Cytarabine; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Male; Ultrasonography | 2006 |
Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Central Nervous System; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gingiva; Humans; Hydrocortisone; Idarubicin; Infant; Infant, Newborn; Japan; Kaplan-Meier Estimate; Leukemia, Myeloid; Leukemic Infiltration; Male; Methotrexate; Orbit; Prognosis; Remission Induction; Sarcoma, Myeloid; Skin; Testis | 2007 |
Myeloid sarcoma of the urinary bladder and epididymis as a primary manifestation of acute myeloid leukemia with inv(16).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Genital Neoplasms, Male; Humans; Idarubicin; In Situ Hybridization; Male; Middle Aged; Remission Induction; Sarcoma, Myeloid; Urinary Bladder Neoplasms | 2006 |
Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Pilot Projects; Prognosis; Remission Induction | 2006 |
AmBisome treatment of fungal sinusitis in severe immunocompromised patient with acute lymphoblastic leukemia relapsed after autologous peripheral blood transplantation.
Topics: Adult; Amphotericin B; Anti-Infective Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Combined Modality Therapy; Cytarabine; Cytomegalovirus Infections; Enterococcus faecalis; Fatal Outcome; Humans; Idarubicin; Immunocompromised Host; Immunoglobulins, Intravenous; Liposomes; Male; Mycoses; Peripheral Blood Stem Cell Transplantation; Pneumonia; Postoperative Complications; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pseudomonas putida; Pulmonary Edema; Pyrimidines; Sinusitis; Staphylococcus epidermidis; Transplantation, Autologous; Triazoles; Voriconazole | 2006 |
[Bulky lymphadenopathy in acute myeloid leukemia with inv (16) (p13q22): a case report].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid; Lymphatic Diseases; Male; Neoplasm, Residual; Prognosis | 2006 |
Neutrophilic eccrine hidradenitis masquerading as facial cellulitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cellulitis; Cytarabine; Diagnosis, Differential; Facial Dermatoses; Female; Follow-Up Studies; Hidradenitis; Humans; Idarubicin; Immunohistochemistry; Leukemia, Myeloid, Acute; Risk Assessment | 2007 |
Late relapses in acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mastoid; Mitoxantrone; Recurrence; Time Factors; Tretinoin | 2007 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Epidemiologic Methods; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Severity of Illness Index; Treatment Outcome | 2007 |
Multiple complete remissions over a period of 6 years in a patient with acute myeloid leukemia after intensive chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Monocytic, Acute; Male; Recurrence; Remission Induction | 2007 |
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Pyrimidines; Survival Rate; Treatment Outcome | 2007 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Estrogens; Fatal Outcome; Female; Fluorouracil; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Mastectomy, Modified Radical; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nitriles; Radiotherapy, Adjuvant; Translocation, Genetic; Triazoles | 2006 |
Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cytarabine; Doxorubicin; Etoposide; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia; Methotrexate; Mitoxantrone; Mutation; Protein Kinase C; Staurosporine | 2007 |
Complex chromosome 8;21 translocation with associated hyperdiploidy in acute myeloid leukemia (FAB-M2).
Topics: Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Cytogenetic Analysis; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Nucleic Acid Hybridization; Oncogene Proteins, Fusion; Polymerase Chain Reaction; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic | 2008 |
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Examination; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Organ Specificity; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2007 |
A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2007 |
Aberrant phenotype of plasmacytoid monocytes in acute myeloid leukemia.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Bone Marrow; Cell Differentiation; Clone Cells; Cytarabine; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Megakaryocytes; Methotrexate; Middle Aged; Monocytes; Neoplasm Proteins; Neoplastic Stem Cells | 2008 |
Acute myeloid leukaemia presenting as recurrent generalized urticaria in infancy.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Diagnosis, Differential; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Urticaria | 2008 |
Pseudomembranous necrotizing tracheobronchitis caused by Aspergillus spp--contribution of one case with acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Aspergillus; Bronchitis; Cytarabine; Etoposide; Fatal Outcome; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid; Lung Diseases, Fungal; Male; Necrosis; Opportunistic Infections; Radiography, Thoracic; Tracheitis | 2006 |
Granulocytic sarcoma with massive scalp involvement.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Back; Bone Marrow; Cytarabine; Daunorubicin; Fatal Outcome; Female; Humans; Idarubicin; Leukemic Infiltration; Meninges; Pravastatin; Sarcoma, Myeloid; Scalp; Skin | 2008 |
Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia.
Topics: Chromosomes, Human, Pair 3; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Philadelphia Chromosome; Syndrome; Time Factors | 2008 |
Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bile Ducts; Blast Crisis; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Cytarabine; Drug Eruptions; Hepatocytes; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Function Tests; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2007 |
[A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Evidence-Based Medicine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Quality of Life; Retrospective Studies; Survival Rate; Vincristine | 2007 |
Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Topics: Adolescent; Adult; Aging; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Prognosis; Risk Factors; Survival Analysis; Treatment Outcome | 2008 |
Myeloid sarcoma presenting in muscle-tissue of the lower limb: unusual origin of a compartment-syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Compartment Syndromes; Cytarabine; Humans; Idarubicin; Leg; Magnetic Resonance Imaging; Male; Muscle Neoplasms; Muscle, Skeletal; Peripheral Blood Stem Cell Transplantation; Remission Induction; Sarcoma, Myeloid | 2007 |
Drug-induced hypersensitivity syndrome with rapid hematopoietic reconstitution during treatment for acute myeloid leukemia.
Topics: Aged; Allopurinol; Anti-Infective Agents; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Eruptions; Exanthema Subitum; Female; Fever; Hematopoiesis; Herpesvirus 6, Human; Histiocytosis; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Middle Aged; Skin; Virus Activation | 2008 |
Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Indomethacin; Leukemia, Myeloid, Acute; Multidrug Resistance-Associated Proteins; Phenotype | 2008 |
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrazines; Idarubicin; Irinotecan; Leukemia; Lymphoma; Sulfonamides; Topotecan | 2008 |
Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Dosage; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Proto-Oncogene Proteins; Recurrence; Remission Induction; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Transcription Factors | 2008 |
Modified IDARAM chemotherapy regimen for primary central nervous system lymphoma: experience of three cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cranial Irradiation; Cytarabine; Dexamethasone; Humans; Idarubicin; Immunohistochemistry; Lymphoma, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged | 2008 |
Neutrophilic dermatoses with acute myeloid leukemia associated with an increase of serum colony-stimulating factor.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Folliculitis; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Sweet Syndrome | 2008 |
Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cytarabine; Down-Regulation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Ligands; Signal Transduction; Up-Regulation | 2009 |
[Loeys-Dietz syndrome with acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Marfan Syndrome; Middle Aged; Mutation, Missense; Receptors, Transforming Growth Factor beta; Remission Induction; Translocation, Genetic | 2008 |
The management of prolonged, isolated hyperbilirubinemia following cytarabine-based chemotherapy for acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors | 2009 |
Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytarabine; Diterpenes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Epoxy Compounds; Humans; I-kappa B Proteins; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Common Antigens; Phenanthrenes; X-Linked Inhibitor of Apoptosis Protein | 2008 |
Granulocytic sarcoma of the right humerus in a non-leukaemia patient.
Topics: Aged; Antineoplastic Agents; Arthroplasty, Replacement; Bone Neoplasms; Combined Modality Therapy; Cytarabine; Female; Fractures, Spontaneous; Humans; Humerus; Idarubicin; Osteolysis; Remission Induction; Sarcoma, Myeloid; Shoulder Fractures | 2008 |
Human leukocyte antigen-DR negative de novo acute myeloid leukemia with Philadelphia chromosome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Philadelphia Chromosome; Remission Induction | 2008 |
[Granulocytic sarcoma of the prostate presenting with urinary obstruction which progressed to acute myeloid leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Dysuria; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Remission Induction; Sarcoma, Myeloid | 2008 |
Life-threatening conjunctival presentation of myeloid sarcoma.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Conjunctival Neoplasms; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Second Primary; Sarcoma, Myeloid; Skin Neoplasms | 2008 |
Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII : report on one case and review of other uses in acute leukemias.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Factor VIIa; Female; Gastrointestinal Hemorrhage; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid, Acute; Recombinant Proteins; Remission Induction; Thrombocytopenia; Treatment Outcome | 2010 |
Persistent hiccups as an adverse event to FLAG-IDA regimen for leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Filgrastim; Granulocyte Colony-Stimulating Factor; Hiccup; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Vidarabine | 2009 |
Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers; Case-Control Studies; Cytarabine; Female; Humans; Idarubicin; Immunophenotyping; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies | 2009 |
An uncommon cause of small bowel obstruction: isolated primary granulocytic sarcoma.
Topics: Antineoplastic Agents; Cytarabine; Female; Humans; Idarubicin; Intestinal Obstruction; Intestine, Small; Leukemia, Myeloid, Acute; Middle Aged; Sarcoma, Myeloid; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Blast Crisis; Blotting, Western; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Matrix Metalloproteinase 2; Middle Aged; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Young Adult | 2009 |
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Vincristine | 2009 |
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2009 |
Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone--rituximab
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Incidence; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Mitoxantrone; Prednisolone; Prognosis; Registries; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 2009 |
Pure erythroid leukemia with hemophagocytosis.
Topics: Antineoplastic Agents; Bone Marrow; Cytarabine; Fatal Outcome; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Lymphohistiocytosis, Hemophagocytic; Male; Methylprednisolone; Middle Aged | 2009 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2009 |
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult | 2009 |
Successful treatment of Hodgkin lymphoma and acute leukemia.
Topics: Adult; Biopsy; Bone Marrow Cells; Cytarabine; Hodgkin Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphatic Metastasis; Male; Neoplasms, Second Primary; Remission Induction | 2010 |
Primary multiple cerebral invasion in acute promyelocytic leukemia dramatically worsened by all-trans retinoic acid.
Topics: Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Antineoplastic Agents; Bacillus cereus; Bacterial Infections; Brain Abscess; Brain Neoplasms; Cytarabine; Female; Humans; Idarubicin; Injections, Spinal; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Methotrexate; Tretinoin | 2010 |
The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Gemtuzumab; HL-60 Cells; Humans; Idarubicin; Immunotoxins; Leukemia; Mercaptopurine; Methotrexate; Mitoxantrone; Sialic Acid Binding Ig-like Lectin 3; U937 Cells; Vincristine | 2009 |
Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Cytogenetics; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Republic of Korea; Retrospective Studies; Survival Analysis; Thioguanine; Young Adult | 2010 |
Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Leukemia, Monocytic, Acute; Male; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Remission Induction | 2010 |
Intrathecal chemotherapy and meningeal relapses in myelomonocytic AML. A single institution experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Injections, Spinal; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Male; Meninges; Middle Aged; Mitoxantrone; Testis; Young Adult | 2010 |
Typhlitis due to mucormycosis after chemotherapy in a patient with acute myeloid leukemia.
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Digestive System Surgical Procedures; Enterococcus faecium; Fatal Outcome; Female; Gram-Positive Bacterial Infections; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mucormycosis; Neutropenia; Rhinitis; Shock, Septic; Sinusitis; Typhlitis | 2010 |
Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Female; Genes, Wilms Tumor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Predictive Value of Tests; Survival Rate; Time Factors; Transcription, Genetic; Treatment Outcome; WT1 Proteins; Young Adult | 2010 |
Brucellosis: a rare cause of febrile neutropenia in acute myeloblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brucellosis; Cytarabine; Diagnosis, Differential; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neutropenia; Prognosis; Remission Induction | 2011 |
Toxic shock syndrome caused by hospital-acquired methicillin-resistant Staphylococcus aureus in a patient with pancytopenia.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cross Infection; Cytarabine; Etoposide; Fatal Outcome; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Methicillin-Resistant Staphylococcus aureus; Multiple Organ Failure; Pancytopenia; Shock, Septic; Staphylococcal Infections | 2010 |
A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Colitis; Cytarabine; Dasatinib; Female; Gastrointestinal Hemorrhage; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Rectal Diseases; Thiazoles | 2010 |
Orbital mass as a presenting sign of acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Fatal Outcome; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Orbital Neoplasms | 2010 |
Updates on the treatment of acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Cytarabine; Daunorubicin; Hemorrhage; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Tetrahydronaphthalenes; Tretinoin | 2010 |
Central line-associated bacteremia caused by drug-resistant Staphylococcus caprae after chemotherapy for acute myelogenous leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Staphylococcus | 2010 |
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lomustine; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Leukemia cutis limited to the needle puncture sites.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cytarabine; Fatal Outcome; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Skin Neoplasms | 2010 |
CNS relapse in acute promyeloctyic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Neoplasms; Brain Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cranial Irradiation; Cytarabine; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mercaptopurine; Methotrexate; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins | 2010 |
Fatal hepatitis B reactivation in an immune patient after anti-leukemic chemotherapy.
Topics: Antineoplastic Agents; Cytarabine; Fatal Outcome; Female; Hepatitis B; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Middle Aged; Tretinoin; Virus Activation | 2010 |
Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bacteria; Blood; Cytarabine; Female; Finland; Humans; Idarubicin; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Prospective Studies; Sepsis; Thioguanine; Young Adult | 2010 |
Immunosuppressive treatments in Crohn's disease induce myelodysplasia and leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Budesonide; Chromosomes, Human, Pair 7; Combined Modality Therapy; Crohn Disease; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Monocytic, Acute; Male; Mercaptopurine; Mesalamine; Methyltransferases; Monosomy; Myelodysplastic Syndromes; Prednisone; Young Adult | 2010 |
Leukaemia cutis at the site of striae distensae: an isotopic response?
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrophy; Biopsy; Cytarabine; Female; Humans; Idarubicin; Leukemia; Middle Aged; Skin; Skin Diseases; Skin Neoplasms; Treatment Outcome | 2010 |
Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Trisomy; Young Adult | 2010 |
Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Systemic mastocytosis associated with acute myeloid leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Cells; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mast Cells; Mastocytosis, Systemic | 2010 |
Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Treatment Outcome; Vidarabine | 2010 |
Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neoplasms; Colonic Polyps; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Indoles; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Pyrroles; Remission Induction; Sunitinib; Time Factors; Tretinoin | 2010 |
Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cytarabine; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Survival Rate; Treatment Outcome; Young Adult | 2011 |
[Leukemia cutis arising at the site of injection of a tetanus vaccine booster].
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Etoposide; Fatal Outcome; Humans; Idarubicin; Immunization, Secondary; Leukemia, Myelomonocytic, Chronic; Leukemic Infiltration; Leukosialin; Male; Middle Aged; Radiotherapy, Adjuvant; Shock, Septic; Skin; Tetanus Toxoid | 2010 |
Chemotherapy: Lo and behold, a role for lomustine in acute myeloid leukemia?
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lomustine; Nitrosourea Compounds; Treatment Outcome | 2010 |
Acquired protein C deficiency in a child with acute myelogenous leukemia, splenic, renal, and intestinal infarction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cholecystectomy; Cytarabine; Etoposide; Fibrin Fibrinogen Degradation Products; Fibrinogen; Gallbladder; Heparin, Low-Molecular-Weight; Humans; Idarubicin; Infarction; Kidney; Lebanon; Leukemia, Myeloid, Acute; Male; Protein C; Protein C Deficiency; Remission Induction; Splenectomy; Splenic Infarction; Thrombosis; Tretinoin | 2011 |
Successful treatment of acute promyelocytic leukemia in a patient on hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Kidney Failure, Chronic; Leukemia, Promyelocytic, Acute; Middle Aged; Mitomycin; Remission Induction; Renal Dialysis; Tretinoin | 2011 |
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Binding, Competitive; Clinical Trials, Phase II as Topic; Cytarabine; Drug Synergism; Eukaryotic Initiation Factor-4E; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Ribavirin; RNA Caps; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2011 |
Backtracking to birth of the NUP98-HOXD13 gene fusion in an infant acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Marrow Cells; Chromosome Banding; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 2; Cytarabine; Etoposide; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myelomonocytic, Acute; Male; Molecular Sequence Data; Neonatal Screening; Oncogene Proteins, Fusion; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic | 2011 |
Smoking adversely affects survival in acute myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Smoking; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Utility of myeloperoxidase stain in the differential diagnosis of leukemia cutis vs. hystiocitoid Sweet syndrome.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Diagnosis, Differential; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Peroxidase; Skin; Skin Neoplasms; Staining and Labeling; Sweet Syndrome; Treatment Outcome | 2011 |
t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Breakage; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 4; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Karyotype; Karyotyping; Leukemia, Biphenotypic, Acute; Middle Aged; Phenotype; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic | 2011 |
Use of cytarabine and idarubicin in a newly diagnosed AML patient with a severe wound.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Pancytopenia; Pyoderma Gangrenosum; Wound Healing | 2011 |
Treatment strategies in patients with core-binding factor acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Daunorubicin; Disease-Free Survival; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine | 2011 |
Massive postpartum hemorrhage after chemotherapy in a patient with acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Postpartum Hemorrhage; Pregnancy; Pregnancy Complications, Neoplastic; Tretinoin | 2011 |
Prompt and definitive diagnosis of acute invasive Aspergillus rhinosinusitis in a patient with acute myeloid leukaemia using in situ hybridization: a case report.
Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Aspergillus; Cytarabine; Humans; Idarubicin; In Situ Hybridization; Itraconazole; Leukemia, Myeloid, Acute; Male; Mycological Typing Techniques; Rhinitis; Sinusitis | 2012 |
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Remission Induction; Sorafenib; Survival Rate | 2011 |
Is obesity a prognostic factor for acute myeloid leukemia outcome?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Clinical Trials, Phase I as Topic; Cytarabine; Databases, Factual; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Obesity; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Treatment Outcome; Vidarabine | 2012 |
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Nucleophosmin; Polymorphism, Single Nucleotide; Prognosis | 2012 |
Unique association of systemic mastocytosis and myeloid/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA-Binding Proteins; Fatal Outcome; Gene Rearrangement; Humans; Idarubicin; Male; Mastocytosis, Systemic; Myeloproliferative Disorders; Receptor, Fibroblast Growth Factor, Type 1; Transcription Factors | 2012 |
Myeloperoxidase expression in acute myeloid leukemia helps identifying patients to benefit from transplant.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cytarabine; Disease-Free Survival; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Peroxidase; Retrospective Studies; Young Adult | 2012 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Enzymes; Female; Gemtuzumab; Genetic Heterogeneity; Genotype; Humans; Idarubicin; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine | 2013 |
Copy number variations in normal karyotype acute myeloid leukaemia and their association with treatment response.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Copy Number Variations; Drug Resistance, Neoplasm; Female; Genome-Wide Association Study; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Prognosis; Republic of Korea; Survival Analysis; Young Adult | 2012 |
Acute myeloid leukaemia with abnormal eosinophil precursors without inversion 16.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cytarabine; Eosinophilia; Eosinophils; Granulocyte Precursor Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oncogene Proteins, Fusion | 2012 |
Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Severity of Illness Index; Survival Analysis | 2012 |
[Genetic prognostic factors in childhood acute myeloid leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Cytarabine; DNA Mutational Analysis; Etoposide; Female; fms-Like Tyrosine Kinase 3; Genes, Wilms Tumor; Genetic Markers; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Nuclear Proteins; Nucleophosmin; Prognosis; Survival Rate; Translocation, Genetic | 2012 |
Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fever; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Neutropenia; Obesity; Outcome Assessment, Health Care; Prognosis; Remission Induction; Young Adult | 2013 |
Isolated central nervous system relapse presenting as myeloid sarcoma of acute myeloid leukemia after allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellopontine Angle; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Idarubicin; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Magnetic Resonance Imaging; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Recurrence; Salvage Therapy; Sarcoma, Myeloid; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2013 |
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Genome-Wide Association Study; Humans; Idarubicin; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-kit; Remission Induction; Translocation, Genetic; Young Adult | 2012 |
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Core Binding Factors; Cytarabine; Disease-Free Survival; Exons; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Korea; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Point Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; RUNX1 Translocation Partner 1 Protein; Transcription Factors; Translocation, Genetic; Treatment Outcome; Young Adult | 2013 |
p210 BCR/ABL1 as a secondary change in a patient with acute myelomonocytic leukemia (M4Eo) with inv(16).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Inversion; Chromosomes, Human, Pair 16; Combined Modality Therapy; Cytarabine; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelomonocytic, Acute; Male; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction | 2012 |
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; DNA Mutational Analysis; Female; Glutarates; Granulocyte Precursor Cells; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid; Male; Middle Aged; Mutation; Prospective Studies; Time Factors | 2012 |
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum | 2013 |
Outcome of poor response paediatric AML using early SCT.
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Early Medical Intervention; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Idarubicin; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myeloablative Agonists; Thioguanine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2013 |
Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Cells; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Remission Induction; Retrospective Studies; RNA, Messenger | 2013 |
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Factors; Time-to-Treatment; Treatment Outcome; Young Adult | 2013 |
Core binding factor acute myeloid leukaemia and c-KIT mutations.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Core Binding Factors; Cytarabine; Disease-Free Survival; Etoposide; Exons; Female; Humans; Idarubicin; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-kit; Retrospective Studies; Stem Cell Transplantation; Young Adult | 2013 |
Acquired resistance of leukemic cells to AraC is associated with the upregulation of aldehyde dehydrogenase 1 family member A2.
Topics: Aldehyde Dehydrogenase 1 Family; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Enzyme Induction; Gene Expression Regulation, Leukemic; Humans; Idarubicin; K562 Cells; Leukemia; Leukemia, Erythroblastic, Acute; Neoplasm Proteins; Prodrugs; Retinal Dehydrogenase; RNA Interference; RNA, Small Interfering; Transfection; Up-Regulation | 2013 |
The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; Nucleophosmin; Peripheral Blood Stem Cell Transplantation; Prognosis; Real-Time Polymerase Chain Reaction; RNA, Neoplasm; Survival Analysis; Trans-Activators; Transplantation, Autologous; Treatment Outcome; Tumor Suppressor Proteins; Vidarabine; Young Adult | 2013 |
[Analysis on clinical response of IA and DA regimens in the treatment of 74 newly diagnosed acute myeloid leukemia patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2013 |
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vidarabine | 2013 |
Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Topics: 5'-Nucleotidase; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Cytidine Deaminase; Daunorubicin; Deoxycytidine Kinase; DNA Methylation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Inactivation, Metabolic; Kaplan-Meier Estimate; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Nucleophosmin; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Survival Analysis; Tandem Repeat Sequences; Topoisomerase I Inhibitors; Young Adult | 2013 |
Blue toes and a new pair of shoes--challenges in diagnosis and treatment of acute myelogenous leukemia.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Arterial Occlusive Diseases; Bone Marrow Examination; Combined Modality Therapy; Cyanosis; Cytarabine; Diagnosis, Differential; Disseminated Intravascular Coagulation; Fatal Outcome; Female; Humans; Idarubicin; Ischemia; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Shoes; Thrombectomy; Thrombocytopenia; Thrombosis; Toes; Ultrasonography | 2013 |
The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2013 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status.
Topics: Aged; Aged, 80 and over; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Risk; Severity of Illness Index; Treatment Outcome | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prevalence; Prognosis; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2013 |
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Breakthrough Fusarium solani infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis.
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Fungal; Fatal Outcome; Female; Fever; Fusariosis; Fusarium; Humans; Idarubicin; Leukemia, Myeloid, Acute; Triazoles; Young Adult | 2014 |
[Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Azacitidine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Hepatomegaly; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Serositis | 2014 |
The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Immunophenotyping; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult | 2014 |
Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 5; Comparative Genomic Hybridization; Cytarabine; DNA Copy Number Variations; Drug Administration Schedule; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Karyotype; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Remission Induction | 2014 |
Acute myeloid leukemia of mixed megakaryocytic and erythroid origin following chemotherapy for T-cell lymphoblastic lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Dexamethasone; Erythroid Cells; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Megakaryocytes; Mitoxantrone; Neoplasms, Second Primary; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Vincristine | 2014 |
Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factors; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Translocation, Genetic; Treatment Outcome; Young Adult | 2014 |
Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Cytarabine; Dexamethasone; Female; Humans; Idarubicin; Lymphoma; Male; Methotrexate; Middle Aged; Multimodal Imaging; Neoplasm Staging; Prognosis; Rituximab | 2014 |
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Idarubicin; Lymphoma; Male; Methotrexate; Remission Induction; Thiotepa; Treatment Outcome | 2014 |
HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Graft Survival; Graft vs Leukemia Effect; Histocompatibility; HLA Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Male; Middle Aged; Remission Induction; Tissue Donors | 2014 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
The first Korean case of Moraxella osloensis bacteremia in a patient with acute myeloid leukemia.
Topics: Aged; Ampicillin; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Asian People; Cytarabine; Drug Therapy, Combination; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Moraxella; Moraxellaceae Infections; Republic of Korea; Respiratory Tract Infections; RNA, Ribosomal, 16S; Sequence Analysis, RNA; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sulbactam | 2014 |
Acute basophilic leukemia.
Topics: Aged; Antibiotics, Antineoplastic; Antigens, CD; Antimetabolites, Antineoplastic; Asthenia; Azacitidine; Basophils; Bone Marrow; Cytarabine; Female; Humans; Idarubicin; Leukemia, Basophilic, Acute; Leukemia, Myeloid, Acute | 2014 |
Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Child; Child, Preschool; Cytarabine; Etoposide; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2014 |
Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Daunorubicin; Drug Therapy, Combination; Egg Hypersensitivity; Etoposide; Female; Food Hypersensitivity; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Intestinal Diseases; Leukemia, Myeloid, Acute; Liver Diseases; Male; Middle Aged; Nut Hypersensitivity; Seafood; Tacrolimus; Transplantation Conditioning; Vidarabine | 2014 |
Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Benzamides; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Imatinib Mesylate; Immunosuppressive Agents; Induction Chemotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Interferon-alpha; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Mitoxantrone; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome; Tretinoin | 2015 |
[Neoplastic mastocytosis evolving from a poor prognosis acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunophenotyping; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mast Cells; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Vidarabine | 2015 |
Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
Topics: Aclarubicin; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate | 2015 |
[Clinical curative efficacy of inducing remission for the newly diagnosed aged AML patients by chemotherapy with IA and DA regimens].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies | 2014 |
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Child; Child, Preschool; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Drug Monitoring; Etoposide; Female; Humans; Idarubicin; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mutation; Neoplasm, Residual; Proto-Oncogene Proteins; RUNX1 Translocation Partner 1 Protein; Survival Analysis; Transcription Factors; Translocation, Genetic | 2015 |
Sequential development of different acute leukemia types in the same patient.
Topics: Acute Disease; Antineoplastic Agents; Cytarabine; Humans; Idarubicin; Leukemia; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local | 2014 |
Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Female; Follow-Up Studies; Hospitalization; Humans; Idarubicin; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Survival Analysis; Treatment Outcome; Vidarabine | 2015 |
[The relationship between induction chemotherapy cycles and prognosis in patients with acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Prognosis; Remission Induction | 2015 |
"Cup-like" blasts in acute myeloid leukemia with FLT3 and NPM1 mutations.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin | 2015 |
[Comparison of 10 mg/m² or 8 mg/m² idarubicin plus cytarabine regimen as induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Prognosis; Remission Induction | 2015 |
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Nitriles; Pyrazoles; Pyrimidines; Treatment Outcome | 2016 |
Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Case-Control Studies; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Endostatins; Female; Fibroblast Growth Factors; Gene Expression; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; ROC Curve; Treatment Outcome | 2015 |
Successful Treatment With Total Skin Electron Beam Therapy in a Child With Isolated Cutaneous Relapsed AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Electrons; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Skin Diseases; Vidarabine | 2015 |
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Genome, Human; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Mutation; Outcome Assessment, Health Care; Polymorphism, Genetic; Prognosis; Recurrence; RNA, Messenger; Sequence Analysis, RNA | 2015 |
Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Proliferation; Cytarabine; Drug Delivery Systems; Enzyme Activation; Female; Fingolimod Hydrochloride; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lipids; Mice; Mice, Transgenic; Nanoparticles; Nanotechnology; Propylene Glycols; Sphingosine | 2015 |
Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Cytogenetic Analysis; Etoposide; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Staging; Nuclear Proteins; Nucleophosmin; Prognosis; Survival Rate; Thioguanine; Young Adult | 2015 |
The impact of standard chemotherapy on miRNA signature in plasma in AML patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Female; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Mitoxantrone; Pilot Projects; Real-Time Polymerase Chain Reaction; Remission Induction; RNA, Neoplasm; Transcriptome | 2015 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Mercaptopurine; Methotrexate; Middle Aged; Remission Induction; Treatment Outcome; Young Adult | 2015 |
Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Drug Synergism; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2015 |
The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; China; Cytarabine; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Gene Frequency; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Nuclear Proteins; Nucleophosmin; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-kit; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Idarubicin; Infusions, Intravenous; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome | 2016 |
[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Topics: Cytarabine; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocyte Count; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Wernicke's Encephalopathy in an Acute Myeloid Leukemia Patient: A Case Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Thiamine; Vidarabine; Wernicke Encephalopathy | 2016 |
Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Guideline Adherence; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Practice Guidelines as Topic | 2016 |
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Consolidation Chemotherapy; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2016 |
A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Risk Assessment; Salvage Therapy; Survival Analysis; Vidarabine; Young Adult | 2016 |
Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cytarabine; Daunorubicin; Echinocandins; Febrile Neutropenia; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lipopeptides; Male; Micafungin; Middle Aged; Mycoses; Prospective Studies; Young Adult | 2016 |
Leukaemic infiltration and cytomegalovirus retinitis in a patient with acute T-cell lymphoblastic leukaemia in complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Cytomegalovirus Retinitis; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemic Infiltration; Papilledema; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retina; Retinal Hemorrhage; Vidarabine | 2017 |
[A Case of a Multidisciplinary Team Approach to Serious Hand-Foot Syndrome Induced by High-Dose Cytarabine Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Erythema; Female; Hand-Foot Syndrome; Humans; Idarubicin; Leukemia, Myeloid, Acute; Patient Care Team; Treatment Outcome | 2016 |
The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Prognosis; Retrospective Studies | 2016 |
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Topics: Adult; Aged; Cytarabine; Disease-Free Survival; Female; Flow Cytometry; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction | 2017 |
Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Safety; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Coculture Techniques; Cytarabine; Drug Resistance, Neoplasm; Gene Silencing; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mesenchymal Stem Cells; Mice; Mice, SCID; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Microenvironment | 2017 |
Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Gene Expression; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Survival Analysis; Thioguanine; Tumor Suppressor Protein p53 | 2017 |
Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia.
Topics: Amino Acid Motifs; Base Sequence; Cytarabine; fms-Like Tyrosine Kinase 3; Gene Expression; Genetic Variation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mitoxantrone; Protein Domains; Retrospective Studies; Sequence Analysis, DNA; Survival Analysis; Tandem Repeat Sequences | 2017 |
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.
Topics: Aclarubicin; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Karyotype; Male; Middle Aged; Mutation; Retrospective Studies | 2017 |
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Stem Cell Transplantation; Treatment Outcome; Vidarabine; Young Adult | 2017 |
Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diarrhea; Exanthema; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Mucositis; Neutropenia; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cephalosporins; Cytarabine; Female; Gram-Positive Bacterial Infections; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Vancomycin; Vancomycin-Resistant Enterococci; Young Adult | 2017 |
Marked hypereosinophilia and rash as initial presentation of acute myeloid leukemia with t(8;21).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Diagnosis, Differential; Eosinophilia; Eosinophils; Exanthema; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Skin; Translocation, Genetic; Treatment Outcome; Young Adult | 2017 |
Cell-based evaluation of changes in coagulation activity induced by antineoplastic drugs for the treatment of acute myeloid leukemia.
Topics: Antineoplastic Agents; Benzoates; Cell Line, Tumor; Cytarabine; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Phosphatidylserines; Tetrahydronaphthalenes; Thrombomodulin; Thromboplastin | 2017 |
Escalated anthracycline dose in adult AML.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2017 |
Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous | 2017 |
A life-threatening ruxolitinib discontinuation syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diagnosis, Differential; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Janus Kinase 2; Leukemia, Myeloid, Acute; Middle Aged; Nitriles; Pneumonia; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Remission Induction; Respiratory Distress Syndrome; Substance Withdrawal Syndrome; Thrombocythemia, Essential; Tomography, X-Ray Computed | 2017 |
Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Ear, External; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hearing Loss, Unilateral; Humans; Idarubicin; Leukemia, Monocytic, Acute; Leukemic Infiltration; Male; Orbit; Tumor Lysis Syndrome; Vidarabine | 2017 |
Release of Danger-Associated Molecular Patterns following Chemotherapy Does Not Induce Immunoparalysis in Leukemia Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers; Case-Control Studies; Cells, Cultured; Cholesterol, LDL; Cytarabine; Cytokines; DNA; DNA, Mitochondrial; Female; HLA-DR Antigens; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Leukocytes; Lipopolysaccharides; Male; Middle Aged; Myelodysplastic Syndromes; Young Adult | 2017 |
Blastic plasmacytoid dendritic cell neoplasm: a pathological illustration of two clinical cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Dendritic Cells; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Lymphatic Metastasis; Male; Myeloproliferative Disorders; Recurrence; Skin Neoplasms; Vidarabine | 2017 |
Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; DNA Damage; DNA Repair; Drug Therapy; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplastic Stem Cells; Young Adult | 2017 |
Systemic mastocytosis associated with acute myeloid leukaemia.
Topics: Adult; Biopsy, Needle; Bone Marrow; Cytarabine; Humans; Idarubicin; Immunohistochemistry; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Proto-Oncogene Proteins c-kit | 2017 |
Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Binding Factor; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Myosin Heavy Chains; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Reverse Transcriptase Polymerase Chain Reaction; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; Transplantation, Autologous | 2017 |
FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Survival Analysis; Vascularized Composite Allotransplantation; Vidarabine | 2017 |
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Clofarabine; Cytarabine; Deoxyadenosines; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Proteins; Vidarabine | 2017 |
Anthracycline-induced acute myocarditis and ventricular fibrillation arrest.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cardiopulmonary Resuscitation; Chest Pain; Combined Modality Therapy; Cytarabine; Defibrillators, Implantable; Echocardiography; Etoposide; Heart Arrest; Humans; Idarubicin; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Middle Aged; Myocarditis; Ventricular Fibrillation | 2018 |
Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Propensity Score; Remission Induction; Retrospective Studies; Treatment Outcome | 2018 |
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Vidarabine | 2019 |
Ara-C ears: an actual drug-induced reaction or a distinctive manifestation of a neutrophilic dermatosis?
Topics: Adult; Biopsy; Cytarabine; Drug Therapy, Combination; Ear Diseases; Ear, External; Erythema; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Sweet Syndrome | 2018 |
AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Genes, p53; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult | 2018 |
High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Remission Induction; Salvage Therapy; Survival Analysis; United Kingdom; Vidarabine | 2018 |
Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Nonleukemic granulocytic sarcoma of orbit after blunt trauma: A case report and review of literature.
Topics: Adult; Antineoplastic Agents; Causality; Cytarabine; Early Detection of Cancer; Eye Injuries; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Magnetic Resonance Imaging; Ophthalmologic Surgical Procedures; Orbit; Orbital Neoplasms; Radiotherapy; Sarcoma, Myeloid; Tomography, X-Ray Computed; Treatment Outcome; Wounds, Nonpenetrating | 2018 |
Acute Onset Unilateral Proptosis.
Topics: Aged; Antineoplastic Agents; Cytarabine; Exophthalmos; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Radiotherapy; Sarcoma, Myeloid | 2018 |
[Complete Remission Rate and Adverse Ractions of Three Different Chemotherapy Regimens in the Treatment of Adult Patients with Newly Diagnosed Non-M3 AML].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2018 |
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clofarabine; Cohort Studies; Cytarabine; DNA, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Sequence Analysis, DNA; Vidarabine | 2018 |
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; United Kingdom; Vidarabine; Young Adult | 2018 |
(1-3)-β-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta-Glucans; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Aspergillosis; Retrospective Studies; Risk Factors; Triazoles; Vidarabine | 2019 |
Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing.
Topics: Cell Line, Tumor; Cell Survival; Cytarabine; DNA; DNA Adducts; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mass Spectrometry | 2018 |
FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine; Young Adult | 2019 |
Lomustine in older patients with acute myeloid leukaemia.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lomustine; Male; Middle Aged; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2018 |
Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sorafenib; Treatment Outcome; Vidarabine | 2019 |
Primary Philadelphia chromosome positive acute myeloid leukemia: A case report.
Topics: Antineoplastic Agents; Bone Marrow Examination; Cytarabine; Dasatinib; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Idarubicin; Karyotype; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multiple Organ Failure; Mutation; Philadelphia Chromosome | 2018 |
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Monitoring; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Precision Medicine; Prognosis; Remission Induction; ROC Curve; Treatment Outcome; Workflow; Young Adult | 2019 |
FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Vidarabine | 2019 |
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Europe; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Platelet Count; Prognosis; Reproducibility of Results; Retrospective Studies; Risk Assessment; Survival Rate; Young Adult | 2019 |
Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Time Factors | 2019 |
Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Russia; Survival Rate; Young Adult | 2018 |
Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 2019 |
Clinical Reasoning: A pregnant woman with chin numbness.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Chin; Consolidation Chemotherapy; Cytarabine; Emergency Service, Hospital; Fatigue; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypesthesia; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Paresthesia; Pregnancy; Pregnancy Complications, Neoplastic; Spinal Puncture; Sweating; Upper Extremity | 2019 |
Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Decitabine; Disease-Free Survival; DNA Methylation; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Duplication; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Retrospective Studies; Time Factors | 2019 |
FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Middle Aged; Pakistan; Progression-Free Survival; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; Vidarabine; Young Adult | 2019 |
Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; Cytarabine; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Remission Induction | 2019 |
FLAI induction regimen in elderly patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Remission Induction; Retrospective Studies; Sex Factors; Time Factors; Transplantation, Homologous; Vidarabine | 2019 |
A Case of Granulocytic Sarcoma of the Lung in Acute Myeloid Leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Remission Induction; Sarcoma, Myeloid | 2019 |
Non-allogeneic immunotherapy in acute myeloid leukaemia.
Topics: Cytarabine; Humans; Idarubicin; Immunotherapy; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nivolumab | 2019 |
Does a neutropenic diet reduce adverse outcomes in patients undergoing chemotherapy?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial Infections; Carmustine; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Diet Therapy; Enterocolitis, Neutropenic; Female; Hematologic Neoplasms; Humans; Idarubicin; Male; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies; South Australia | 2020 |
PTEN/AKT signaling mediates chemoresistance in refractory acute myeloid leukemia through enhanced glycolysis.
Topics: Cell Line, Tumor; Cytarabine; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glycolysis; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Oxidative Phosphorylation; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction | 2019 |
Inflammatory Cells in Atypical Eruption of Lymphocyte Recovery Carry the Same Mutations as Neoplastic Myeloid Cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Eruptions; Female; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes | 2020 |
A retrospective study of the correlation of in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia.
Topics: Aclarubicin; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2020 |
The Role of Anthracyclines in Acute Myeloid Leukemia Consolidation.
Topics: Adolescent; Adult; Aged; Anthracyclines; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Young Adult | 2020 |
Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Topics: Adolescent; Adult; Aged; Alleles; Allografts; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Progression-Free Survival; Recurrence; Risk Assessment; Young Adult | 2020 |
Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk Factors; Survival Rate; Vidarabine | 2020 |
Venetoclax for paediatric acute myeloid leukaemia: a step forward.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Child; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Pregnancy; Recurrence; Tretinoin; Young Adult | 2020 |
Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Feasibility Studies; Female; Gemtuzumab; Geriatric Assessment; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Outcome Assessment, Health Care; Survival Analysis | 2020 |
Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Bleomycin; Coronavirus Infections; COVID-19; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Hydroxychloroquine; Idarubicin; Mediastinal Neoplasms; Pandemics; Pneumonia, Viral; Positron-Emission Tomography; Prednisone; Procarbazine; SARS-CoV-2; Treatment Outcome; Vinblastine; Vincristine | 2020 |
Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy.
Topics: Adult; Anti-Bacterial Agents; Bone Marrow; Consolidation Chemotherapy; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Linezolid; Male; Middle Aged; Platelet Count; Retrospective Studies; Thrombocytopenia | 2020 |
Diffuse alveolar hemorrhage during induction therapy for acute myeloid leukemia with inv(16)(p13.1q22).
Topics: Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Diagnosis, Differential; Hemorrhage; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Lung Diseases; Male; Middle Aged; Pulmonary Alveoli; Tomography, X-Ray Computed | 2020 |
FLAG-Ida is back in.
Topics: Anthracyclines; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2020 |
Immunosuppressive role of CD11b
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD11b Antigen; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytarabine; Cytotoxicity, Immunologic; Female; Hematopoietic Stem Cell Transplantation; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid-Derived Suppressor Cells; Phenotype; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes, Cytotoxic; Treatment Outcome; Tumor Escape | 2020 |
Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2020 |
An evaluation of no-treatment decisions in patients with newly diagnosed acute myeloid leukemia.
Topics: Adolescent; Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Cytarabine; Databases, Factual; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate | 2021 |
Diagnosis of oesophageal mucormycosis managed with medical therapy alone.
Topics: Amphotericin B; Antifungal Agents; Cytarabine; Esophageal Diseases; Esophagus; Humans; Idarubicin; Immunocompromised Host; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mucormycosis; Rhizopus; Triazoles | 2020 |
The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Middle Aged; Prognosis; Prospective Studies; Receptors, Immunologic; Survival Rate; Young Adult | 2021 |
Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2021 |
Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Pancytopenia; Retrospective Studies; Salvage Therapy; Survival Rate; Vidarabine; Young Adult | 2021 |
Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Salvage Therapy; Sulfonamides; Vidarabine | 2021 |
Ultraviolet recall due to cytarabine chemotherapy for acute myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2021 |
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Prospective Studies; Remission Induction; Sulfonamides; Vidarabine; Young Adult | 2022 |
Granulocytic sarcoma of cervix: A rare case report.
Topics: Cervix Uteri; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Sarcoma, Myeloid | 2022 |
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies | 2022 |
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cytarabine; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Recurrence; Remission Induction; Treatment Outcome; Tretinoin | 2022 |
Pneumocystis jirovecii pneumonia [PJP]: An unrecognized concern in AML patients on Venetoclax.
Topics: Aged; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pneumocystis carinii; Pneumonia, Pneumocystis; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
[A comparative clinical study of modified IA "3+4" regimen and intermediate-dose cytarabine regimen in the consolidation treatment of low-risk acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2022 |
Long term follow-up of refractory/relapsed acute myeloid leukemia patients treated with the FLAG-Ida regimen as bridge therapy to allotransplantation: 10-year results from a single centre experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridge Therapy; Cytarabine; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Recurrence; Vidarabine | 2023 |
Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine | 2023 |
Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2023 |
Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mutation; Remission Induction; Staurosporine | 2023 |
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Forkhead Transcription Factors; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; RNA, Messenger; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2023 |
[Acute myeloid leukemia with t (8;21) translocation diagnosed at 21 weeks of gestation resulting in full-term delivery without chemotherapy].
Topics: Adult; Cesarean Section; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pregnancy; Translocation, Genetic | 2023 |